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Neurodegenerative diseases have a devastating impact on patients, and they are 
becoming more prevalent due to the increasing age of the global population. 
However, despite intensive research there are no disease-modifying therapies 
for any neurodegenerative conditions. Dysregulation of RNA binding protein 
(RBP) and mitochondrial function are key hallmarks of the molecular pathology 
of neurodegenerative diseases such as amyotrophic lateral sclerosis, 
polyglutamine (polyQ) disorders and Parkinson’s disease. This thesis aims to 
contribute to the understanding of how RBPs mediate neurodegenerative 
pathology, and to investigate pharmacological modulation of mitochondrial 
function as a neuroprotective strategy. The expression of the RBP scaffold 
attachment factor 1 (SAFB1) was investigated in degenerating human brains. 
These studies revealed a novel, abnormal SAFB1 cytoplasmic expression pattern 
associated specifically with polyQ disease including spinocerebellar ataxias and 
Huntington’s disease. Spinocerebellar ataxia type 1 is caused by an expansion 
of the polyQ tract in the ATXN1 gene. The interaction between SAFB1 protein 
and pathological expanded tandem repeat RNA (xtrRNA) was therefore 
investigated. RNA immunoprecipitation confirmed SAFB1 interacted with ATXN1 
transcripts and demonstrated that a pathological CAG expansion confers a 
relative increase in the level of ATXN1 associated with SAFB1. This result 
suggests that an interaction between SAFB1 and expanded polyQ tracts may 
result in the mislocalisation of SAFB1 to the cytoplasm in degenerating polyQ 
neurons. Furthermore, these findings support the hypothesis that it is RBP 
dysfunction that leads to neurodegenerative pathology. Drugs that promote 
mitochondrial function may be effective in treating neurodegenerative conditions 
such as Parkinson’s disease. Using an in-vitro phenotypic screen, kenpaullone, 
a GSK-3 beta/CDK5 inhibitor, was identified as a novel modulator of parkin 
recruitment. Kenpaullone was also found to increase mitochondrial length, 
protect against mitochondrial toxins and alter respiratory function. Based on 
these findings, further investigations are recommended to explore the potential 
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1. Chapter 1  
General Introduction 
1.1 Neurodegenerative disease 
1.1.1 The impact of neurodegenerative disease 
Human neurodegenerative diseases are characterised by the deterioration 
and loss of cell populations within the brain or spinal cord over time, which 
ultimately causes permanently debilitating clinical symptoms. 
Neurodegenerative disease represents a major public health concern 
worldwide, especially within the older population. The World Health 
Organisation reports that in 2015 the global financial cost of dementia, the 
most common syndrome associated with neurodegenerative diseases, was 
818 billion US dollars (World Health Organisation, accessed March 2019). 
With ongoing advances in medicine and healthcare across the planet, life 
expectancy is increasing. A global increase of 5.5 years between 2000-2015 
was recorded by the World Health Organisation (accessed February 2020). 
The United Nations reports that the global population aged over 60 is 
growing faster than all age groups, whilst the number of people aged over 
80 is predicted to triple by 2050 (accessed February 2020). As increasing 
age is the greatest risk factor for neurodegenerative disease (Hou et al. 
2019) a rise in incidence of these disorders will occur, further increasing the 
global impact. 
In the UK there are over two million people living with a progressive 
neurological illness (The Neurological Alliance, Table 1.1) and they suffer 
the lowest health-related quality of life of any long-term condition (NHS 
England). Patients with neurodegenerative disorders are diagnosed with the 
knowledge that they have a condition which will severely worsen with time, 
and for which there is no curative treatment. With high quality person-
centred care regimens many patients are able to maintain a good quality of 




physical and cognitive deterioration on the individual and their family should 
not be understated. 
The clinical presentation of neurodegenerative diseases varies widely. 
Patients experience physical, cognitive and psychological symptoms. Main 
symptoms are usually related to cognition, and movement or coordination 
problems. Patients also frequently experience a wide range of other 
symptoms which have a huge impact on their quality of life. These include 
sleep disturbances, gastrointestinal dysfunctions and psychiatric 
manifestations (Martinez-Martin et al. 2007). Family members and friends 
who assume caregiver roles are also likely to experience a reduction in their 
quality of life (Caga et al. 2019, Sturm et al. 2019, Yu et al. 2019).  
 
Despite decades of research and medical innovation, there are currently no 
approved disease-modifying or neuroprotective treatments available for any 
neurodegenerative disease (Cummings 2017). Current treatment regimens 
aim to provide symptomatic relief and eventually palliative care (Braga Neto 
et al. 2016, Dickey and La Spada 2018). The challenge of delivering curative 
or disease-modifying therapies is further complicated by the fact that a 
significant proportion of irreversible degenerative loss has already occurred 
Table 1.1 Approximate number of patients living with selected neurodegenerative 
diseases in the UK. AD Alzheimer’s disease, PD Parkinson’s disease, MS multiple 
sclerosis, FTD fronto-temporal dementia, HD Huntington’s disease, ALS 
amyotrophic lateral sclerosis. 
Neurodegenerative 
disease 
Approximate number of patients 







PD 137,000 Parkinson’s UK 
MS 100,000 MS Society 
FTD 17,000 Alzheimer’s Society 










by the time of clinical presentation in most sporadic neurodegenerative 
conditions (Cheng et al. 2010). 
The road to developing disease-modifying therapies highlights key research 
challenges; first, the need to gain greater depth of understanding of the 
molecular mechanisms driving neurodegenerative pathology, and second, 
the ability to detect disease early, for instance using novel biomarkers or 
diagnostic technologies. The research presented in this thesis focuses on 
the first of these challenges and aims to make a contribution of knowledge 
towards our understanding of the molecular pathology of 
neurodegeneration, with the hope that ongoing research will make it 
possible to offer disease-modifying therapies to patients in the future. 
1.1.2 Molecular hallmarks of neurodegeneration 
Classification of this highly complex and diverse group of diseases can be 
based upon clinical presentation or anatomical location of pathological 
changes, but this does not necessarily correlate to the underlying molecular 
pathology. The human brain is necessarily comprised of extreme 
anatomical complexity, containing approximately 170 billion cells in a 1:1 
ratio of neuronal to non-neuronal types (Azevedo et al. 2009). There are 
hundreds of identified sub-types of neuron in the brain, alongside macroglia 
(including astrocytes and oligodedrocytes) and microglial cells. The 
importance of non-neuronal brain cells in the molecular pathology of 
neurodegenerative disorders is now widely recognised and has been 
extensively reviewed (Singh and Joshi 2017, Luca et al. 2018, Peteri et al. 
2019). Although further discussion is beyond the scope of this project, it is 
important to consider the context of neurons within this highly complex in-
vivo environment.  
It is recognised that an intricate combination of genetic and environmental 
factors are usually involved in the aetiology of neurodegenerative disease. 
Environmental triggers most recently associated with disease pathology 
include inflammation and immune activation caused by infectious agents 




established that mutations in specific genes can directly cause inherited 
forms of many neurodegenerative diseases. Examples include PARK2 
(encoding the E3 ubiquitin ligase parkin), mutations in which cause familial 
PD (Bras et al. 2015), and mutations in the RNA binding protein (RBP) TDP-
43 which cause forms of amyotrophic lateral sclerosis (ALS) (Mackenzie 
and Rademakers 2010). In other cases, specific neurodegenerative disease 
can be exclusively caused by a genetic mutation. This is exemplified by the 
polyglutamine (polyQ) disorders which include Huntington’s disease (HD) 
and forms of autosomal dominant spinocerebellar ataxia (SCA), which are 
caused by a CAG trinucleotide expansion repeat within an exon of the 
affected gene. More recently, genetic risk loci are being identified using 
genome-wide association studies (GWAS) to identify novel genetic risk 
factors in the development of conditions such as Alzheimer’s disease (AD) 
(Jansen et al. 2019) and PD (Singleton and Hardy 2019). 
Despite diverse aetiology, the cellular pathology of neurodegenerative 
diseases can be classified into characteristic hallmark features which are 
common across numerous diseases (Tofaris and Buckley 2018). The 
combination and relative contribution of these features varies with disease 
and is likely to differ between individual patients and with disease stage. 
Many of these features are extremely well-established, and some are only 
more recently becoming well understood. A selection of these key 
mechanisms are summarised in Figure 1.1.  
As non-dividing cells, neurons are unable to dilute damaged cell contents 
through cell division, leaving them vulnerable to accumulation of cellular 
deficits at the RNA, protein and organelle level over time. One of the earliest 
discovered cellular hallmarks of neurodegeneration is the accumulation of 
intracellular protein inclusions which are often formed from misfolded, 
aggregated or mislocalised proteins (Dziewulska and Rafalowska 2005). 
Protein inclusions may be nuclear and/or cytoplasmic, with key examples 





Toxic loss or gain of function may arise directly or indirectly from protein 
inclusions. Proteinopathies are associated with alterations in protein 
processing and dysfunction of the ubiquitin-proteasome system, which are 
also common features of many neurodegenerative diseases (Zheng et al. 
2016). Dysregulation of the ubiquitin system is exemplified in PD through 
the critical role of parkin, which is involved in mitochondrial quality control. 
Indeed, mitochondrial dysfunction is one of the most important pathological 
processes underlying neuronal loss in PD. Mitochondrial dysfunction also 
contributes to the molecular pathology of AD, HD and ALS (Filosto et al. 
2011), representing a key target for potential therapeutic intervention (Gao 
et al. 2017). The role of mitochondria in neurodegenerative disease is 
discussed in detail in sections 1.7-1.9, and is investigated in Chapter 5. 






Intraneuronal protein inclusions 
AD Cytoplasmic neurofibrillary tangles containing 
phosphorylated tau 
ALS Varies with genetic type. Inclusions may contain 
SOD1, TDP-43, FUS, ubiquitin or C9ORF72. 
 
FTD Varies with genetic type. Cytoplasmic inclusions 
may contain TDP-43, FUS and ubiquitin. Some 
types feature tau-positive neurofibrillary tangles. 
HD Nuclear and cytoplasmic inclusions containing 
polyQ expanded huntingtin 
PD, 
Lewy body dementia 
Cytoplasmic Lewy bodies composed of alpha-
synuclein, parkin and ubiquitin 
PolyQ SCA Nuclear and/or cytoplasmic inclusions containing 
disease-specific polyQ expanded ataxin proteins 
Spongiform 
encephalopathies 
Intracellular prion protein inclusions 
In addition to cellular hallmarks which manifest at the organelle and protein 
level, RNA level pathology has now been established as a driver of neuronal 
degeneration (De Conti et al. 2017).  The transcription of RNA from DNA 
and translation of RNA into peptides is exquisitely highly regulated. mRNA 
processing confers the diversity of protein expression necessary for the 
functioning of highly complex, differentiated cells such as neurons. Post-
transcriptional regulation occurs through many mechanisms including 3’ 
polyadenylation, splicing, and post-transcriptional silencing. 
RBPs are trans-acting effectors of RNA processing, interacting with RNA 
transcripts and other proteins in complex functional networks of 
ribonucleoproteins (RNPs) to regulate gene expression. Dysfunction of the 
RBPs TDP-43 and FUS cause forms of ALS and FTD, and recent research 
has implicated RBPs in the pathogenesis of many other neurodegenerative 
conditions including SCAs, AD and HD (Conlon and Manley 2017). The role 
of RNA level pathology and RBPs in neurodegenerative conditions is 





discussed further in sections 1.3-1.4, and is investigated in Chapters 3 and 
4. 
Overall, investigations in this thesis focus on two of the most important 
molecular hallmarks of neurodegenerative disease which carry promising 
translational potential for therapeutic intervention. Firstly, Chapter 3 and 
Chapter 4 explore the role of RBPs, with specific focus on the novel role of 
Scaffold Attachment Factor B1 (SAFB1) in polyQ disorders. Secondly, 
investigations in Chapter 5 focus on mitochondrial dysfunction, a well-
established neurodegenerative disease hallmark, to identify novel 
pharmacological modulators of mitochondrial health and function. 
1.2 Polyglutamine disorders 
The polyglutamine (polyQ) disorders are a group of late-onset inherited 
neurodegenerative diseases caused by exonic CAG trinucleotide expansion 
and subsequent translation of pathological polyQ-containing protein (Table 
1.3). Although rare diseases, the impact of the nine known polyQ disorders 
is substantial and there are currently no curative or disease-modifying 
therapies available for any of the conditions (Lieberman et al. 2019). 
Although they are caused by CAG expansions in many different genes 
which confer relatively diverse clinical presentations, common pathological 
features of all the disorders include correlation between CAG repeat number 
and disease phenotype, instability of CAG repeat number, and aggregation 
of polyQ proteins (Ghosh and Tabrizi, 2018). 
Each polyQ disorder has a threshold number of CAG repeats above which 
disease symptoms occur (Table 1.3). It has been long established that an 
increasing number of CAG repeats correlates to earlier disease onset and 
increasing severity of clinical symptoms (Gusella and MacDonald 2000, 
Figure 1.2). As CAG expansions are located in exonic regions, the first 
stage of pathology is the transcription into expanded tandem repeat RNA 




of polyQ disorders is hypothesised to manifest at both the RNA and protein 
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Table 1.3 Neurodegenerative diseases caused by polyQ expansion repeats. 
Normal CAG refers to the physiological number of CAG repeats, Path. CAG refers 
to the number of CAG repeats associated with disease. A.D. autosomal dominant, 
DRPLA Dentatorubral-pallidoluysian atrophy, I.P. inheritance pattern, SBMA 






Figure 1.2 Relationship between age of onset of polyQ disorders and CAG 
repeat length. Data was obtained by Gusella and MacDonald (2000) by 
compiling literature searches and calculating mean patient age at disease onset 
before plotting best-fit curves. Filled circles represent age of onset for 
homozygotes, plotted according to the longest CAG expansion. Figure from 
Gusella and MacDonald (2000), reproduced with permission from Springer 
Nature under licence number 4845231063665. 
Figure 1.3 CAG expansion pathology is exerted at both the RNA and protein 
level. Exonic CAG repeat expansions are transcribed into xtrRNA (expanded 
tandem repeat RNA) which is translated into pathological peptides containing 
polyQ. Figure reproduced with adaptations from Rohilla and Gagnon (2017), 




1.2.1 Neuropathology of HD 
HD is caused by the autosomal dominant inheritance of an expanded CAG 
trinucleotide repeat in exon 1 of the HTT gene, which encodes the huntingtin 
protein (MacDonald et al. 1993). Huntingtin is highly expressed in the brain 
and is essential for normal development (Nasir et al. 1995). Despite its 
discovery nearly three decades ago, ongoing work continues to fully 
elucidate the exact functions of the huntingtin protein. Mutant huntingtin 
containing expanded amino-terminus polyQ tracts is highly aggregation 
prone (Labbadia and Morimoto 2013). Intracellular inclusions of huntingtin 
protein are found in the nucleus and cytoplasm of degenerating neurons 
where they may confer toxic gain of function (Labbadia and Morimoto 2013). 
Average age of onset of HD is 40 years with most patients diagnosed 
between the ages of 30 and 50, although mild motor disturbance and 
cognitive dysfunctions may precede diagnosis by many years (McColgan 
and Tabrizi 2017). HD is currently fatal, and death occurs on average 15-20 
years after symptom onset. HD is primarily classified as a movement 
disorder, with symptoms categorised as motor, cognitive or psychiatric. The 
dominant motor symptom is chorea, a term used to describe dyskinesia 
defined by abnormal rapid, irregular and involuntary movements. Chorea 
often develops into hypokinesia, rigidity and dystonia in later stages 
(Waldvogel et al. 2015). Motor symptoms are accompanied by 
neuropsychiatric and behavioural changes which can be highly distressing 
and difficult to manage, and manifest as both a direct consequence of 
neuronal degeneration and as a psychological response to living with the 
disease (Gray et al. 2013). Symptoms include agitation, anxiety, apathy, 
psychosis and sleep disorders (Anderson et al. 2018). The clinical 
symptoms of HD are caused by the selective degeneration of striatal 
dopaminergic neurons. 
The striatum is the largest nucleus of the forebrain basal ganglia. It is 
comprised of several individual structures, including the caudate nucleus 
and the putamen (together forming the dorsal striatum) alongside the 




striatum) (Rub et al. 2016). The striatum projects to the closely associated 
external and internal segments of the globus pallidus (GPe and GPi, 
respectively), basal ganglia nuclei which are responsible for regulation of 
voluntary movement. The caudate and putamen are separated by a white 
matter tract (the internal capsule) which is overlaid by numerous tracts of 
grey matter, giving the structure its striated, or striped, appearance. The 
striatum is responsible for motor action and planning, cognition and reward 
perception (Waldvogel et al. 2015). 
Over 95% of the striatal neuronal population comprises medium spiny 
neurons (MSNs), GABAergic inhibitory projection neurons which express 
D1 or D2 G-protein coupled dopamine receptors (Gerfen 2004). The 
striatum receives dopaminergic inputs from the cortex which converge onto 
D1 and D2-type MSNs which in turn form two efferent pathways, the direct 
pathway (mediated by D1) and the indirect pathway (mediated by D2). 
MSNs project to the basal ganglia, to either the substantia nigra or globus 
pallidus (Gerfen 2004). 
Initial hyperkinesia and chorea arise as a result of degeneration of indirect 
pathway MSNs (Plotkin and Surmeier 2015). This confers reduced inhibitory 
action on the GPe, consequently increasing inhibition on the subthalmic 
nucleus (STN). STN hypoactivity results in disinhibition of the thalamus 
through reduced inhibitory action of the GPi, ultimately resulting in motor 
cortex overactivation (Waldvogel et al. 2015). Direct pathway MSN neuronal 
loss induces the hypokinesia characteristic of later stage disease, caused 
by increased inhibition of the thalamus by the GPi, resulting in decreased 
motor cortex activation (Waldvogel et al. 2015).  
HD neuropathology is graded according to both gross and microscopic 
observations of the striatum from 0 to 4 using a system originally developed 
by Vonsattel et al. (1985) (Table 1.4). Macroscopic pathology manifests as 
bilateral atrophy of the striatum and the cerebral cortex (Waldvogel et al. 
2015, Figure 1.4A). On the microscopic level, striatal histopathology is 




astrogliosis. Astrogliosis is the response of astrocytes to pathological 
changes in the brain and is visible as an infiltration of small glial cell nuclei 
within the striatal neuropil (Figure 1.4B). The hallmark pathological 
inclusions in HD contain mutant huntingtin protein which accumulates in 
both the nuclei and cytoplasm of affected MSNs, forming various 
histological inclusion types (Herndon et al. 2009) (Figure 1.4C). HD striatum 
often exhibits clusters of dystrophic, degenerating neurons. Surviving MSNs 
may be morphologically normal, can appear shrunken (Waldvogel et al. 
2015) or conversely may demonstrate a ballooned appearance (Rub et al. 









Proportion of HD 
brains  
Grade 0 Indistinguishable 
from control brain 




Grade 1 Slight shrinkage 
of the striatum 
At least 50% loss 
of striatal neurons 
with RA 
4% 
Grade 2 Mild to moderate 
striatal atrophy 
Moderate-severe 
neuronal loss with 
RA 
16% 
Grade 3 Severe striatal 
atrophy 
Severe neuronal 
loss (less than 
95%) with RA 
52% 
Grade 4 Severe striatal 
atrophy 
At least 95% loss 
of striatal neurons 
with RA 
28% 
Table 1.4 Vonsattel grading of post-mortem striatum of HD patients. RA reactive 
astrogliosis. Information summarised from Vonsattel et al. 1985 and Waldvogel 
















There are currently no disease-modifying therapies available to patients 
with HD. Symptomatic medications are usually combined with physical, 
speech and occupational therapies to maintain patient quality of life for as 
long as possible (McColgan and Tabrizi 2017). Treatments which target the 
dopaminergic system have long been the mainstay of pharmacological 
treatment regimens. Anti-chorea medications counteract over activation of 
D2 indirect pathway circuitry either by blocking dopaminergic receptors or 
depleting presynaptic dopamine. Examples include haloperidol (a D2 
receptor antagonist) and tetrabenazine (a vesicular monoamine transporter 
2 (VMAT2) inhibitor which depletes synaptic monoamines) (Schwab et al. 
2015). However, current pharmacological treatment regimens are 
unfortunately associated with potentially serious side effects including 
exacerbation of depression (tetrabenazine) (Poon et al. 2010). Furthermore, 
development of current treatment regimens has largely focussed on 
amelioration of motor symptoms, leaving neuropsychiatric and non-motor 
manifestations largely untreated (Schwab et al. 2015). 
Taken together, this section demonstrates the devastating effect of HD and 
the substantial clinical need to further understand the neuropathology of HD 
in order to inform development of effective, disease-modifying therapies for 
current and future patients. 
Figure 1.4 (previous page) Gross and histological neuropathology of HD. A) 
Coronal brain sections at the level of the striatum and the nucleus accumbens 
from a control case and a patient with HD. Major shrinkage of the caudate 
nucleus (CN) and putamen (P) is apparent in the HD case (arrows). Figure 
reproduced with adaptations from Waldvogel et al. 2015, with permission from 
Springer Nature under licence number 4845250493940. B) Micrographs of HD 
striatum. a) Age-matched control striatum stained with haematoxylin and eosin 
b) HD striatum featuring reduced number of neurons and reactive astrogliosis. 
N=normal neuron, D=degenerating neuron, O=oligodendrocyte. c) HD striatum 
immunostained for GFAP highlights reactive astrogliosis (dark brown staining). 
d-f) immunostaining for polyQ using 1C2 antibody. PolyQ protein inclusions are 
present in the nuclei, cytoplasm and neurites of surviving striatal neurons. 
Figure reproduced from den Dunnen 2013 (CC BY 4.0). C) Staining patterns of 
polyQ inclusions in HD striatal neurons. Immunoreactivity with 1C2 antibody 
featuring (a) diffuse, (b) aggregated, (c) diffuse and aggregated nuclear staining 
and (d) diffuse, (e) aggregated and (f) diffuse and aggregated cytoplasmic 
staining. Scale bar is 20μm. Figure reproduced from Herndon et al. 2009, with 







1.2.2 Neuropathology of polyQ SCAs 
SCAs are a group of autosomal dominantly inherited neurodegenerative 
conditions characterised by degeneration of the cerebellum which causes 
coordination and balance problems (ataxia). Inherited SCAs are caused by 
mutations in specific genes which are most frequently conferred by point 
mutations or DNA rearrangements (found in SCA15, 16 and 20), or by 
trinucleotide repeat expansions (Sullivan et al. 2019). Expansion repeat 
mutations in non-coding regions cause SCA8, 10, 12, 31, 36 and 
Friedreich’s ataxia (FA) (Sullivan et al. 2019). Which is caused by an intronic 
GAA expansion in the frataxin gene. This thesis focuses on autosomal 
dominant SCAs caused by exonic CAG trinucleotide repeat expansions 
(SCA1, 2, 3, 6, 7 and 17). 
PolyQ SCAs are rare diseases which usually feature increased severity and 
shorter survival time in comparison to other inherited ataxias (Buijsen et al. 
2019). Prevalence data indicates that polyQ SCAs overall affect around 3 
in 100,000 people worldwide (Ruano et al. 2014). SCA3 is estimated as the 
most common type (Lieberman et al. 2019) whilst prevalence of some polyQ 
SCAs are extremely low, affecting <1 in 100,000 people (Buijsen et al. 2019, 
Table 1.5). 
All polyQ SCAs are clinically characterised by progressive ataxias of the 
trunk and extremities, gaze nystagmus, dysarthria and cognitive decline 
(Lieberman et al. 2019). Additional clinical characteristics are summarised 
in Table 1.5. Gait ataxia is usually the first identified symptom, but age of 
onset is variable, falling between 30-50 years, and has been demonstrated 
to correspond with the number of CAG repeats (Tezenas du Montcel et al. 
2014).  In some rare and severe cases, juvenile onset can appear in patients 
below 13 years of age (Zoghbi et al. 1988). Prognosis is poor after symptom 
onset, with patients typically dying between 10-30 years after diagnosis 
(Table 1.5). SCA1 typically features the most rapid disease progression 




Neuropathology of SCAs is complex and varied but in all cases 
involves cerebellar and brainstem degeneration (Figure 1.5A). The 
cerebellum is responsible for motor control and coordination as well as 
regulating some cognitive functions. It receives inputs from the spinal cord 
and projects efferent fibres to motor neurons of the cerebral cortex via the 
thalamic nuclei. Degeneration of cerebellar motor systems alongside spinal 
cord proprioceptive pathways leads to characteristic progressive ataxias 
(Koeppen et al. 2013). 
The external appearance of the cerebellum arises from the tightly folded 
cerebellar cortex, beneath which lies white matter containing the grey-
matter deep cerebellar nuclei (dentate, emboliform, globase and fastigi). 
The cerebellar cortex forms distinctive histological layers which are readily 
identifiable: the granule cell layer, Purkinje cell layer and molecular cell layer 
(Figure 1.5B) (Koeppen 2018). The cerebellar cortex is densely packed with 
granule cells, small glutamatergic neurons with bifurcated axonal 
projections (parallel fibres) which run through the cortical layer making 
connections with Purkinje cells. Purkinje cells are very large specialised 
GABAergic neurons with a highly distinctive appearance (Figure 1.5D). 
Their cell soma form the Purkinje cell layer of the cerebellum (alongside 
Bergmann glia). They project extensive dendritic processes into the 
cerebellar molecular layer (the outermost layer of the cerebellar cortex 
which also contains parallel fibres alongside inhibitory stellate and basket 
neurons) (Binda et al. 2020). 
The dentate nucleus (DN) is the largest of the cerebellar nuclei. It connects 
the cerebellum to the rest of the brain and is critical for the planning and 
control of voluntary movement (Koeppen 2018). It is highly convoluted and 
contains large principle neurons which mediate communication between the 
DN and the cerebellar cortex (Figure 1.5E). The cerebellar nuclei receive 





The neurodegenerative pattern of the cerebellum in polyQ SCAs varies 
between type and is summarised in Table 1.6. The relative extent of 
degeneration of the molecular layer (including Purkinje cells) and DN in 
various polyQ SCAs was previously compared to control patients by 
Koeppen et al. (2013) (summarised in Table 1.7). 
Loss and atrophy of Purkinje cells is characteristic, except in SCA3 where 
they are largely preserved (Koeppen et al. 2005). SCA2 usually features the 
most severe cerebellar cortical atrophy (Koeppen et al. 2018). Purkinje cell 
degeneration is characterised histologically by loss of cell number, reduction 
in cell soma size, and small nuclei with a “deflated” appearance. There is 
also simplification and thickening of the dendritic tree (Figure 1.5D). 
Proximal axonal swellings (known as torpedoes, Figure 1.5C) occasionally 
form in response to cerebellar injury and Purkinje cell stress in normal brain, 
and there is an increase in frequency of torpedoes associated with SCA 
(Louis et al. 2014). Torpedoes may not be apparent in cases with severe 
Purkinje cell loss. 
  
Disease 






SCA1 1 10-30 Spasticity, weakness, 
hyperreflexia, dysphagia 
SCA2 0.1-5.8 10-15 Postural tremor, 
hyporeflexia, chorea 
SCA3 1-2 6-29 Weakness, spasticity, 
Parkinsonism 





SCA7 <1 10-30 Retinal degeneration, 
akinesia, oculomotor 
disturbance 




Table 1.5 Prevalence, disease duration (from onset of clinical symptoms) and 
symptoms of polyQ SCAs. Additional clinical symptoms refer to those commonly 
manifesting alongside trunk and extremity ataxia, gaze nystagmus and 
dysarthria. Information summarised from Lieberman et al. 2018, Tezenas du 


















DN neuronal loss and synaptic degeneration is a major histopathological 
characteristic of most types of polyQ SCA. It is hypothesised that DN 
neuronal atrophy may be a result of transsynaptic degeneration caused by 
reduced Purkinje cell GABAergic input (Koeppen 2018). There is extensive 
neuronal loss and synaptic degeneration in the DN in SCA1, 2 and 7, with 
general preservation of this region in SCA6 and 17 (Koeppen et al. 2005, 
Tables 1.6 and 1.7). SCA3 exhibits a unique histological “grumose reaction” 
in the DN, a hazy staining visible with cresyl violet and 
immunohistochemical staining, associated with neuronal pathology 
(Koeppen et al. 2005). Mutated disease-causing proteins containing 
expanded polyQ tracts form both nuclear and cytoplasmic protein inclusions 
in neurons affected by SCA (Table 1.6). The precise role of these inclusions 
in pathogenesis is not fully understood but is discussed further in section 
1.3.1. 
Figure 1.5 (previous page) Gross and histological neuropathology of autosomal 
dominant SCA. A) Cerebellum and brainstem of a control case and a SCA1 
patient. The SCA1 case features (1) atrophic anterior lobe (AL), (2) atrophic 
posterior lobe (PL), (3) widened posterior fissure (PF), (4), widened 
postereolateral fissure (PLF), (5) enlarged fourth ventricle, (6) flattened pons 
and (7) atrophic medulla oblongata. Figure reproduced from Seidel et al. 2012, 
with permission from Springer Nature under licence number 4845251122833. 
B) Micrographs showing control and SCA cerebellum stained with haematoxylin 
and eosin. In the SCA case, there is significant loss of granule layer cells (GL) 
and loss of Purkinje cells (arrow). Figure reproduced from den Dunnen 2013 
(CC BY 4.0). C) Histological features of cerebellar degeneration in the Purkinje 
cell layer. i) Degenerating PC (longer arrow) associated with an axonal torpedo 
(shorter arrow). ii) Basket cell projections form “empty baskets” where Purkinje 
cells have been lost. iii) Bergman astrogliosis is apparent as dark brown 
staining. Figure reproduced with adaptations from den Dunnen 2013 (CC BY 
4.0). D) Immunofluorescent staining of Purkinje cells with anti-calbindin antibody 
in a control case and patient with SCA6. The SCA6 Purkinje cell has reduced 
cell body size, a shrunken appearance and simplification of the dendritic tree. 
Scale bar is 50µm. Figure reproduced with adaptations from Koeppen 2005, 
with permission from Springer Nature under licence number 4845260114693. 
E) Haematoxylin and eosin staining of the cerebellar dentate nucleus from a 
control case and an autosomal dominant SCA patient. There is severe depletion 
of large principle neurons (arrows) in disease. Figure reproduced with 
adaptations from Houlden et al. 2007, with permission from Springer Nature 




















SCA1 Cell loss, 
atrophy 
Neuronal loss  PolyQ positive nuclear 
inclusions in neurons 





Relatively small polyQ nuclear 








Small ubiquitin and polyQ 
positive nuclear inclusions in 
neurons 





Cytoplasmic PolyQ inclusions in 
Purkinje cells. Nuclear 
inclusions are very rare. 
SCA7 Cell loss, 
atrophy 
Neuronal loss Nuclear polyQ inclusions in 
neurons 





High abundance of nuclear 
inclusions in molecular cell layer 
and Purkinje cells. Inclusions 






Normal 0 0 
SCA1 9 14 
SCA2 15 9 
SCA3 0 13 
SCA 6 11 11 
Table 1.6 Neuropathological features of cerebellar degeneration in polyQ 
SCA. Cellular inclusions refers to intranuclear or intracytoplasmic bodies, 
positive for polyQ (1C2 staining) and/or ubiquitin. Summarised from Koeppen 
et al. 2005, Koeppen et al. 2013 and Rolfs et al. 2003. 
Table 1.7 Summary of representative neuropathological grading in normal and 
polyQ SCA cerebellum by Koeppen 2018. Pathology of the molecular layer 
(Purkinje cells) and DN (dentate nucleus) was graded for abnormalities on a 
scale of 0-3 (0=normal, 1=mild, 2=moderate, 3=severe). Numbers in the table 
are the combined total scores for the following immunohistochemical stains 
from one representative patient per diagnosis: Calbindin-D28k, NSE (neuron-
specific enolase), GAD (glutamic acid decarboxylase), VGluT1 (vesicular 




No drugs are approved for the specific treatment of polyQ SCA (Buijsen et 
al. 2019), and current treatment regimens are limited to supportive 
therapies, use of walking aids and home modifications (Opal 2017). 
Pharmacological treatment may be offered to alleviate some secondary 
symptomatic complications such as depression and pain (Opal 2017). 
Current research is aimed at developing disease-modifying therapies to 
prevent, halt or slow neuropathology.  
Current opinion indicates that effective future treatments will aim to reduce 
mutated RNA and protein containing pathological expansions (Paulson et 
al. 2017). Candidate disease-modifying drugs include AAV (adeno-
associated virus) mediated delivery of miRNA to prevent transcription of 
mutated genes, and in the case of SCA1, evidence for animal models 
indicates that an MSK1 inhibitor could reduce ataxin1 levels and alleviate 
pathology (Ashizawa and Paulson 2018). Overall, the polyQ SCAs are rare 
but devastating diseases with no approved treatments, indicating a large 
unmet clinical need to further investigate their molecular pathology and 
inform the development of disease-modifying therapies. 
1.3 Molecular pathology of polyQ disorders 
This section describes the current state of knowledge on the molecular 
biology underlying polyQ disease. Although characterised by their presence 
of neuronal polyQ protein inclusions, current research indicates an 
increasingly well understood role for CAG repeat xtrRNA. This section 
focuses on HD, the most common polyQ disorder, and polyQ SCAs, in 
particular SCA1, which features in the studies carried out in Chapters 3 and 
4. 
1.3.1 Protein-level pathology in polyQ disorders 
It has been long established that the histopathology of HD is characterised 
by inclusions of polyQ huntingtin protein which are found primarily in the 
nucleus but also the cytoplasm of degenerating MSNs (section 1.2.1). 




2009). More recently, the occurrence of mixed proteinopathies in HD has 
been discovered; 88% of HD patients with Vonsattel grade 4 
neuropathology were found to exhibit at least one non-huntingtin 
proteinopathy (St-Armour et al. 2018).  
Several hypotheses have been postulated to explain how polyQ huntingtin 
protein induces neurodegeneration, involving both loss and gain of function. 
There is evidence that altered protein folding, impaired protein degradation, 
mitochondrial dysfunction and disrupted neuronal circuitry may all be 
induced by the presence of mutant huntingtin (reviewed by Labbadia and 
Morimoto 2013). It is also hypothesised that the formation of neuronal 
inclusions of mutant huntingtin could be a cellular coping mechanism, rather 
than directly exerting neurotoxicity, as there is a disparity between the 
formation of aggregated protein and neurotoxicity in both animal models and 
patient tissues (Arrasate and Finkbeiner 2012). Disturbances to 
nucleocytoplasmic compartmentalisation have also been described in HD. 
Gasset-Rosa et al. (2017) demonstrated that polyQ huntingtin disturbs 
mRNA and protein transport between the nuclear and cytoplasmic 
compartments. Furthermore, this study discovered a role for compromised 
nuclear envelope integrity in polyQ pathology. More recently it has been 
hypothesised that huntingtin protein may spread inter-cellularly via a prion-
like mechanism within the brain (Tang 2018, Srinageshwar et al. 2020). 
In polyQ SCAs, it is hypothesised that misfolding and accumulation or 
aggregation of expanded polyQ proteins disrupts protein and RNA 
homeostasis. Some of the genes affected in polyQ SCAs are involved in the 
regulation of gene expression at the transcriptional and post-transcriptional 
level, so these processes would be disturbed by polyQ-induced loss of 
normal function. SCA1 is caused by mutation of the ATXN1 gene (Orr et al. 
1993, Banfi et al. 1994), which encodes a chromatin binding factor involved 
in RNA regulation (Tsai et al. 2004). Ataxin1 is also able to bind RNA in a 
manor dependent on the length of its polyQ tract (Yue et al. 2001). Like 




localisation sequence (NLS) motif and can shuttle between the nuclear and 
cytoplasmic compartments.  
Neurons of SCA1 patients were initially discovered to contain nuclear 
inclusions of aggregated expanded ataxin1 protein associated with the 
nuclear matrix (Skinner et al. 1997). A single amino acid substitution in the 
NLS was later found to prevent expanded ataxin1 entering the nucleus and 
eliminated toxicity (Klement et al. 1998), indicating a pathogenic role of 
expanded ataxin1 protein in the nucleus. Indeed, Irwin et al. (2005) 
discovered that ataxin1-mediated neurodegeneration was dependent on its 
nuclear localisation, and that pathologically expanded ataxin1 is unable to 
export from the nucleus where it forms inclusions dependent on the 
presence of RNA. Ataxin1 polyQ expansion does not necessarily lead to 
aggregate formation (Krol et al. 2008), supporting the lack of correlation 
between neuronal polyQ inclusions and disease progression in SCA1 
patients. 
Both wildtype and expanded ataxin1 protein interact with components of 
nuclear DNA. Importantly, ataxin1 interacts via its HBP1 domain with 
capicua (CIC), a DNA binding protein and transcriptional repressor (Lam et 
al. 2006). Mice expressing both pathologically expanded ataxin1 and a loss-
of-function CIC mutant had reduced cerebellar degeneration and fewer 
motor and cognitive deficits in comparison to mice with wildtype CIC (Fryer 
et al. 2011). Ataxin1 also binds the RNA splicing factor RBM17 (Lim et al. 
2008). It is hypothesised that ataxin1 enters the nucleus and readily binds 
CIC. The ataxin1-CIC complex then binds DNA, targeting chromatin and 
transcription sites. Ataxin1 may shuttle between complexing with CIC and 
RBM17, with polyQ expansion conferring a dynamic shift in favour of 
RBM17 over CIC complexing (Lim et al. 2008, Paulson et al. 2017). This 
hypothesis was recently further explored by Rousseaux et al. (2018), who 
demonstrated that the interaction of ataxin1 with CIC is critical for cerebellar 




1.3.2 RNA-level pathology in polyQ disorders  
Despite the research summarised above which explores the protein-level 
pathology of polyglutamine peptides in HD and polyQ SCAs, there is 
currently no causative evidence to demonstrate that any polyQ protein 
inclusions directly lead to neuronal degeneration. As genes containing 
polyCAG expansions are transcribed into xtrRNA, research is now leading 
us to further investigate the role of pathological RNA transcripts in the 
aetiology of polyQ disorders. 
RNA-level pathology mediated by repeat expansions is a well-established 
feature of several neurodegenerative diseases; in SCA8, non-coding 
trinucleotide expansions confer neuronal toxicity in the absence of 
expanded peptides (excluding the possibility of those generated by RAN 
translation). In addition, the most common genetic cause of ALS and FTD 
is intronic hexanucleotide expansions in the C9ORF72 gene, which causes 
formation of pathological sense and antisense repeat expansion RNA foci 
(Prudencio et al. 2015, Zu et al. 2013).  
There is a so-called paradoxical absence of polyQ protein inclusions in the 
Purkinje cells of many hereditary ataxia patients (Koyano et al. 2002). This 
could be explained by assuming that damaged cells with nuclear inclusions 
are more likely to degenerate and be lost before those without inclusions, 
although the authors conclude that their finding is more likely to point 
towards a lack of correlation between polyQ protein inclusions and Purkinje 
cell degeneration (Koyano et al. 2002). A study in Drosophila found that 
interspersing CAG repeat tracts with glutamine-encoding CAA codons 
lessens ataxin3 degeneration, indicating that CAG triplicate expansion 
confers specific neuronal toxicity at the RNA level (Li et al. 2008). More 
recently, it was discovered that targeting CAG expansion HTT RNA in-vivo 
with an antisense oligonucleotide reduced neurodegeneration, and this was 
independent of huntingtin protein levels (Rue et al. 2016).  Furthermore, a 
recent GWAS by Lee et al. (2019) demonstrated strong evidence that HD 
age of onset is determined by CAG repeat length, not polyglutamine length. 




altered cellular localisation, dysregulated splicing and protein binding (Marti 
2016). Some of these are further discussed below, with a focus on the 
aberrant interaction of CAG xtrRNA with RBPs. 
1.3.3 Structure of CAG xtrRNA 
Tandem repeats are naturally occurring simple sequence repeats within the 
genome comprising base pair motifs, usually up to six nucleotides long (Pan 
et al. 2018). Trinucleotide repeats are a form of this microsatellite DNA, 
located throughout the genome and most frequently formed of AAT, AAC 
and AAG codons. The presence of trinucleotide repeats affects the 
secondary structure of nucleic acids as defined by Watson-Crick base 
pairing. Whilst double stranded DNA forms double helices as a result of 
complementary base pairing, single stranded RNA transcripts may form 
multiple secondary structures. RNA often forms stem loops, also known as 
hairpin loops, comprising two stretches of base-paired nucleotides within 






Figure 1.6 Illustration representing the 2D secondary structure of a 
single strand of RNA forming a stem loop, comprising paired 





Trinucleotide repeats are categorised into four structural RNA classes 
(Sobczak et al. 2010, Figure 1.7). Whilst RNA G-quadruplexes are 
associated with a number of human diseases (Kharel et al. 2020), here we 
will focus on the role of CAG-repeat containing hairpin loops. Biophysical 
and thermodynamic characterisation confirmed that CAG trinucleotides with 
17 or more repeats form stable self-complimentary RNA hairpin structures, 
which are noted sites of interaction with RBPs (Sobczak et al. 2010). de 
Mezer et al. (2011) investigated the secondary structure of huntingtin mRNA 
in-vitro, determining that CAG expansion repeats alter secondary RNA 
structure, increasing the length of the hairpin loop. The same study also 
identified that CAG repeat expansion mRNA forms hairpin loops which 
accumulate in ribonuclear foci co-localised with RBPs.  
1.3.4 CAG expansion instability 
PolyQ diseases are often associated with genetic anticipation, whereby as 
a genetic disorder is passed down generations, an earlier age of onset and 
increase in severity is observed (Nestor and Monckton, 2011). This is 
caused by the instability of CAG repeats and their propensity to expand in 
length through the insertion of extra CAG codons. This often occurs through 
replication slippage, or during DNA repair or recombination (Kraus-Perrotta 
and Lagalwar 2016). 
Figure 1.7 Illustration representing secondary RNA structures of 
trinucleotide repeats. CAG repeats which cause polyQ disorders 





1.3.5 CAT interruptions 
Unexpanded CAG repeat tracts in ATXN1, ATXN2 and genes associated 
with fragile x-associated disorders are interrupted by other codons (Kraus-
Perrotta and Lagalwar 2016). For example, in wildtype ATXN1, tracts of up 
to 38 CAG repeats are interrupted by 1-3 CAT (histidine) codons, whilst 
mutated ATXN1 does not contain interruptions (Paulson et al. 2017). CAT 
interruptions regulate DNA and RNA secondary structure. In ATXN1 their 
inclusion inhibits replication slippage and destabilises hairpin structures, 
reducing the propensity of expanded CAG tracts to form long hairpins 
associated with pathogenesis (Sobczak and Krzyzosiak 2004). Interruptions 
can also change the secondary structure of RNA; in ATXN2, CAA 
interruptions induce formation of branched hairpins (Sobczak and 
Krzyzosiak 2005). As RNA secondary structure is important in mediating 
protein interactions (Sanchez de Groot et al. 2019), it is therefore possible 
that hairpin loop destabilisation by CAT interruption could alter transcript 
interaction with RBPs. It has been established that the number of CAT 
interruptions is critical in determining age of onset in SCA1 (Matsuyama et 
al. 1999), with age of onset inversely correlating to increased length of 
uninterrupted CAG stretch (Menon et al. 2013). 
1.3.6 RAN translation 
Repeat-associated non-ATG (RAN) translation occurs in the absence of a 
start codon and can be initiated in long hairpin structures of CAG repeats. 
This results in translation of additional proteins containing polyQ, polyserine 
or polyalanine repeats (Nalavade et al. 2013). RAN translation can also 
occur in the anti-sense direction, meaning that expanded CAG tracts can 
produce multiple potentially toxic transcripts (Pearson 2011). This 
mechanism may contribute to polyQ disease pathology as both sense and 
anti-sense RAN proteins accumulate in HD brains (Banez-Coronel et al. 
2015). RAN translation has also been described in SCA8 (Zu et al. 2011), 
fragile x tremor ataxia syndrome (Todd et al. 2013) and C9ORF72-
associated ALS (Ash et al. 2013). To date there is no evidence 




SCAs, but current opinion indicates that this is a potential disease 
mechanism (Paulson et al. 2017). 
1.3.7 Protein interactions of CAG xtrRNA 
Mutant xtrRNA transcripts have been previously shown to interact with 
RBPs which mediate critical cellular processes such as RNA processing 
(Osborne and Thornton 2006, Tsoi et al. 2012) and nucleocytoplasmic 
transport (Tsoi et al. 2011). The best well-characterised expansion repeat 
RNA-protein interaction is that between musclebind-like 1 (MBNL1) protein 
and CAU repeat RNA in DMPK transcripts, the mutation underlying type 1 
myotonic dystrophy (Ciesiolka et al. 2017). CAG expansion repeat RNA is 
known to sequester and interact with proteins (McLaughlin et al. 1996, de 
Mezer et al. 2011, Nalavade et al. 2013). Current well-supported opinion 
describes abnormal structure-dependent interactions of xtrRNA with RBPs 
as a key contributing factor to the pathogenesis of expansion repeat 
disorders (Ciesiolka et al. 2017). Many polyQ disorders are characterised 
by binding of specific proteins to xtrRNA or colocalization of proteins with 
xtrRNA focal aggregates, including HD and polyQ SCAs (Rohilla and 
Gagnon 2017). 
1.4 RNA binding proteins 
1.4.1 Structure and function of RBPs 
The human genome encodes at least 1500 RNA binding proteins (RBPs) 
(Dominguez et al. 2018) which are key mediators of transcriptional 
regulation. All RBPs contain at least one RNA binding domain (RBD) which 
facilitates direct interaction with RNA via van der Waals interactions, 
electrostatic bonds and hydrogen-bonding (Morozova et al. 2006). The 
“canonical” RBDs include RNA recognition motifs (RRM), zinc-fingers, K-
homology (KH), double-stranded RNA binding domains (dsRBD), Asp-Glu-
Ala-Asp (DEAD/DEAH) boxes and Pumillo homology (PUF) domains 
(Lunde et al. 2007). These are structurally well-defined and have been the 
most well-studied RBDs to date. RBPs are usually modular in structure 




binding specificity (Maris et al. 2005). Interdomain linker peptides allow 
flexibility of secondary structure to accommodate substrate interaction 
(Lunde et al. 2007). Short linker regions separating RRM domains are also 
directly involved in RNA binding (Daubner et al. 2013, Varadi et al. 2015). 
Previous work has described RBP “interactomes”, characterisations of 
RNA-protein interactions across whole genomes. For example, Castello et 
al. (2012) generated an atlas of HeLa cell mRNA-protein interactions using 
cross-linking and mass spectrometry. This work discovered that repetitive, 
unstructured protein sequences comprise motifs which frequently interact 
with mRNA substrates. The discovery of novel RNA-protein interactions is 
a dynamic and rapidly advancing field of research and more recently, there 
have been several RBPs discovered which do not contain a well-
characterised RBD (Beckmann et al. 2015 and reviewed by Hentze et al. 
2018). This indicates that RNA-protein interactions cannot always be 
predicted by protein sequence or structural analysis. 
Eukaryotic RNA processing in the nucleus involves 5’ capping, 3’ cleavage 
and polyadenylation, and splicing. The resultant functional mRNA is 
transported to the cytoplasm for further processing and translation. RBPs 
are important modulators of RNA processing, and regulate gene expression 
through transcription, mRNA stability, modulation of splicing and RNA 
transport and translation. They are usually multifunctional and often interact 
with other proteins as part of large macromolecular complexes, with multiple 
RBPs often interacting with individual RNA transcripts (Hegele et al. 2012). 
They bind transiently to their substrates to allow rapid assembly and 
disassembly of these complexes (Blanco and Montoya 2011), conferring 
highly dynamic control over RNA processing events. The interaction 
between RBPs and their RNA substrates also modulates the function, 
stability and localisation of the RBP itself (Hentze et al. 2018, Figure 1.8).  
There are estimated to be over 400 RBPs which also bind DNA, termed 
DNA-RNA binding proteins (DRBPs) (Hudson and Ortlund 2014). DRBPs 




binding of their DNA and RNA targets, by regulating gene expression at 
multiple levels (binding the promoters and RNA transcripts of a gene), and 
by simultaneously binding both DNA and RNA (Hudson and Ortlund 2014). 
The biology of DRBPs is especially interesting in the context of 
neurodegenerative disease because mutations in two DRBPs, transactive 
response DNA binding protein-43 (TDP-43) and fused in sarcoma (FUS), 
directly cause forms of ALS and fronto-termporal dementia (FTD). This sets 
a precedent for the involvement of RBPs in the pathology of 
neurodegenerative diseases, which is discussed in further detail below. 
1.4.2 RBPs in neurodegenerative disease 
RBPs modulate complex processes required for the function and survival of 
neurons, including RNA transcription, RNA transport, pre-mRNA splicing 
and translation (De Conti et al. 2017, Figure 1.9). Dysregulated RBP 
function is implicated in both sporadic and inherited neurodegenerative 
disease (Cookson 2017, Table 1.8), and current opinion indicates that RBPs 
are important in mediating protein aggregation as well as RNA dysregulation 
in a range of neurodegenerative pathologies (Maziuk et al. 2017). 
In this section the role of TDP-43 and FUS, two prototypical RBPs 
associated with neurodegenerative disease, are summarised. The 
Figure 1.8 Diagram summarising the functional crosstalk between RBPs and 
RNA. The interaction of an RBP with its RNA substrate is highly complex and can 
modulate the processing, modification, stability and localisation of both the RNA 
transcript and the RBP itself. Figure reproduced from Hentze et al. 2018, with 





increasing knowledge contributing to the role of RBPs in neurodegeneration 
is discussed, particularly relating to alterations in their neuronal expression. 
1.4.2.1 TDP-43 
TAR DNA binding protein 43 (TDP-43, encoded by the TARDBP gene) is a 
ubiquitously expressed and evolutionarily conserved DRBP. TDP-43 acts 
as a splicing factor and is involved in transcriptional repression and 
translational regulation (Conlon and Manley 2017). The critical role of TDP-
43 is exemplified by the embryonic mortality induced in knockout mice 
(Kraemer et al. 2010). In neurons, TDP-43 binds thousands of individual 
RNA transcripts and is critical for normal neuronal function (Sephton et al. 
2011, Sephton and Yu 2015).  
  
 
Figure 1.9 RBPs and their functions in neuronal metabolism. RBPs listed in red 
are predominantly or exclusively expressed in neurons. Many of these RBPs 
have been associated with neurodegenerative disease through altered 
expression levels, mutations or aberrant aggregation. Figure reproduced from 







RBP Function Associated diseases Ref. 




Orr et al. 1993, Irwin et al. 
2005 
Ataxin2 RNA binding Expansions cause SCA2 
and associated with ALS 
Imbert et al. 1996, 
Elden et al. 2010 




Most commonly mutated 
protein associated with 
FTD and ALS (GGGGCC 
hexanucleotide repeats) 
DeJesus-Hernandez et al. 
2011 





granules in PD. 
Mutations cause familial 
PD. 
Repici and Giorgini 2019 




with ALS. Deletion 
induces motor 
dysfunction in mice. 
Yoon et al. 2018 





Mutations cause ALS 
and rare familial FTD. 
Implicated in the 
pathology of HD. 
Kino et al. 2016 
hnRNP A1 Packaging of pre-
mRNA into hnRNP 
particles, mRNA 
transport 
Mislocalised to the 
cytoplasm in MS. TDP-




Salapa et al. 2018, 
Deshaies et al. 2018 
hnRNP A3 Cytoplasmic 
trafficking of RNA 
Present in inclusions in 
FTLD and ALS neurons. 
Sequestered to RNA foci 
in ALS. 
Cooper-Knock et al. 
2015, Davidson et al. 
2017 




with ALS. Mislocalisation 
of non-mutated protein 
causes neurotoxicity. 
Malik et al. 2018 
TAF15 Involved in RNA 




Neumann et al. 2011, 






with ALS and FTD. Also 
implicated in AD, HD, 
Lewy body dementia, PD 
and SCA. 
Kabashi et al. 2008, 
Kwiatkowski et al. 2009 
TIA1 Involved in 
induction of 
apoptosis 




Mackenzie et al. 2017, 
Apicco et al. 2018 






TDP-43 was identified as a component of neuronal cytoplasmic inclusions 
and dystrophic neurites in FTD and ALS (Arai et al. 2006, Neumann et al. 
2006).Intracellular inclusions of phosphorylated TDP-43 were also later 
identified in brain tissue of patients with AD and dementia with Lewy bodies 
(Arai et al. 2009). In addition to its hyperphosphorylated and ubiquitin 
positive state, pathological TDP-43 was further characterised as featuring 
nuclear depletion and aberrant post-translational cleavage (Arai et al. 2006, 
Neumann et al. 2006).  
It was later discovered that genetic mutations in TDP-43 are associated with 
rare familial cases of ALS and FTD (Kabashi et al. 2008, Kwiatkowski et al. 
2009). There are now at least 55 known TDP-43 mutations associated with 
familial ALS (Conlon and Manley 2017), alongside several rare mutations 
associated with sporadic ALS and FTD (Buratti 2015). Almost all known 
mutations occur in the C-terminal domain of TDP-43 and would not be 
expected to directly affect RNA binding (Buratti 2015). However, recent 
research identified a mutation in close proximity to the RRM domain which 
promotes cytoplasmic mislocalisation and aggregation of TDP-43 (Chen et 
al. 2019). Furthermore, the ability of TDP-43 to bind mRNA in the cytoplasm 
was found to be critical for its pathological function as a translational 
enhancer of specific mRNAs linked to neurodegeneration (Neelagandan et 
al. 2018). A systematic study of disease-associated TDP-43 isoforms was 
performed in Drosophila and chicks, revealing that the RNA binding function 
of TDP-43 is required for in-vivo neurotoxicity (Voigt et al. 2010). This finding 
is supported by further evidence for the mechanistic importance of the RNA 
binding function of TDP-43 in-vivo presented by Ihara et al. (2013) who 
expressed human TDP-43 containing disease-associated mutations in 
Drosophila to induce neurodegenerative phenotypes. Neuronal 
degeneration was abolished when the RRM domain of TDP-43 was mutated 
to ablate its RNA-binding function. Although the majority (at least 90%) of 
ALS cases are sporadic and only rare cases are associated with TDP-43 
mutations, TDP-43 proteinopathy is a feature of most ALS cases (Arai et al. 
2006), and also features in a diverse set of neurodegenerative diseases 




acquired functional abnormalities of wildtype TDP-43 in neurons underly its 
involvement in neurodegenerative pathology. 
1.4.2.2 FUS 
Fused in sarcoma (FUS) is one of the FET family of DRBPs which also 
includes EWSR1 and TAF15, originally discovered as oncogenes and now 
known to be associated with ALS (Kwiatkowski et al. 2009). In addition to 
ALS, mutations in FUS (for example in the NLS or DNA binding domain) 
can also more rarely cause familial FTD (Ederle and Dormann 2017). FUS 
has functional homology to TDP-43, being associated with many critical 
RNA processing functions such as pre-mRNA splicing, mRNA stabilisation, 
trafficking and translation, as well as DNA repair (Ederle and Dormann 
2017). In ALS, FUS becomes mislocalised to the cytoplasm where it forms 
pathological inclusions (Vance et al. 2009). 
In addition to their close association with ALS and FTD, the role of TDP-43 
and FUS in other neurodegenerative diseases has also been investigated. 
TDP-43 aggregates were found to co-localise with huntingtin inclusions in 
HD patient brain (Schwab et al. 2008).  In human cell lines, expanded 
huntingtin protein was found to induce the accumulation of phosphorylated 
TDP-43 (Coudert et al. 2019). Furthermore, FUS was previously shown to 
be a component of huntingtin aggregates in both a cell model (Doi et al. 
2008) and mouse model of HD (Kino et al. 2016). The latter study also 
identified that FUS acts as a modifier of polyQ disease pathology, whereby 
degenerative phenotype was worsened with heterozygous FUS knockout. 
Tauffenberger et al. (2013) also discovered that both FUS and TDP-43 
modified polyQ pathology in-vivo (in C. elegans), although their results 
conversely suggest that upregulating expression of the RBPs promotes 
polyQ toxicity. 
1.4.2.3 Implications of RBP mislocalisation in neurodegenerative disease 
Dysregulated nucleocytoplasmic transport of proteins is both a feature of 
normal ageing and an emerging mechanistic hallmark of neurodegenerative 




possible that protein mislocalisation in neurons could occur through 
increased or decreased export from the nucleus, pathological nuclear 
retention, dysregulated nuclear import, disturbance to nuclear envelope 
integrity or altered expression of nuclear receptors or transporters. 
Dysregulation in the binding partners of mislocalised proteins which 
facilitate their nucleocytoplasmic shuttling may also play an important role. 
Proteins associated with neurodegeneration which are also involved in 
nucleocytoplasmic mislocalisation were recently summarised by Hutten and 
Dormann (2019) (Figure 1.10).  
Control of protein subcellular localisation is especially important in the case 
of RBPs (Hutten and Dormann 2019), a number of which are featured in the 
summary in Figure 1.10. The RBPs FUS and TDP-43 are both 
predominantly expressed within the nucleus, and under normal conditions 
a proportion is expressed within the cytoplasm so that they can carry out 
Figure 1.10 Nucleocytoplasmic transport deficits in neurodegeneration. Protein 
deposits that aggregate in the nucleus or cytoplasm are listed in black/grey. 
Proteins depleted form the nucleus and localised to the cytoplasm are listed in 
black. Disorders listed in red have confirmed protein import/export deficits. Figure 
from. Figure reproduced from Hutten and Dormann 2019, with permission from 




cytosolic functions including regulation of mRNA stability, mRNA transport 
and translation (Birsa et al. 2019). In ALS and FTD, TDP-43 (and more 
rarely, FUS) become depleted from the nucleus and accumulate in the 
cytoplasm, conferring a loss of nuclear function and potential toxic gain of 
function in the cytoplasm (Gao et al. 2018). Mutations in the NLS of FUS 
which affect its shuttling are associated with ALS, and impaired nuclear 
import has been identified as a key mechanism in ALS pathology (Dormann 
and Haass 2011, Hutten and Dormann 2019).  
Mislocalisation of RBPs to both the nucleus and cytoplasm is now emerging 
as a more general mechanism of neurodegenerative disease. RBPs in the 
cytoplasm are often sequestered to stress granules, non-membranous 
aggregates comprising protein and mRNA molecules which assemble as 
part of the cellular stress response to supress the translation of non-
essential proteins (Baradaran-Heravi et al. 2019). The regulated formation 
of stress granules and their sequestration of RBPs may act as a protective 
mechanism in neurons by initiating controlled translational arrest, but 
aberrant redistribution of RBPs to the cytoplasm and accumulation of 
excess stress granules is likely to be an important pathological mechanism 
(Hutten and Dormann 2019). Stress granule formation is associated with 
the pathogenesis of several neurodegenerative diseases including ALS (Li 
et al. 2013, Chen and Liu 2017, Wolozin 2012).  
In addition to the prototypical examples of TDP-43 and FUS, many other 
RBPs have been described as mislocalised in neurodegenerative disease. 
As previously referred to, the pathological function of polyQ expanded 
ataxin1 is associated with its pathological retention in the nucleus. In 
addition, cytoplasmic redistribution of the RBP Matrin 3 was found to 
mitigate degeneration in primary neurons, indicating that nuclear Matrin 3 
mediates toxicity (Malik et al. 2018). EWSR1, a FET family RBP similar to 
FUS and TDP-43, was discovered to be as mislocalised to the cytoplasm in 
sporadic ALS cases (Couthouis et al. 2012). Further evidence of RBP 
mislocalisation is described by Salapa et al. (2018), who observed that 




although this study looked at only a single patient case. It is not always clear 
from descriptive or observational studies whether this abnormal expression 
is related to impaired nucleocytoplasmic transport, or if alternative 
mechanisms are implicated. 
Our research group is interested in the scaffold attachment factor B (SAFB) 
family of RBPs, which are emerging as important mediators of many cellular 
functions including the cellular response to stress (Norman et al. 2016). Like 
TDP-43 and FUS, SAFB proteins are DRBPs which contain RRM domains, 
are expressed in both the nucleus and the cytoplasm, they are important for 
RNA processing, critical for development and implicated in many aspects of 
neuronal function. 
1.5 Scaffold Attachment Factor B 1 (SAFB1) 
1.5.1 Discovery, structure and expression of SAFB1 
The SAFB family of DRBPs includes SAFB1, SAFB2 and SLTM (SAF-like 
transcriptional modulator). SAFB1 was initially discovered through its ability 
to bind nuclear scaffold/matrix attachment regions (S/MARs), DNA 
sequences which confer attachment of chromosomes to the nuclear matrix 
(Renz and Fackelmayer 1996). The same protein was independently 
discovered by two separate research groups: Weighardt et al. (1999) 
identified SAFB1 as a protein interactor of the RBP hnRNPA1, whilst 
Oesterreich et al. (1997) reported its interaction with the heat-shock protein 
(HSP) 27 promoter. SAFB2 was later discovered as a gene paralogue of 
SAFB1, with which it shares a bidirectional dual promoter and high 
sequence homology (Townson et al. 2003, Figure 1.11). SLTM, the third 
and more distantly related member of the SAFB family, was identified as an 
epithelial mesenchymal transition factor by Colley et al. (2002) and later 
characterised as a mediator of apoptosis (Chan et al. 2007). The 
investigations in this thesis focus primarily on SAFB1.  
SAFB1 is a large multifunctional protein which contains a characteristic AT-




binding (RRM) domain and a nuclear localisation sequence (NLS). A C-
terminal arginine-glycine rich motif (RGG or R/G domain) is the site of post-
translational modifications e.g. by methylation and sumoylation, conferring 
increased functional complexity (Golebiowski et al. 2009). SAFB1 is larger 
than, but similar in structure to RBPs associated with neurodegenerative 
disease such as TDP-43 and FUS, which also contain RRM and glycine-
rich domains, and N-terminal NLS (Figure 1.11). 
SAFB1 is expressed in tissues throughout the body but is enriched within 
the brain (Townson et al. 2003, The Human Protein Atlas (SAFB)), 
especially within the cerebellum and hippocampus (Rivers et al. 2015, 
Norman et al. 2016). In-house immunohistochemical characterisation 
demonstrates high SAFB1 and SAFB2 expression throughout the mouse 
brain including within the hippocampus, cortex, cerebellum and striatum 
(Figure 1.12). Characterisation of SAFB1 and SAFB2 expression in the rat 
brain confirms this distribution pattern, with high levels of both within the 
cerebral cortex, hippocampus, striatum and cerebellum (Hashimoto et al. 
2020). 
Figure 1.11 Functional domains of SAFB1, SAFB2, SLTM, TDP-43 and FUS. 
Black rectangles denote methylation sites. Red rectangles denote nuclear 
localisation sequence (NLS). Percentages indicate homology between SAFB1 
and SAFB2. Numbers indicate amino acid length of each protein. HS High 
similarity region, NES Nuclear export signal, R/E Arginine/glutamic acid-rich motif, 
R/G Arginine-glycine rich motif, RRM RNA recognition motif, SAP SAF-A/B, 




Despite their close structural homology, evolutionary retention of both 
SAFB1 and SAFB2 indicates functional distinction between the two proteins 
(Nadeau and Sankoff 1997). This differential function is also indicated by 
their subcellular distribution. Under baseline conditions in rodent cortical 
neurons, SAFB1 is expressed primarily in the nucleus whilst the distribution 
of SAFB2 is both nuclear and cytoplasmic (Norman et al. 2016, Hashimoto 
et al. 2020, Figure 1.13). This subcellular expression pattern is observed 
within primary cortical neurons in-vitro, as well as in mouse brain tissue 
(Figure 1.13). In HeLa cells, SAFB1 expression was observed as punctate 
within the nucleus with lack of expression within the nucleoli (Norman et al. 
2016). This distribution pattern is also observed in human fibroblasts (Figure 
1.13). 
1.5.2 Functions of SAFB1 mediated by protein interaction 
The extensive distribution of SAFB1 expression in the brain is indicative of 
its diverse and important functionality. The functions of SAFB1 are complex 
and involve RNA processing, regulation of transcription, alternative splicing, 
chromatin structure, DNA repair and nuclear stress body formation (Norman 
et al. 2016). Regulation of RNA processing is critical for the health and 
function of neurons, which are highly complex post-mitotic cells and 
extremely transcriptionally active (Andreassi et al. 2018).   
Figure 1.12 Expression of SAFB1 and SAFB2 visualised by 
immunohistochemical staining in various brain regions of wildtype mouse brain. 




SAFB1 has been shown to interact with many proteins including splicing 
factors, transcriptional-related proteins (including RNA polymerase II) and 
steroid receptors (Norman et al. 2016). A summary of the known protein 
interactors of SAFB1 was comprised by Norman et al. (2016) and is 
reproduced in Table 1.9 with the addition of more recently discovered 
interacting partners. Since the discovery that SAFB1 binds RNA polymerase 
II with high affinity (Nayler et al. 1998), it has also been shown to associate 
with splicing factors such as SRSF1 (Denegri et al. 2002). SAFB1 also 
interacts with SLM-1 (Stoss et al. 2004) and Sam-68 (Sergeant et al. 2007), 
members of the STAR family of proteins which regulate pre-mRNA splicing, 
RNA export and translation.  
Figure 1.13 The subcellular distribution of SAFB1 and SAFB2. Human primary 
fibroblasts, rodent primary cortical neurons and mouse cerebellar tissue was 
immunostained using antibodies specific to SAFB1 or SAFB2. SAFB1 is distinctly 
nuclear whilst SAFB2 is expressed in the nuclei and cytoplasm of cortical neurons 
and cerebellar Purkinje cells.  Images of rodent cortical neurons are reproduced 
with adaptations from Norman et al. 2016 (CC BY 4.0). Fibroblast and cerebellar 




Heterogenous ribonucleoprotein particles (hnRNPs) are nuclear RNA-
protein complexes which regulate RNA transcription and post-
transcriptional modification (Han et al. 2010). SAFB1 was demonstrated to 
interact with many of these proteins (Weighardt et al. 1999, Arao et al. 2000) 
but loss of co-immunoprecipitation of hnRNPs with SAFB1 in the presence 
of RNAse indicates that these interactions depend on binding to associated 
RNAs (Norman et al. 2016).  
SAFB1 colocalises with the transcription factor and oestrogen receptor ER-
alpha, mediating its association with the nuclear matrix and negatively 
regulating ER-alpha dependent transcription by influencing nuclear mobility 
of the receptor (Matsuda et al. 2018). The interaction of SAFB1 with ER-
alpha was recently confirmed by immunoprecipitation in the rat brain 
(Hashimoto et al. 2020). Additional recently published evidence 
demonstrated that SAFB1 interacts with LC3, which is required for its 
secretion within extracellular vesicles (Leidal et al. 2020).  
Interestingly, SAFB1 was shown to interact with FUS via its N-terminal SAP 
domain (Yamaguchi and Takanashi 2016). This interaction was 
demonstrated to tether FUS to chromatin, a function critical for the actions 
of FUS on RNA splicing and ligand-dependent transcription (Yamaguchi 
and Takanashi 2016). This demonstrates the importance of SAFB1 as an 
interacting partner with other RBPs and specifically with those directly 





1.5.3 Functions of SAFB1 mediated by nucleic acid interaction 
SAFB1 was first identified as a DNA binding protein, interacting with the 
nuclear matrix via its SAP domain (Renz and Fackelmayer 1996, Kipp et al. 
2000). More recently it was discovered that SAFB1 mediates DNA damage-
response signalling and is recruited to DNA double-strand breaks to 
facilitate repair (Altmeyer et al. 2013). Despite its discovery as a DNA 
binding protein, the study of nucleic acid binding functions of SAFB1 have 
so far primarily concerned its role as an interactor of RNA. The RRM domain 
of SAFB1 is likely to mediate its interaction with RNA, but the RGG domain 
may also be involved (Kiledjian and Dreyfuss 1992).  
 
Process Class Interacting proteins 
RNA processing 
SAFB proteins 
SAFB1/SAFB2 (homo- and 
hererodimerisation) 
hnRNP proteins 
hnRNPA1, hnRNPC, hnRNPD, 
hnRNPG, hnRNPI, hnRNPK, 
hnRNPU 
SR proteins 
SRSF1, SRSF7, SRSF9, 
SREK1, SRRM1 
SR protein kinase SRPK1 
STAR proteins Sam68, SLM-1 
TET proteins 
FUS (Yamaguchi and 
Takanashi 2016) 
E(R) proteins ERH (Drakouli et al. 2017) 
Chromatin  
CHD1, NCOR1, HDAC3, 
BRG1, Matrin 3 
Transcription  
RNA pol II, TAFII68, steroid 
receptors, p53 
Autophagy  LC3 (Leidal et al. 2020) 
Miscellaneous  PIAS1, ZO-2, Zbed4 
Table 1.9 Protein interacting partners of SAFB1. Table is reproduced with 





Mass spectrometry identified that SAFB1 directly binds mRNA (Baltz et al. 
2012). In addition to its interaction with protein-coding transcripts, SAFB1 
has been demonstrated to interact with various non-coding RNA (ncRNA) 
(Rivers et al. 2015, Hong et al. 2015). A key ncRNA mediated role for 
SAFB1 is in the cellular stress response, an orchestrated and evolutionarily 
conserved mechanism which has been characterised experimentally using 
heat-shock. Upon cellular stress, SAFB1 recruits to a locus encoding long-
non coding microsatellite DNA at the pericentromeric region of chromosome 
9 called satellite 3 (SatIII) where it recruits heat shock factor 1 (HSF1) 
(Denegri et al. 2002, Jolly et al. 2004). HSFs activate transcription of heat-
shock proteins (HSPs), molecular chaperones which facilitate protein 
folding and assembly. During the cellular stress response, the cell 
undergoes many adaptations with the most marked change occurring within 
the nucleus; release of proteins from the nucleoli induce its disintegration, 
and formation of characteristic nuclear stress bodies (nSBs) (Velichko et al. 
2013). nSBs are small electron-dense granules which form at the SatIII 
sequence. They are ribonucleoprotein complexes containing HSF1 and 
other associated RNA processing factors such as SRSF1 and RNA 
polymerase II (Velichko et al. 2013). Formation of nSBs alters cellular 
transcription to protect proteins and nucleic acids from the injurious effects 
of stress (Jolly et al. 2004). nSBs act as “molecular traps” sequestering 
constitutive splicing and transcription factors to temporarily prevent 
transcription and translation during stress (Weighardt et al. 1999, Norman 
et al. 2016). Recent research carried out in our lab has further characterised 
in detail the role of SAFB1 in the heat stress response (Raele 2020).  
Recently published work by Huo et al. (2019) showed that SAFB1 binds 
major satellite RNAs to regulate chromatin condensation and the 3D 
organisation of heterochromatin. The interaction of SAFB1 with repeat 
element RNAs was disrupted upon treatment with RNase, indicating that 
the interaction of SAFB1 with repeat element RNAs to regulate chromatin 




Individual nucleotide resolution cross-linking and immunoprecipitation 
(iCLIP) has been utilised to study the detailed interactions of SAFB1 with 
RNA in both human neuroblastoma cells (Rivers et al. 2015) and human 
breast cancer cells (Hong et al. 2015). In MCF-7 cells, SAFB1 cross-links 
were enriched at ncRNAs, intergenic regions and open reading frames as 
well as at intronic regions and 3’ and 5’ untranslated regions (UTRs) (Hong 
et al. 2015). This study also identified that SAFB1 interacts with and 
transcriptionally represses SHF (Src homology 2 domain containing F). SHF 
was previously described as a regulator of apoptosis (Lindholm et al. 2000), 
implicating a role for SAFB1 in regulation of programmed cell death. Indeed, 
redistribution of SAFB1 to the nucleolus, the site of extensive RNA 
processing, was discovered to be a critical step in the modulation of 
programmed cell death (Lee et al. 2007). Furthermore, overexpression of 
SAFB1 was previously shown to induce apoptosis (Norman et al. 2016). 
The RNA interaction profile of SAFB1 in SH-SY5Y cells was investigated 
using iCLIP by Rivers et al. (2015). Gene ontology analysis of RNAs 
interacting with SAFB1 indicated involvement in chromosome organisation, 
RNA processing, the cellular stress response and neuronal morphogenesis. 
The study discovered that the highest density of SAFB1 cross-link sites was 
found at exons in proximity to intron-exon boundaries, indicating an 
important role of SAFB1 in gene splicing. This role was confirmed by 
knockdown of SAFB1 which altered the splicing pattern of various genes 
including NCAM1, an important regulator of neuronal development and 
synaptic function (Rivers et al. 2015). Results from this study also 
demonstrated that SAFB1 regulates dendritic spine density of hippocampal 
neurons, further defining an important neuronal role for SAFB1. An RNA-
mediated neuronal function of SAFB1 is also indicated by a huge 
enrichment of SAFB1 tags at the ATXN1 gene, corresponding to both within 
and adjacent to the CAG repeat tract (Rivers et al. 2015). Pathological CAG 
expansions in ATXN1 cause the polyQ disorder SCA1, therefore this finding 





1.5.4 SAFB1 in disease and neurodegeneration 
The role of SAFB1 in-vivo was investigated by the creation of SAFB1 
knockout in mice, which induced embryonic lethality with surviving animals 
exhibiting significant growth and developmental deficits (Ivanova et al. 
2005). Interestingly, homozygous SAFB2 knockout mice are viable and do 
not exhibit the severe deficits induced in their SAFB1 knockout counterparts 
(Jiang et al. 2015). Deletion of the C. elegans homologue to SAFB1 affected 
eating behaviour and altered the lifespan of animals (Kumar et al. 2019) 
further indicating that the importance of SAFB1 in-vivo is evolutionarily 
conserved. 
The association of SAFB proteins with nuclear hormone receptors underlies 
past investigations which established an association of SAFB1 with breast 
cancer progression and its role as a tumour suppressor gene (Hong et al. 
2012). Although there are currently no known disease-causing mutations in 
SAFB1, mutations in the gene were previously discovered in primary breast 
tumour tissue (Oesterreich et al. 2001), and low SAFB1 expression levels 
have been associated with poor prognosis in breast cancer patients 
(Hammerich-Hille et al. 2010). 
As detailed in section 1.4.2, RBPs have been implicated in several 
neurodegenerative diseases. Dysregulation of RBPs is exemplified by 
mutations in TDP-43 and FUS which directly cause ALS and FTLD. SAFB1 
features several structural and functional similarities with both TDP-43 and 
FUS. Additionally, as mentioned above, SAFB1 was shown to directly 
interact with FUS (Yamaguchi and Takanashi 2016). 
Although the SAFB-associated cellular stress response is not yet 
understood in neurons (San Gil et al. 2017), it is known that HSPs are 
implicated in mediating neurodegenerative disease pathology. For example, 
protein misfolding of expanded polyQ huntingtin is ameliorated by HSF1, 
and HSF1 expression levels have shown to be decreased in in-vivo models 
of HD and in striatum from HD patients (Gomez-Pastor et al. 2017). As 




possible that SAFB1 may play a role in neuronal stress associated with 
neurodegeneration, although to date no studies have been carried out to 
provide direct evidence of this speculation. 
The discovery that SAFB1 directly interacts with ATXN1 RNA (Rivers et al. 
2015) provides evidence indicating a potential involvement of SAFB1 in 
SCA1, the condition caused by pathogenic ATXN1 CAG expansion. Taken 
together with the increasing evidence that RBPs are involved in 
neurodegenerative processes in diseases including polyQ disorders, there 
emerges a precedent for dysregulated binding of xtrRNA transcripts to 
nucleic acid binding proteins in the aetiology of polyQ degeneration. 
1.5.5 Hypotheses for Chapter 3 and Chapter 4 
In summary, the RBP SAFB1 is highly expressed in the brain and has 
functions important for neuronal and synaptic maintenance. SAFB1 is also 
critical for neuronal development and mediates the cellular stress response. 
The dysregulation of similar RBPs including TDP-43 and FUS in neuronal 
pathology set a precedent for the potential involvement of other RBPs such 
as SAFB1 in neurodegeneration. SAFB1 also directly interacts with FUS, 
further implicating a role in mediation of neurodegenerative pathology. The 
highly enriched interaction of SAFB1 with ATXN1 RNA at the site of 
disease-causing polyCAG expansion further supports the hypothesis that 
SAFB1 may be implicated in neurodegenerative disease. 
Taken together, these findings represent a growing body of evidence 
indicating that SAFB1 is associated with neurodegenerative disease, and 
specifically that it may play a role in the neuropathology of polyQ disorders. 
The expression of SAFB1 in human neurodegenerative disease has not yet 
been studied, therefore Chapter 3 investigates the expression of SAFB1 in 
human post-mortem brain tissue from patients with neurodegenerative 
disorders including polyQ SCA and HD. Chapter 4 builds upon this to further 
explore methods to investigate the role of SAFB1 in polyQ expansion 
pathology, and to examine the interactions of SAFB1 protein with CAG 




1.6 Parkinson’s disease 
The second part of this thesis (Chapter 5) focuses on mitochondrial 
dysfunction as a key hallmark of neurodegenerative disease, which is 
exemplified in the pathogenesis of Parkinson’s disease (PD) (Abou-Sleiman 
et al. 2006). 
1.6.1 Neuropathology and treatment of PD 
PD is the second most common form of neurodegenerative disease in the 
UK (Table 1.1). The average age of symptom onset is 55 years, but 
incidence increases markedly with age (Dauer and Przedborski 2003). PD 
is a debilitating disease characterised by disturbance to motor function. 
Clinical symptoms are caused by loss of dopaminergic neurons of the 
substantia nigra pars compacta (SNpc), resulting in massively reduced 
dopamine levels in the striatum. By the time symptoms become clinically 
apparent, up to 80% of dopaminergic neurons are already lost (Dauer and 
Przedborski 2003).  
The substantia nigra is a subcortical nucleus of the basal ganglia comprised 
of the pars compacta (SNpc) and pars reticulata (SNpr) which are important 
for regulating reward processes and motor control. The SNpc contains 
dopaminergic neurons which form the main output pathways of the 
substantia nigra, projecting into the striatum via the nigrostriatal pathway. 
The dark neuromelanin pigment within dopaminergic neurons of the SNpc 
give the structure its characteristic dark appearance (Kandel et al. 2013). 
The SNpc regulates movement by projecting excitatory input to the striatum 
via the D1 pathway, which in turn disinhibits the effect of the globus pallidus 
on the thalamic nucleus. Subsequent excitation of thalamocortical pathways 
stimulates cortical motor neurons to allow initiation of movement (Kandel et 
al. 2013). In PD, there is a loss of dopaminergic excitatory input to the 
striatum which results in decreased disinhibition of the globus pallidus and 
subsequently a reduced excitatory output from the thalamus to the motor 




tremor at rest, rigidity, slowness (bradykinesia) or reduction (hypokinesia) 
of voluntary movement, and postural instability (Postuma et al. 2015). 
Patients also suffer from impaired cognitive function which can develop into 
dementia, alongside mood disorders such as depression (Dickson et al. 
2009). 
Macroscopically, PD pathology presents as a loss of pigment in the 
substantia nigra caused by degeneration of neuromelanin-containing 
dopaminergic neurons. Histologically, surviving nigrostriatal neurons 
contain proteinaceous Lewy bodies within the cytoplasm. Smaller inclusions 
in neuronal processes (Lewy neurites) are also present, and both inclusions 
are ubiquitin-positive and composed primarily of alpha-synuclein (Dickson 
2012). 
Approximately 95% of PD cases are classified as sporadic with no clear 
genetic linkage (Dauer and Przedborski 2003). GWAS have identified single 
nucleotide polymorphisms (SNPs) associated with increased risk of 
developing PD including many in genes which affect mitochondrial and 
lysosomal function such as glucocerebrosidase (GBA) (Sidransky et al. 
2009), which has exclusively enriched expression in neuronal cell types 
(Nalls et al. 2019). Rare monogenic inherited cases of PD are associated 
with mutations in specific genes (Bras et al. 2015), discussed in further 
detail below (section 1.9.1.1). 
The selective vulnerability of dopaminergic neurons of the SNpc is not well 
understood. The formation of aminochrome during the oxidation of 
dopamine to neuromelanin could play a role in pathogenesis (Herrera et al. 
2017). Axonal arborisation has also been implicated to render dopaminergic 
SNpc neurons vulnerable to neurodegenerative damage in PD (Pacelli et 
al. 2015).  
There is currently no cure or readily available disease-modifying therapy for 
PD patients. The motor symptoms of PD are treated with dopamine 
replacement therapy, often delivered as levodopa or dopamine agonists 




cause side effects for example levodopa is associated with dyskinesias 
(Charvin et al. 2018). Overall there is an unmet clinical need to further 
understand the molecular pathology of PD to inform development of 
disease-modifying therapies. In Chapter 5, dysregulated mitochondrial 
function in neurons is further investigated as a key hallmark of PD and as a 
potential target for disease modification. 
1.7 Mitochondria 
1.7.1 Structure and function of the mitochondrial network 
Mitochondria are double membrane-bound organelles comprising of a 
central mitochondrial matrix, an inner mitochondrial membrane (IMM) which 
infolds to form cristae, and an outer mitochondrial membrane (OMM). 
Mitochondria contain maternally inherited mitochondrial DNA (mtDNA) in 
the form of nucleoids (circular double-stranded DNA complexed with 
protein) which encode 37 genes including 13 mitochondrial-specific proteins 
(Mishra and Chan 2014). The IMM and OMM are structurally and 
functionally distinct structures which surround the intermembrane space. 
The OMM is similar in composition to the cell membrane and contains 
various membrane-bound enzymes and many integral membrane proteins 
(porins) allowing the transport of molecules into and out of the organelle. 
The IMM contains specialist proteins comprising the electron transport chain 
(ETC) alongside specific transport proteins to regulate the selective 
movement of metabolites, and proteins which regulate mitochondrial fission 
and fusion (Labbe et al. 2014).  
Mitochondria exist within a dynamic network of organelles which undergo 
continual remodelling. Motility and trafficking of mitochondria within the 
cytoplasm is facilitated by OMM proteins such as Miro (Mitochondrial Rho 
GTPase, encoded by the RHOT1 gene) which associate with microtubules 
via adaptor protein complexes (Mishra and Chan 2014). Mitochondria are 
closely associated with other organelles especially the endoplasmic 
reticulum (E.R.) and lysosomes. The physical and functional association of 




damaged mitochondria via mitophagy, and dysregulation of this process is 
closely associated with neurodegenerative conditions such as PD (Audano 
et al. 2018). 
Mitochondria are required for cell survival. Key mitochondrial functions 
include oxidative phosphorylation, regulating levels of reactive oxygen 
species (ROS), mediation of apoptosis, and buffering of cytosolic calcium. 
The protein complexes of the ETC are responsible for the oxidation of 
nutrients to produce cellular energy in the form of ATP. Complexes I, III and 
IV pump protons across the inner mitochondrial membrane to establish an 
electrical potential between the cytoplasm and the mitochondrial matrix, 
described as the mitochondrial membrane potential, or mitochondrial 
polarisation. Protons flow back across this electrochemical gradient via ATP 
synthase (complex V), which uses the energy to generate ATP from ADP 
by phosphorylation. Loss of this proton gradient acts as a cellular signal for 
mitochondrial dysfunction. 
In addition to normal physiological function and cell survival, mitochondria 
are important in regulating pathological processes and programmed cell 
death. Mitochondria regulate apoptosis via the intrinsic pathway by 
releasing molecules which activate the apoptotic initiator caspase-9, and 
are also critical for the function of proapoptotic proteins such as Bax and 
Bak (Wang and Youle 2009). 
The mitochondrial permeability transition pore (mPTP) of the IMM is a non-
selective channel of undefined structure (Baines and Guiterrez-Aguilar 
2018). Channel opening induces massive release of calcium and other 
molecules below 1.5KDa (Narita et al. 1998), leading to mitochondrial matrix 
swelling, uncoupling of oxidative phosphorylation and eventual apoptotic or 
necrotic cell death. Pore opening has been associated with the 
pathogenesis of neurodegenerative diseases including AD, PD, HD and 
ALS (Kalani et al. 2018). For example, in PD pathological oligomeric alpha-
synuclein protein was shown to induce mPTP opening and cell death in 





1.7.2 Mitochondrial dysfunction and quality control 
Mitochondrial dysfunction is defined as abnormalities in the physiological 
processes of the mitochondrial network. This includes loss of mitochondrial 
membrane potential, uncoupling of oxidative respiration and altered ATP 
production, increased generation and dysregulated detoxification of ROS, 
dysregulated calcium homeostasis and altered mitochondrial trafficking and 
dynamics (biogenesis, fission, fusion and mitophagy) (Brand and Nicholls 
2011). 
The mitochondrial network exists in a state of balance to maintain overall 
cellular health and energy homeostasis (Figure 1.14A). In healthy cells, the 
balance is directed towards a network of properly functioning mitochondria 
which adapt appropriately to metabolic demands and regulate 
mitochondrial-associated cellular processes. Even under normal conditions, 
mitochondria are continually subjected to low levels of naturally occurring 
damage, for example as a result of exposure to ROS and as a part of normal 
ageing processes. This damage is offset by mitochondrial quality control 
systems which repair or remove damaged mitochondria (Sugiura et al 2014, 
Figure 1.15). In disease states including PD, an imbalance occurs as a 
result of increased exposure to mitochondrial damage and/or deficits in 
mitochondrial quality control mechanisms (Schapira 2012) (Figure 1.14B). 
This leads to pathological accumulation of dysfunctional organelles, 
resulting in loss of energy homeostasis and eventual cell death. 
Figure 1.14 (next page) Mitochondrial homeostasis in health and disease. A) In 
normal cells, the mitochondrial network is balanced towards a healthy and 
functional phenotype. Damaged and dysfunctional mitochondria are kept at low 
levels and either removed or restored. In disease states including 
neurodegeneration, pathological factors disrupt mitochondrial balance in favour 
of a damaged and dysfunctional phenotype. This leads to disruption of cellular 
energy homeostasis associated with neurodegeneration. B) Factors which 
control the balance of mitochondrial health and damage. Healthy mitochondria 
maintain an active membrane potential (ΔΨm) and carry out physiological 
functions critical for cellular survival such as oxidative respiration, calcium 
regulation and modulation of apoptosis. External stressors, mtDNA mutations 
and imbalances in quality control mechanisms can accumulate in non-dividing 
cells such as neurons, leading to build up of dysfunctional mitochondria. This 
results in dysregulation of cellular energy balance, increased ROS, release of 
pro-apoptotic factors and calcium imbalances associated with 
neurodegeneration. Physiological mitochondrial phenotype can be 










1.7.3 Mitochondrial dynamics 
The dynamic nature of mitochondria results in a highly complex, 
interconnected network of organelles which structurally and functionally 
interact not only with each other but with other organelles such as the E.R. 
and lysosomes (Bernard-Marissal et al. 2018). The mitochondrial network 
undergoes rapid and continual remodelling in response to cellular energy 
demands and cellular stress. Old or dysfunctional mitochondria are 
removed, and new organelles created by biogenesis. Mitochondria are also 
continually remodelled through fission (division of a single organelle into two 
or more separate mitochondria) and fusion (the combination of two or more 
organelles into a single mitochondrion) (Seo et al. 2010, Figure 1.16). 
Mitochondrial biogenesis in neurons usually occurs in the cell soma due to 
the requirements of co-ordinating complex interactions between nuclear 
and mtDNA gene products (Uittenbogaard and Chiaramello 2014). Newly 
synthesised mitochondria are then trafficked within the neuron to maintain 
energetic homeostasis. The processes of biogenesis and removal of 
damaged mitochondria through mitophagy are coupled through AMPK 
Figure 1.15 Diagram outlining the four main pathways of mitochondrial quality 
control. 1) Activation of mitochondrial proteases are a first-line defence against 
unfolded or oxidised proteins within the organelles. 2) Removal of damaged OMM 
proteins is mediated by ubiquitination and proteasomal degradation. 3) 
Components of more severely damaged mitochondria are removed by degradation 
in mitochondrial-derived vesicles (MDVs). 4) Irreparably damaged mitochondria 
undergo fission and are ubiquitinated before removal via LC3 expressing 
autophagosomes in PINK1/parkin dependent mitophagy. Figure reproduced from 







signalling (Palikaras et al. 2015), although the specific relation between the 
two processes in neurons is currently not understood. Disturbances in 
mitochondrial biogenesis may directly contribute towards development of 
mitochondrial dysfunction in neurons (Rugarli and Langer 2012), and recent 
research indicates that PD-associated mitochondrial damage reduces 
biogenesis (Lee et al. 2019a) whilst upregulation of biogenesis may 
counteract neuronal damage, indicating a potential mechanism for disease-
modification (Chuang et al. 2019, Weng et al. 2019).   
Mitochondrial fission and fusion are active processes which require several 
specialised proteins. Fission is mediated by a complex molecular machinery 
which includes Fis1, an OMM receptor for the cytosolic GTPase dynamin-
related protein 1 (Drp1). Fusion is also dependent on dynamin-related 
GTPases, in particular the mitofusins (Mfns) 1 and 2 of the OMM and optic 
atrophy 1 (OPA1), a GTPase associated with the IMM and intramembrane 
space (Scott and Youle 2010).  
The balance between the two processes regulates the morphology of the 
mitochondrial network, whereby increased fission promotes a high number 
of smaller, more rounded individual organelles and increased fusion results 
Figure 1.16 Under normal conditions, quality control of the mitochondrial 
network is maintained by continual re-modelling by fission, fusion, biogenesis 
and mitophagy. Figure reproduced from Seo et al. 2010, with permission from 




in highly interconnected networks of extended mitochondrial tubules (Scott 
and Youle 2010). In neurons, the mitochondrial network is elongated in 
dendrites and within the cell body but becomes more fragmented in axons 
(Popov et al. 2005). Neurons also require extensive mitochondrial trafficking 
machinery and mitochondrial quality control mechanisms to regulate axonal 
energy demands (MacAskill et al. 2010). 
Cycles of mitochondrial fission and fusion impart quality control. The 
importance of these processes in neuron survival are highlighted by 
inherited neurodegenerative disease; mutations in OPA1 (required for 
mitochondrial fission) cause dominant optic atrophy (Alexander et al. 2000), 
whilst GDAP1 mutations (encoding a protein important for mitochondrial 
fission) cause Charcot-Marie-Tooth disease 4A (Baxter et al. 2002). Fusion 
events are associated with baseline or low-stress conditions, whereas 
increased fission is an indication of stress within the mitochondrial network 
(Fischer et al. 2012). Moving the balance of mitochondrial dynamics towards 
increased fusion can be considered a rescue event against mitochondrial 
damage (Seo et al. 2010). Fusion promotes the mixing of mitochondrial 
protein and mtDNA within the cell, enabling mtDNA repair and redistribution 
of metabolites to maintain healthy mitochondria (Chen et al. 2007). 
Meanwhile, protective mechanisms prevent dysfunctional mitochondria 
from fusing with healthy ones. For example, loss of IMM potential causes 
proteolytic inactivation of OPA1 which halts membrane fusion (Head et al. 
2009). Fragmentation of mitochondria by fission may be a pre-requisite for 
the autophagic removal of mitochondria through mitophagy (Twig et al. 
2008), whilst stress-induced hyperfusion protects mitochondria against 
degradation and increases mitochondrial ATP production to promote cell 
survival (Gomes et al. 2011). Mitochondrial damage can induce imbalances 
in fission and fusion events. ROS induced stress results in fragmentation of 
the mitochondrial network and cell dysfunction (Wu et al. 2011). 
Furthermore, the mitochondrial toxins rotenone, MPP+ and MPTP (used to 
pharmacologically model Parkinson’s disease) all promote increased 






Repair of mitochondria can be achieved via regulation of mitochondrial 
dynamics or by selective degradation of damaged molecules in intact 
organelles (Roberts et al. 2016). Irreparably damaged mitochondria are 
removed by mitophagy to maintain cellular energy homeostasis and 
ameliorate mitochondrial dysfunction (Youle and Narendra 2011). 
Mitophagy is a mitochondrial-selective form of macroautophagy, 
characterised by the sequestration of damaged mitochondria into double-
membrane bound autophagosomes (Rodriguez-Enriquez et al. 2006).  
Autophagosomes are identifiable by their expression of LC3-II which is 
recruited to their membranes from the cytosol (Kabeya et al. 2000). 
Autophagosomes deliver damaged mitochondria to lysosomes, acidic 
membrane-bound vesicles characterised by expression of lysosomal 
membrane associated proteins (LAMP) 1 and 2 (Schwake et al. 2013). 
Lysosomal-autophagosomal fusion results in the degradation of 
mitochondria by lysosomal hydrolases.  
It is important to differentiate between basal mitophagy which is responsible 
for the continual turnover of organelles, and induced mitophagy which is 
activated as a protective stress-response mechanism under conditions of 
starvation, oxidative stress or mitochondrial damage (Martinez-Vicente 
2017). Three types of mitophagy have been previously characterised 
(Lemasters 2014). Type 1 occurs in response to nutrient deprivation and is 
dependent on PI3K signalling. Type 2 occurs following stress-induced 
mitochondrial damage and sustained depolarisation. Type 3 
(micromitophagy) involves formation of mitochondria-derived vesicles 
(MDVs) which transit into multivesicular bodies prior to lysosomal fusion. 
MDV formation occurs under baseline conditions and as an early response 
to oxidative stress, selectively removing damage macromolecules from 




1.8.1 PINK1/parkin mediated mitophagy 
Damage-induced (Type 2) mitophagy can be mediated by various OMM 
receptors facilitating direct interaction with LC3, or by indirect association 
with autophagosomes via IMM proteins such as cardiolipin (Martinez-
Vicente 2017). However, the best characterised signalling pathway in 
mammalian cells involves the ubiquitin ligase parkin, and the serine-
threonine kinase protein phosphatase and tensin homologue (PTEN)-
induced kinase 1 (PINK1) (Figure 1.17). Mutations in parkin (PARK2) and 
PINK1 (PARK6) cause autosomal recessive PD (Bras et al. 2015, Table 
1.10), highlighting the importance of this signalling pathway in maintaining 
dopaminergic neuronal health and function.  
Parkin-mediated mitophagy was first described by Narendra et al. (2008), 
and since this discovery extensive research has elucidated detailed insights 
into PINK1/parkin mediated signalling (as reviewed by Eiyama and 
Okamoto 2015). Figure 1.18 and Figure 1.19 summarise the stages of 
PINK1/parkin mediated mitophagy signalling. Parkin is a RBR (RING-
between-RING) type E3 ubiquitin ligase with several known splice variants. 
Parkin mediates the transfer of active ubiquitin from ubiquitin-conjugating 
UbE2 enzymes to target proteins on the OMM. Under baseline conditions, 
parkin exists in an auto-inhibited cytoplasmic form, with its N-terminal UBL 
(ubiquitin-like) domain blocking the E2 binding site. Activation of parkin 
results in its translocation to the OMM. This is triggered by phosphorylation 
Figure 1.17 Functional domains of PINK1 and parkin. MTS mitochondrial targeting 
sequence, TM transmembrane domain, IBR in between RING. Figure reproduced 







at ser65 which induces a conformational change, releasing the RING2 
domain and permitting binding of E2 ligases to the RING domain (Gladkova 
et al. 2018). This facilitates discharge of ubiquitin onto a catalytic cysteine 
in the RING2 domain, yielding a thioester intermediate which is then 
conjugated as ubiquitin onto the substrate protein. Recent work showed that 
parkin ubiquitinates mitochondrially-tagged artificial proteins, indicating it 
has low substrate specificity which is not determined by a consensus 
sequence (Koyano et al. 2019). 
PINK1 is responsible for the phosphorylation and activation of parkin, 
through both direct phosphorylation of parkin’s UBL domain at ser65, and 
by phosphorylation of cytosolic ubiquitin which subsequently activates 
parkin (Kane et al. 2014). PINK1 is ubiquitously expressed, and 
constitutively imported from the cytoplasm into the mitochondrial 
intermembrane space via translocase of the outer membrane (TOM) and 
into the mitochondrial matrix by translocase of the inner membrane (TIM). 
Under baseline conditions it is cleaved by presenilins-associated rhomboid-
like protein (PARL), an IMM protease, which inactivates and degrades 
PINK1 (Spinazzi and De Strooper 2016, Pickrell and Youle 2015). This 
results in rapid turnover of PINK1 at healthy mitochondria. 
PINK1 acts as a mitochondrial damage detector. Import of PINK1 via TIM is 
disrupted when mitochondrial membrane potential is lost (i.e. the IMM 
becomes depolarised), resulting in accumulation of uncleaved PINK1 at the 
OMM (Jin et al. 2010). Uncleaved PINK1 is free to activate parkin via 
phosphorylation. Once PINK1-activated parkin is localised to the OMM, a 
feed-forward loop of ubiquitination occurs with activated parkin linking 
numerous cytosolic and OMM proteins with K48- and K63-linked ubiquitin 
chains (Newton et al. 2008). Polyubiquitinated proteins coating the 
mitochondria are recognised by adaptor proteins (such as p62/SQSTM1) 
which facilitate connection of the damaged mitochondria to an 






Figure 1.18 PINK1/Parkin signalling mediates mitochondrial quality control by 
mitophagy. Schematic diagram illustrating PINK1-dependent parkin recruitment to 
the outer mitochondrial membrane of damaged/depolarised mitochondria, 
resulting in autophagosome recruitment and eventual degradation of damaged 





1.8.2 Induction and measurement of mitophagy 
Basal mitophagy is not readily apparent in cell lines under standard culture 
conditions and it is therefore necessary to experimentally induce mitophagy. 
This is often achieved pharmacologically using ionophores such as carbonyl 
cyanide m-chlorophenyl hydrazine (CCCP) or valinomycin. These drugs 
disrupt the ion gradient across the IMM, resulting in depolarisation of 
mitochondria and uncoupling of oxidative phosphorylation. Inhibitors of 
cellular respiration are also used to experimentally induce mitochondrial 
damage and subsequent mitophagy. Examples include antimycin A which 
binds to and inhibits cytochrome C reductase in the ETC, inhibiting ATP 
production. Rotenone inhibits the transfer of electrons from ETC complex I, 
inducing reduction of cellular oxygen to damaging ROS. 1-methyl-4-phenyl-
Figure 1.19 Flow diagram summarising the key stages of 




1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-4-
phenylpyridinium (MPP+) also inhibit complex I, likewise generating 
damaging free radicals and inducing mitochondrial damage by oxidative 
stress. Both rotenone and MPTP are used to induce Parkinsonian 
symptoms in animal models of PD. 
These pharmacological insults represent acute severe mitochondrial stress 
by inducing global damage to mitochondria. To more closely mimic 
mitochondrial damage as it might occur in disease, use of optogenetic tools 
to inactivate subsets of mitochondria has been reported. KillerRed is a 
fluorescent protein which produces high levels of ROS upon illumination. 
Expression of mitochondrial KillerRed in subsets of C. elegans neurons 
followed by in-vivo illumination results in specific disruption to neuronal 
function (Williams et al. 2013). It is also possible to induce a more mild 
pharmacologically-induced damage to subsets of organelles within the 
same cell by plating neurons across microfluidic chambers and restricting 
perfusion of drugs such as antimycin A to either cell soma or axonal 
compartments (Ashrafi et al. 2014). 
Experimental cell lines such as HeLa express almost no endogenous parkin 
(Denison et al. 2003). Parkin recruitment to mitochondria can readily be 
visualised and measured by expressing fluorescently-tagged parkin in 
cultured cells. As a straightforward system which is easily quantifiable, this 
technique is especially suitable for use in screening assays (Villace et al. 
2016, Scott et al. 2020). Although it represents a critical stage of mitophagy 
signalling, parkin recruitment alone does not offer direct measurement of 
mitophagy. Direct detection relies on measurement of mitochondrial 
targeting to autophagocytic vesicles or lysosomes. This is made possible by 
expression of specific fluorescently-tagged proteins; lysosomes can be 
visualised by expressing GFP-tagged LC3, whilst autophagosomes are 
identifiable by fluorescently tagging LAMP1. For example, quantification of 
GFP-LC3 vesicles and LAMP1/GFP-LC3 (late endosome/lysosome) 
overlap was utlilsed by Chandrachud et al. (2015) in a high-content 




Direct measurement of mitophagy in-vivo is possible through the expression 
of fluorescent reporter proteins with readouts dependent on the delivery of 
mitochondria to acidic lysosomal compartments (McWilliams et al. 2016, 
Rodger et al. 2018). The mito-QC mouse expresses a tandem mCherry-
GFP tag at the OMM, and mitochondrial targeting to lysosomes quenches 
the GFP signal (McWilliams and Ganley 2016). Keima is a fluorescent 
protein which has an excitation spectrum dependent on pH. Mitochondrial 
targeting of mt-Keima therefore allows detection of mitochondrial 
engulfment in lysosomes (Sun et al. 2015). These tools have been utilised 
to further understand the role of mitophagy signalling and mitochondrial 
dysfunction in complex neuronal systems. 
1.8.3 The role of mitophagy in neurons and in-vivo 
Neurons are highly dependent on balanced mitochondrial function and 
quality control systems. Maintenance of normal neuronal function is 
incredibly energetically “expensive”, with the brain requiring at least 20% of 
the body’s energy budget, most of which is utilised in synaptic transmission 
(Rolfe and Brown 1997, Harris et al. 2012). Furthermore, neurons contain 
extensive mitochondrial networks and generate energy almost entirely 
through oxidative phosphorylation (Rangaraju et al. 2014, Yamano et al. 
2016). Neurons have the most complex architecture of all cells in the body 
and form a highly polarised structure. Their extensively arborised axonal 
and dendritic projections require widespread transportation and 
maintenance of the mitochondrial network (Mandal and Drerup 2019). 
Furthermore, neurons are differentiated, post-mitotic cells which do not 
divide and therefore must remain functional throughout the entire lifespan 
of the organism. This necessitates precise control over mitochondrial quality 
through biogenesis, fission/fusion cycles and mitophagy (Corti 2019). 
The majority of studies which established our understanding of mammalian 
mitophagy use in-vitro immortalised cell lines, raising questions about the 
relevance of these findings in post-mitotic neurons or in-vivo. Much work 
has been carried out in recent years to answer these questions. It was 




neurons in response to mitochondrial depolarisation (McWilliams et al. 
2018). Cai et al. (2012) report direct evidence of mitophagy in primary 
mouse neurons challenged with CCCP by demonstrating that parkin-
positive mitochondria are engulfed by lysosomal vesicles. When 
endogenous parkin expression was knocked down using RNAi in the same 
study, depolarised mitochondria accumulated within cells, indicating a role 
for mitophagy in clearing damaged mitochondria in neurons. Conversely, 
similar studies have reported absence of parkin recruitment to mitochondria 
and mitochondrial recruitment to autophagocytic vesicles (Van Laar et al. 
2011). Other recent evidence indicates that damaged mitochondria in 
neurons may be removed by parkin-independent retrograde transport as 
opposed to by mitophagy (Lin et al. 2017). Cultured dopaminergic neurons 
derived from human iPSCs and treated with mitochondrial toxins have been 
shown to recruit endogenously expressed parkin to mitochondria in a 
PINK1-dependent manner (Wang et al. 2011, Cai et al. 2012, Seibler et al. 
2011). Parkin also translocates to mitochondria in human iPSC-derived 
dopaminergic neurons challenged with CCCP or rotenone (Oh et al. 2017). 
It should be noted that these in-vitro studies utilise mitochondrial toxins such 
as CCCP, valinomycin or rotenone to induce global mitochondrial 
depolarisation and subsequent mitophagy, a severe stress scenario which 
is unlikely to occur in-vivo. Baseline mitophagy was observed in cultured 
hippocampal neurons via lysosomal mt-Keima accumulation, which was 
reduced when parkin or PINK1 expression was knocked down (Bingol et al. 
2014). Induction of a milder stress could more accurately represent the 
chronic mitochondrial dysfunction which occurs in neurodegenerative 
disease. To more closely mimic the removal of deploarised fragments of 
mitochondria, mt-KillerRed was used to induce selective ROS-mediated 
damage to mitochondria within rat hippocampal neurons which resulted in 
parkin recruitment and autophagosome formation (Ashrafi et al. 2014). 
In addition to the experimental study of neuronal mitophagy in-vitro, 
research efforts have focussed on further defining the role of mitophagy in-




in Drosophila by measurement of protein turnover (Vincow et al. 2013). 
PINK1-dependent mitophagy was later directly demonstrated by 
Cornelissen et al. (2018) using flies expressing mtKeima. This finding is 
supported by that of Kim et al. (2019) who also detected mitophagy in-vivo 
using the mtKeima model, and abolished mitophagy induction in response 
to hypoxic stress with knockdown of PINK1 or parkin using RNAi. 
Mice with either PINK1 or parkin knockout do not have dopaminergic neuron 
degeneration but do exhibit neurochemical abnormalities and evidence of 
mitochondrial dysfunction (Goldberg et al. 2003, Perez and Palmiter 2005, 
Gispert et al. 2009). Basal levels of mitophagy in the dopaminergic midbrain 
neurons of mito-QC mice has been demonstrated, but this was not altered 
with PINK1 knockout or parkin mutation (McWilliams et al. 2018, McWilliams 
et al. 2018a). In rats, knockout of PINK1 or DJ-1 induced 50% nigral 
dopaminergic neuron loss by 8 months of age, whereas rats with parkin 
knockout did not have any neuropathological changes (Dave et al. 2014). 
Models combining knockout of PINK1 or parkin with mitochondrial stress 
have also shown variable results, indicating a complex dynamic between 
mitophagy signalling and mitochondrial dysfunction. Parkin knockout mice 
which also accumulate dysfunctional mitochondria through accelerated 
generation of mtDNA mutations exhibit dopaminergic neuron death (Pickrell 
et al. 2015). In contrast, combining parkin deletion with knockout of a 
mitochondrial biogenesis transcription factor did not induce dopaminergic 
neuron loss, and parkin was found to be dispensable for the clearance of 
damaged mitochondria in these mice (Sterky et al. 2011). Further recent 
evidence for mammalian mitophagy in-vivo comes from the findings of Sliter 
et al. (2018). This research demonstrates that mitochondrial stress in-vivo 
induced by ether exhaustive exercise or mtDNA mutation triggers 
mitophagy which was directly measured in heart tissue and which was 
dependent on PINK1. This provides direct evidence for PINK1-dependent 
clearance of damaged mitochondria in-vivo, although this was 




In terms of clinical translation, PINK1/parkin dependent mitophagy has been 
of great interest to researchers in part due to the causative association 
between mutations in these genes and familial PD (discussed further in 
section 1.9.1.1). Ubiquitin phosphorylated at ser65 partially overlaps with 
mitochondrial and lysosomal markers and was upregulated in post-mortem 
brains of patients with neurodegenerative diseases (Fiesel et al. 2015), 
providing indirect evidence for PINK1/parkin mediated mitophagy in the 
human brain. This staining pattern in human brain was also observed by 
Shiba-Fukushima et al. (2017) in midbrain dopaminergic cells.  
Overall, in-vitro studies in immortalised cell lines which have been the 
mainstay in mitophagy research have been followed-up by several studies 
which collectively provide evidence that PINK1/parkin mediated mitophagy 
occurs in neurons in-vitro. However, this has not always been consistently 
replicated across studies. There is also a scarcity of evidence to 
convincingly directly demonstrate PINK1/parkin mediated mitophagy in 
mammalian neurons in-vivo. Drosophila and mouse studies indicate that 
PINK1/parkin-mediated mitophagy occurs at both basal levels and in 
response to stress in neurons in-vivo, but the exact role of this mitochondrial 
quality control mechanism and how it is regulated is still uncertain. 
The wider context should be considered, as mitophagy represents just one 
aspect of overall organelle-level mitochondrial quality control. Non-
mitophagic pathways alongside mitochondrial fission, fusion and biogenesis 
are likely to act in synergy with mitophagy to maintain overall mitochondrial 
health (Gustafsson and Dorn 2019). It is therefore important to recognise 
the contribution of various aspects of mitochondrial quality control and 





1.9 Mitochondrial dysfunction in PD 
1.9.1 Evidence for mitochondrial dysfunction and dysregulated quality 
control as a key pathological hallmark of PD 
Impaired biogenesis, altered mitochondrial dynamics and trafficking, 
defective mitophagy, ETC dysfunction, oxidative stress and calcium 
imbalance have all been implicated as contributing to mitochondrial 
dysfunction in PD (Park et al. 2018). This relationship has been confirmed 
by extensive genetic, molecular and clinical evidence. 
The earliest example of such evidence was the discovery that the 
mitochondrial toxin MPTP replicated the motor and non-motor symptoms of 
PD in seven drug users who had inadvertently administered the toxin 
(Ballard et al. 1985). This finding lead to the development of MPTP-induced 
neurotoxicity in animals as a model of PD. Later, post-mortem studies 
demonstrated reduced complex I activity in the substantia nigra of idiopathic 
PD patients (Schapira et al. 1989). Mitochondrial dysfunction was further 
demonstrated clinically by magnetic resonance spectroscopy revealing 
reduced ATP levels in the putamen and midbrain of both early and 
advanced stage PD patients (Hattingen et al. 2009). Genetics and molecular 
biology also contribute to the knowledge that mitochondrial dysfunction is a 
critical driver of PD pathogenesis. 
1.9.1.1 Evidence from clinical genetics 
Loss of normal function in genes important for mitochondrial function directly 
causes familial PD (Bras et al. 2015) (Table 1.10). The first gene to be 
associated with genetically inherited PD was PARK1 (SNCA) which 
encodes alpha-synuclein, a cytoplasmic protein involved in vesicular 
trafficking which is the main component of Lewy bodies. Increasing 
evidence now links alpha-synuclein pathology to mitochondrial dysfunction, 
for instance accumulation of alpha-synuclein is associated with increased 
ROS production in post-mortem PD brain (Devi et al. 2008). Furthermore, 
aggregated alpha-synuclein was shown to inhibit mitochondrial complex I 




Mutations in parkin were first linked to inherited PD in 1998 by Kitada et al. 
Shortly after, PINK1 mutations were discovered to cause hereditary early-
onset PD (Valente et al. 2004), providing evidence linking mitophagy 
dysfunction to disease pathogenesis in PD patients. Ongoing research is 
continually identifying various mutations in parkin, for example a recent 
study describes a ser65 deletion mutation discovered in two patients, which 
also induces parkinsonian phenotype in mice (McWilliams et al. 2018). 
The most common form of monogenetic PD is caused by mutations in 
LRRK2, and SNPs in this gene are a risk factor for development of sporadic 
PD (Bras et al. 2015). Extensive evidence links LRRK2 with mitochondrial 
function (reviewed by Singh et al. 2019). Mitochondrial impairment is a 
neuropathological feature of patients carrying the G2019S mutation in 
LRRK2 (Mortiboys et al. 2010). Mechanistic studies demonstrate that the 
same mutation promotes mitochondrial uncoupling (Papkovskaia et al. 
2012), excess mitochondrial fission (Ho et al. 2019), increased ROS release 
and impaired respiratory capacity (Walter et al. 2019). 
Other genes with PD-causing mutations include DJ-1, which binds 
mitochondrial complex I subunits (Hayashi et al. 2009) and is a negative 
modulator of mitophagy signalling (Joselin et al. 2012). DJ-1 deficiency also 
reduced mitochondrial membrane potential, decreased ATP levels and 
induced aberrant complex I assembly in neurons (Heo et al. 2012) as well 
as inducing defective mitochondrial morphology in patient cells (Irrcher et 
al. 2010).  Mutations in ATP13A2 cause juvenile-onset PD characterised by 
lysosomal and mitochondrial dysfunction (Park et al. 2015). Meanwhile, 
recent work has revealed that PD-causing mutations in the phospholipase 
PLA2G6 induces dopaminergic neurodegeneration via mitochondrial 
dysfunction (Chiu et al. 2019).  
In addition to genes which cause monogenic mendelian inheritance of PD, 
evidence for the critical role of mitochondrial function in PD pathogenesis 
emerges from the study of SNPs associated with increased disease risk. 




for development of PD (Sidransky et al. 2009, Gegg and Schapira 2016). 
Reduced GBA activity leads to deficits in autophagic-lysosomal functions, 
and GBA mutation was shown to induce early mitochondrial dysfunction in  
3D neurospheres, impairing clearance of damaged mitochondria (Moren et 
al. 2019). This indicates a further link between development of PD and 
mitochondrial quality control. A recent GWAS meta-analysis by Billingsley 
et al. (2019) identified that genes associated with mitochondrial function 
underly the heritability of sporadic PD, demonstrating robust evidence for 
the involvement of mitochondrial processes in PD pathogenesis. 
Finally, somatic mutations in mtDNA and mtDNA copy-number loss are 
known to contribute to mitochondrial dysfunction (Dolle et al. 2016). mtDNA 
does not contain histones and is around ten times more susceptible to 
mutations than nuclear DNA, with over 200 different mtDNA mutations 
reported in human patients (Schapira 2012). No mtDNA mutations have 
been discovered to directly cause PD, but deletions were shown to occur at 
higher levels in dopaminergic neurons of the substantia nigra in human 
tissue in comparison to other brain areas (Bender et al. 2006). 
1.9.1.2 Evidence from dopaminergic neuron vulnerability 
It is currently not understood why specific subsets of neurons in the brain 
degenerate in different neurodegenerative disease. As previously 
discussed, dopaminergic neurons of the SNpc have several traits which 
may render them vulnerable to pathologic changes in PD. Specifically, it is 
hypothesised that their extensive arborisation and metabolic profile may 
leave SNpc neurons especially vulnerable to imbalances in energy 
homeostasis caused by stress-induced mitochondrial dysfunction (Pacelli et 






The differential role of mitochondria throughout the brain was recently 
investigated by Fecher et al. (2019), who profiled mitochondria from specific 
cerebellar cell types, revealing distinctive mitochondrial composition within 
individual neuronal populations. This premise that mitochondrial-specific 
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Table 1.10 Selected genes associated with PD pathogenesis and their 
mitochondrial functions. A.D. autosomal dominant, A.R. autosomal recessive, 





phenotypes exist throughout the brain complements a previous study which 
demonstrated that reduced rates of mitophagy and increased numbers of 
defective mitochondria were present in mouse substantia nigra when 
compared to cortex (Diedrich et al. 2011). This further implicates 
dopaminergic mitochondrial phenotype as a risk factor for 
neurodegeneration. 
Interestingly, the most extensively arborised nigral dopaminergic cells in-
vitro were shown to contain elevated rates of mitochondrial oxidative 
phosphorylation and associated levels of pathological oxidative stress 
(Wong et al. 2019). Furthermore, parkin deletion in mouse dopaminergic 
SNpc cultures was shown to preferentially pathologically affect highly 
arborised DA neurons (Giguere et al. 2018). 
 
1.9.1.3 Evidence from patient cells and tissue 
In addition to the mitochondrial dysfunction associated with monogenically 
inherited PD, there is also evidence to demonstrate its importance in non-
familial (also called sporadic or idiopathic) PD, which accounts for the vast 
majority of cases. The genetic evidence presented by Billingsley et al. 
(2019) (section 1.9.1.1) clearly demonstrates the association between 
mitochondrial dysfunction and the aetiology of sporadic PD. Evidence from 
molecular biology using cells and tissues derived from PD patients further 
evidences the role of mitochondria in PD pathogenesis. 
Reduced mitochondrial biogenesis leading to decreased mitochondrial 
mass and altered respiratory function was observed in stem cells of patents 
with non-genetic Parkinsonism (Angelova et al. 2018). Furthermore, cells 
derived from the platelets of sporadic PD patients featured fragmented 
mitochondrial networks alongside increased Drp1 and decreased OPA1 
expression, evidencing a role for disease-associated imbalance of fission 
and fusion (Santos et al. 2015). There is also evidence to suggest altered 
mitochondrial respiratory function in non-familial PD. The activity of 
mitochondrial ETC complex I is downregulated and subjected to significantly 




2006). In a further study, neurons from patients with idiopathic PD had 
significantly reduced expression of mitochondrial ETC complexes I and II 
(Grunewald et al. 2016). Alongside the overall decrease in mitochondrial 
proteins in PD, a more recent study discovered that individual surviving 
dopaminergic axons and synapses in PD patient brain in fact expressed 
increased levels of complex I and IV and higher numbers of mitochondria 
compared to control brains. This indicates a pathological compensatory 
mechanism potentially associated with oxidative damage (Reeve et al. 
2018). 
Alongside evidence of altered mitochondrial dynamics and ETC function in 
PD patients, dysregulated mitophagy signalling has been demonstrated in 
PD brain tissue (Hou et al. 2018, Shaltouki et al. 2018).  Dopaminergic 
neurons differentiated from iPSCs of PD patients with parkin mutations have 
impaired mitophagy (Suzuki et al. 2017). In a separate study also using 
iPSC-derived dopaminergic neurons from familial PD patients, parkin 
mutations were found to induce mitochondrial dysfunction and imbalance in 
mitochondria-associated apoptosis (Konovalova et al. 2015). Using iPSC-
derived dopaminergic neurons, Hsieh et al. (2016) identified both disrupted 
mitophagy and impaired mitochondrial motility in both familial LRRK2 
associated and sporadic PD patient cells. 
Taking together the evidence from clinical genetics, animal models, patient 
tissue and patient-derived neurons, the importance of dysregulated 
mitochondrial dynamics and impaired quality control systems leading to 
mitochondrial dysfunction is clear. Modulation of the signalling pathways 
which control these processes could therefore be neuroprotective and 
represent a potential therapeutic approach in PD to ameliorate neuronal 
cellular stress caused by mitochondrial dysfunction (Schapira et al. 2014, 
Lee 2016, Gao et al. 2017).  
1.9.2 Modulation of mitochondrial health and function as a therapeutic 
approach to neurodegenerative disease 
Considerable efforts in recent years have been made investigating 




(Mortiboys et al. 2018). Indeed, selective modulation of mitophagy is 
currently regarded as one of the most promising approaches to developing 
neuroprotective therapies for disorders such as PD (Scrivo et al. 2018). 
Several potentially disease-modifying drugs for PD and other 
neurodegenerative conditions which target the mitochondrial system have 
been taken to clinical trials in recent years (Table 1.11). Although ongoing 
trials indicate promise for some drugs such as AZD3241, many compounds 
have unfortunately failed to translate into clinical efficacy for PD patients 
(Athauda and Foltynie 2015). A contributing  




carrier for ETC 
complex I and II 
Phase III demonstrated 
safety and tolerability but 




Phase III trial terminated 
due to lack of efficacy over 
placebo 




Phase III trial had no 
benefit over placebo (small 
sample size) 






No clinical efficacy in 
Phase II trial 






Clinical efficacy in PD 
patient motor symptoms in 





MPTP rodent models 
Tolerated in PD and MSA 
patients in Phase IIa trials 
Table 1.11 Summary of clinical trial outcomes for pharmacological 
disease-modifying therapies targeting mitochondrial dysfunction in 





factor may be that patients are not stratified enough to reflect the differential 
extent of mitochondrial dysfunction underlying their symptoms. An ongoing 
trial aims to develop a biochemical protocol for grouping PD patients based 
on mitochondrial biomarkers (SysMedPD, accessed January 2020). The 
results could have important implications for the way disease-modifying 
mitochondrially targeted drugs are tested in clinical trials in future and for 
the targeting of future disease-modifying therapeutics. 
1.9.3 Hypothesis for Chapter 5 
Taken together, sections 1.7-1.9 demonstrate the unmet clinical need for 
development of disease-modifying therapies and detail the importance of 
mitochondrial dysfunction in PD. The evidence demonstrating that the 
mitochondrial network offers a promising option for potential therapeutic 
intervention is also outlined. Identification and development of 
pharmacological modulators of the mitochondrial network, especially using 
repurposed drugs, offers timely therapeutic promise in the treatment of PD. 
In Chapter 5, an in-vitro phenotypic screen is developed and utilised for this 
purpose. 
1.10 Overall thesis hypotheses and aims 
Overall, this thesis aimed to investigate two important molecular hallmarks 
of neurodegenerative disease: RBP dysfunction and mitochondrial 
dysfunction. Chapters 3 and 4 hypothesise that the RBP SAFB1 is 
associated with the pathology of polyQ disease. Chapter 3 aimed to 
characterise the expression of SAFB1 in human tissue from patients with 
the polyQ disorders SCA and HD. Chapter 4 aimed to further investigate the 
potential mechanisms underlying the association of SAFB1 with the 
pathology of polyQ disorders. The second part of this thesis investigates 
mitochondrial dysfunction in neurodegenerative conditions such as PD. 
Chapter 5 hypothesises that novel modulators of mitochondrial function 
could be therapeutically useful and aims to use an in-vitro screening 
approach to identify novel pharmacological modulators of mitochondrial 




2. Chapter 2 
General Methods 
2.1 Overview 
This chapter provides descriptions of experimental procedures used in this 
thesis. Additional information relating to the experiments in Chapter 3, 
Chapter 4 and Chapter 5 can be found within the Methods section of each 
chapter. 
2.2 Materials and resources 
This section summarises the materials and resources used in this thesis. 
Recipes for reagents and solutions are listed in Table 2.1. Details of 
materials and resources can be found in Table 2.2. A list of the primary and 
secondary antibodies used in this study can be found in Table 2.3 and Table 






Reagent or solution Recipe (all chemicals from Sigma unless stated) 
Cell culture 
Media for H4 cells and HeLa 
cells 
High glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), 10% (v/v) foetal bovine serum (Thermo 
Fisher Scientific), 10mM l-glutamine, 100U/ml 
penicillin, 0.1mg/ml streptomycin 
Media for SH-SY5Y cells Dulbecco’s Modified Eagle’s Medium: Nutrient 
Mixture F-12 (DMEM/F12), 10% (v/v) foetal bovine 
serum (Thermo Fisher Scientific), 10mM l-
glutamine, 100U/ml penicillin, 0.1mg/ml 
streptomycin 
Media for primary human 
fibroblasts 
High glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), 1% (v/v) MEM non-essential amino acids 
solution, 10% (v/v) foetal bovine serum (Thermo 
Fisher Scientific), 10mM l-glutamine, 100U/ml 
penicillin, 0.1mg/ml streptomycin 
Media for Kolf2 iPSCs Essential 8 medium + supplement (Thermo Fisher 
Scientific)  
Media for plasmid DNA and 
siRNA transfections 
Opti-MEM Reduced Serum Media (Gibco) 
Media for Seahorse Mito 
Stress Test 
Seahorse XF DMEM medium, pH 7.4 (Agilent 
103575-100) freshly supplemented with 10mM 
glucose, 1mM sodium pyruvate and 2mM L-
glutamine 
Media for live cell imaging 20mM HEPES pH7.4, 137mM NaCl, 5mM KCl, 
2mM MgCl2, 1.5mM CaCl2, 5.6mM glucose, 1mg/ml 
BSA, 0.5mM NaH2PO4  
Media for hfNPC maintenance High glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen), F12 (Invitrogen) (DMEM/F12 
ratio: 3:1), 2% (v/v) Glutamax (Invitrogen), 2% (v/v) 
B27 supplement, 20 ng/ml fibroblast growth factor 
(FGF-2) (Peprotech), 20 ng/ml epidermal growth 
factor (EGF), 5μg/ml heparin, 100U/ml penicillin, 
0.1mg/ml streptomycin. 
Media for hfNPC differentiation High glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen), F12 (Invitrogen) (DMEM/F12 
ratio: 3:1), 2% (v/v) Glutamax (Invitrogen), 1% (v/v) 
N2 supplement, 100U/ml penicillin, 0.1mg/ml 
streptomycin. 
Western Blotting 
2x SDS Laemmli sample buffer 125mM Tris base, 20% (v/v) glycerol, 4% (w/v) 
SDS, 0.04% (w/v) bromophenol blue, pH 6.8, 
100mM DTT (added fresh) 
RIPA buffer 150mM sodium chloride, 50mM Tris-HCl pH 8, 1% 
(v/v) Triton-X 100, 1% (w/v) sodium deoxycholate, 
0.1% (w/v) SDS, protease inhibitors (11836170001 
Roche, 1 tablet per 10 ml added fresh) 
Running buffer 25mM Tris base, 250mM glycine, 0.1% (w/v) SDS 
Transfer buffer 48mM Tris base, 39mM glycine, 0.037% (w/v) SDS, 
20% (v/v) methanol 
 
  




Reagent or solution Recipe (all chemicals from Sigma unless stated) 
Immunostaining 
IHC wash buffer for FFPE 
tissue staining 
PBS (phosphate-buffered saline), 0.1% (v/v) Triton-
X 100 
IHC wash buffer for frozen 
tissue staining 
TBS (Tris-buffered saline), 50mM Tris-Hcl, 150mM 
NaCl, pH 7.4, 0.1% (v/v) Triton-X 100 
IHC wash buffer for cell 
staining 
PBS (phosphate-buffered saline), 0.1% (v/v) Triton-
X 100 
Mowiol mounting medium 
40% (v/v) Mowiol 4-88 (Millipore), 200mM Tris-HCl, 
pH 8.5 in glycerol 
Phosphate-buffered saline 
(PBS) 
137mM sodium chloride, 2.7mM potassium 
chloride, 10mM phosphate buffer solution (pH 7.4) 
Sodium citrate buffer 
10mM tri-sodium citrate in distilled water, pH to 6 
using hydrochloric acid, 0.05% (v/v) Tween-20 
RNA immunoprecipitation 
Cross-linking wash buffer PBS pH 7.4 + 0.02% (v/v) Tween-20 
Cross-linking coupling buffer 
0.2M Triethanolamine in PBS + 0.01% (v/v) Tween, 
(pH 9) 
Cross-linking quenching buffer 50mM ethanolamine in PBS + 0.01% (v/v) Tween 
Cross-linking elution reagent 0.2M glycine + 0.01% Tween (v/v) (pH 2.5) 
Lysis buffer 
50mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA, 1% 
(v/v) IGEPAL CA-630, 1 tablet/10ml protease 
inhibitor, 10 U/ml RNase inhibitor, 10 U/ml RNase-
free DNAse (inhibitors and enzymes added fresh) 
CRISPR 
Cas9 storage buffer  10mM Tris-HCl pH 7.4, 300mM NaCl, 0.1mM 









Reagent or resource Source Identifier/cat. # 
Antibodies 
Donkey anti-mouse Cy3 conjugated Jackson immunoresearch 715-165-151 
Donkey anti-rabbit IgG Cy2 conjugated Jackson Immunoresearch 711-225-152 
Donkey anti-rabbit IgG Cy3 conjugated Jackson Immunoresearch 711-165-152 
Donkey anti-mouse peroxidase-linked IgG GE Healthcare NA931 
Donkey anti-rabbit peroxidase-linked IgG  GE Healthcare NA934 
Goat anti-mouse Alexa Fluor 488 Invitrogen A-11001 
Goat anti-rabbit Alexa Fluor 555 Invitrogen A27039 
Horse anti-mouse/rabbit biotin conjugated Vector Laboratories PK-6200 
Mouse anti-polyglutamine Merck 5TF1-1C2 
Mouse anti-hyperphosph. neurofilament BioLegend  Smi-34 
Mouse anti-calbindin Abcam CB-955 
Mouse anti-alpha-tubulin Sigma T5168 
Mouse anti-FLAG Millipore F3165 
Mouse anti-TUBB3 BioLegend MMS-435P 
Rabbit anti-SAFB1 Bethyl IHC 00142 
Rabbit anti-SAFB1 Bethyl A300-811 A 
Rabbit anti-SAFB1 Invitrogen custom  AB1895 
Rabbit anti-SAFB2 Bethyl A301-112A 
Rabbit anti-SAFB2 Invitrogen custom AB1897 
Rabbit normal IgG Cell signalling technology 2729S 
Biological samples 
FFPE human tissue sections and frozen 
human tissue samples 
MRC Neurodegeneration 
Brain Bank 
See Chapter 3 
for ethics details 
FFPE human tissue sections (Cerebellar 
tissue from MS patients) 
Kind gift from Dr. Kevin 
Kemp, Univeristy of Bristol 
See Chapter 3 
for ethics details 
Commercial kits and assays 
DAB substrate kit Vector Labs SK-4100 
ECL Prime Western Blotting detection 
reagent 
Amersham RPN2236 
GoScript Reverse Transcription System Promega A5000 
mirVANA PARIS kit Invitrogen AM155 
P3 primary cell nucleofector kit Lonza V4XP-3012 
Pierce BCA Protein Assay kit Thermo Fisher 23225 
QuickStart HiFi PCR kit Roche 3553400001 
ReliaPrep RNA Cell Miniprep System Promega Z6010 
Seahorse XFp Cell Mito Stress Test Kit Agilent 103010-100 
SuperSignal West Pico PLUS substrate Thermo Fisher 34580 
Vectastain Elite ABC HRP kit Vector Labs PK-6200 
Wizard genomic DNA purification kit Promega A1120 
  






Reagent or resource Source Identifier/cat. # 
Experimental cell lines 
C1 control human fibroblasts 
Kind gift from Dr. Lucy 
Crompton, University of 
Bristol 
N/A 
H4 N/A N/A 
H4 eGFP-parkin 
Cell line created by Dr. 
Helen Scott 
N/A 
HeLa N/A N/A 
Kolf2 
Kind gift from Professor Nick 




SH-SY5Y N/A N/A 
SH-SY5Y eGFP-parkin 




Kind gift from Dr. Oscar 
Cordero-Llana, University of 
Bristol 
See Chapter 5 
for ethics details 
Oligonucleotides and plasmid DNA 
pEGFP-ATXN1-2Q Addgene 33239 
PEGFP-ATXN1-30Q Addgene 33238 
PEGFP-ATXN1-52Q Addgene 32492 
pcDNA1 Flag ATXN1[2Q] Addgene 33235 
pcDNA1 Flag ATXN1[30Q] Addgene 33236 





PCR primers ThermoFisher Scientific N/A 
Software 
INCell Analyzer Workstation GE Healthcare Version 3.7.1 
Fiji Image J Version 1.51r 




GraphPad Prism GraphPad Version 7.04 
ImageScope Aperio Version 12.3.3 
Image Studio Lite Licor Version 5.2 
Seahorse Wave  Agilent Version 2.6.1 
SerialCloner SerialCloner Version 2.6.1 
SnapGene Viewer SnapGene Version 4.3.4 











Alpha-tubulin T5168 Sigma Mono Mouse Western blot 1:2000 




FLAG F3165 Millipore Mono Mouse 
IF (cells) 1:500 
















Western blot 1:1000 
































Poly Rabbit IF (cells) 1:300 
TUBB3 MMS-435P BioLegend Mono Mouse IF (cells) 1:500 









Conjugation Cat. # Supplier Application Dilution 
Donkey Mouse Cy3 
715-165-
151(JIR) 
Stratech IF 1:300 
Donkey Rabbit Cy2 
711-225-
152(JIR) 
Stratech IF 1:300 
Donkey Rabbit Cy3 
711-165-
152-JIR 
Stratech IF 1:300 




























































Table 2.4 Secondary antibodies and their applications 




2.3 Cell Culture 
2.3.1 Human cell lines 
Human neuroglioma (H4), human neuroblastoma (SH-SY5Y) and human 
cervical carcinoma (HeLa) cell lines were used in this study. H4 and SH-
SY5Y cell lines which stably express eGFP-parkin were used in Chapter 5. 
All cells were maintained in a humidified incubator at 37oC, with 5% CO2. 
Cells were regularly tested for mycoplasma by PCR analysis of conditioned 
media, which determined that the lines were free of contamination. H4 cells 
and HeLa cells were maintained in high-glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma) and SH-SY5Y cells were maintained in 
DMEM/F-12 (Sigma), both supplemented with foetal bovine serum, l-
glutamine and penicillin-streptomycin (Table 2.1). For siRNA and plasmid 
transfections, cells were cultured in media without antibiotics. Cells were 
passaged when they reached confluency of approximately 80%, by 
harvesting with 0.5% (w/v) trypsin with EDTA. After inactivating the enzyme 
with complete media, cell suspensions were centrifuged at 1200rpm for 2 
minutes and the cell pellet quickly and gently resuspended in fresh culture 
media. Stock flasks were maintained by splitting cells in a ratio of between 
1 in 8 and 1 in 20 every 3-4 days. For experiments, H4 cell lines and SH-
SY5Y cell lines were used up to passage 20 and HeLa cells were used up 
to passage 25. Prior to seeding cells into plates for experimental assays, a 
sample of the cell suspension was stained with 50% trypan blue (v/v) and 
the viable cells counted using a standard haemocytometer.  
2.3.2 Transient transfection of human cell lines 
Cell lines were transiently transfected with either siRNAs to knockdown 
gene expression, or with DNA plasmids to induce gene expression. Cell 
lines were plated without antibiotics and transfected 24 hours later. In siRNA 
knockdown experiments, a non-targeting control (NTC) siRNA was 
transfected as a control on each plate. Plasmid DNA or siRNAs were diluted 
in Opti-MEM reduced serum media (ThermoFisher Scientific) and combined 




transfection reagent. The combined reagents were mixed gently and left to 
equilibrate for up to 15 minutes at room temperature. The resultant 
transfection mixture was added dropwise to cells, on top of a reduced 
volume of their usual growth media and the culture vessel rocked gently to 
mix. After transfection, cells were left for 6 hours in transfection media 
before carrying out a full media change. Cells were left for 48 hours post-
transfection before further use in experimental assays. 
2.3.3 Primary human cells 
Skin fibroblasts from a 49 year-old patient with no history of neurological 
disease were a kind gift from Dr. Lucy Crompton (School of Biochemistry, 
University of Bristol). Human fibroblasts were maintained in high-glucose 
DMEM with non-essential amino acids, foetal bovine serum, l-glutamine and 
penicillin-streptomycin (Table 2.1). Fibroblasts were grown in culture 
vessels or on glass coverslips coated in sterile 0.1% gelatin. 
2.3.4 Human induced pluripotent stem cells (iPSCs) 
Human iPSCs were a kind gift from the research group of Professor 
Nicholas Allen (School of Biosciences, Cardiff University). Undifferentiated 
iPSCs were maintained in E8 media (Gibco) in culture vessels pre-coated 
with vitronectin. Culture media was changed a minimum of every 48 hours.  
iPSC colonies were observed to ensure maintenance of stem-cell like 
morphology. When iPSC colonies were approximately 80% confluent, they 
were passaged by incubating in ReLeSR (stem cell technologies) at 37oC 
for approximately 3 minutes, until the edges of colonies began to detach 
from the culture vessel. The ReLeSR was aspirated leaving iPSC colonies 
adhered to the vessel. Dulbecco’s phosphate-buffered saline with no 
calcium or magnesium (DPBS) was gently washed over the culture vessel 
to lift the colonies, and the cell suspension centrifuged at 1000rpm for 3 
minutes. Supernatant was removed from the cell pellet, and colonies gently 
resuspended in E8 media. Cultures were typically split at a ratio of 1 in 6 by 
adding the resuspended colonies drop-wise into a new vitronectin-coated 




overly dissociated during passaging, 1µl/ml ROCK inhibitor (StemCell 
Technologies) was added to the media and removed after 24 hours. 
2.3.5 Human foetal neuroprogenitor cells (hfNPCs) 
hfNPCs were a kind gift from the research group of Dr. Oscar Cordero-
Llana, and were utilised with the technical assistance of Ms. Andriana Gialeli 
(University of Bristol). Human foetal tissue was collected from medical 
terminations of pregnancy with full donor consent, through the SWIFT 
human foetal tissue bank at Cardiff University and with ethical approval of 
the project from the local research ethics committee (SWIFT-RTB 46). 
hfNPCs were grown as neurospheres in non-adherent culture in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Invitrogen) with 
Glutamax, fibroblast growth factor (FGF-2) (Peprotech), epidermal growth 
factor (EGF) (Sigma) and heparin (Sigma) (Table 2.1). hfNPCs were 
cultured in flasks coated with or without poly-2-hydroxyethyl methacrylate 
(poly-HEMA). Growth medium was replenished twice a week, and the cells 
were mechanically passaged with a McIlwain tissue chopper. 
2.4 High-content florescent cell imaging and analysis 
2.4.1 High-content image acquisition 
Automated image capture of fluorescence in fixed and live cells was carried 
out using an INCell Analyzer 2200 (GE Healthcare). Cells were plated in 
black-walled 96-well plates (either Corning 3904 or Greiner 655090). The 
INCell Analyzer laser autofocus trace tool was used to calculate and set 
plate bottom height and thickness. Images were acquired using laser 
autofocus with power set between 10-50%. Two acquisition modes were 
utilised in this study: 2D imaging (image from a single focal plane with no 
post-processing) and 2D deconvolution imaging (image from a single focal 
plane with post-processing to reverse blurring caused by the objective). 
Images were capturing using either a 10x objective (Nikon 10x/0.45 NA Plan 
Apo, CFI/60), 20x objective (Nikon 20x/0.45, Plan Fluor, correction collar 0-




0-2.0, CFI/60). Details of the fluorescent excitation channels used for cell 























Nuclei Hoechst DAPI 390/18 432.5/48 
Cell  eGFP FITC1 475/28 511.5/23 
Cell MitoTracker Red Cy3 542/27 597/45 
Parkin eGFP FITC1 475/28 511.5/23 
Mitochondria MitoTracker Red Cy3 542/27 597/45 
Table 2.6 Excitation and emission wavelengths (nm) for fluorescence 




2.4.2 Quality control of high-content imaging 
The INCell Analyzer 2200 uses a laser autofocus to assess the location of 
interface between the bottom of the well and the liquid in the well, to identify 
the location of the biological sample and obtain an automatically focussed 
image. However, due to various factors (e.g. small imperfections in the wells 
from the manufacturing process) a small percentage of acquired images 
may be out of focus. The small size of the organelles of interest in this study 
(parkin puncta and mitochondria, which can be less than 1µm long), 
necessitate accurate segmentation by the analysis software. Images 
therefore were required to be of the highest possible standard of quality and 
focus. To avoid error caused by out of focus objects being inaccurately 
identified by the analysis software, images from each field were manually 
checked after acquisition and any wells which contained an image which 
was not in focus were removed from the final data set. An excess number 
of wells replicating each experimental condition ensured that the minimum 
number of well replicates was met per plate (see 2.8.2 Experimental 
replicates). 
2.4.3 High-content image analysis 
All images acquired using the INCell Analyzer 2200 were quantified using 
INCell Analyzer Workstation software (version 3.7.1, GE Healthcare). Cell 
analysis protocols were created within the Multi Target Analysis (MTA) 
mode. Pre-programmed algorithms within the software, designed to identify 
objects within cells (granularity assays) were modified to create assays to 
segment cellular organelles. Assays were used to quantify parkin 
recruitment, mitochondrial network morphology, MitoTracker Red CMX Ros 
fluorescence intensity and cell counts. A description of the individual MTA 
output measures utilised in this study can be found in Table 2.7. Details of 
the settings used for each Workstation analysis protocol can be found in 
Table 2.8, Table 2.9, Table 2.10 and Table 2.11. Data was outputted from 
the Workstation software as Microsoft Excel .xlsx files. Raw data files 
remained unedited, and summarisation of data was carried out within 





Segmentation MTA measure Description 
Nuclei Count Number of nuclei 
Cell Intensity Mean intensity of pixels within the 
cytoplasm region, in the cells channel 
Organelles Count Number of inclusions attributed to the 
cell 
Organelles Total Area Total area of inclusions attributed to the 
cell 
Organelles Distance to 
Nucleus 
Mean distance from the inclusion centre 
to the nucleus centre (averaged by all 
inclusions within the cell) 
Organelles Elongation Mean ratio of the short axis of the 
inclusion to the long axis of the inclusion 
(averaged by all inclusions within the 
cell). If the value is 1 then the object is 
center-symmetric (not elongated) 
Organelles Inclusion/Cell 
Intensity 
Ratio of the average pixel intensity 
within inclusions to the average pixel 
intensity in the cell region immediately 
adjacent to the inclusions (both 
intensities measured in the Inclusion 
channel) 
Table 2.7 Multi-target analysis (MTA) parameter descriptions as specified 



















Objective  10x 20x 
Fields per well  2 3-4 
Nuclei  
Channel DAPI DAPI 
Acquisition 2D 2D 
Segmentation Top-Hat Top-Hat 
Cells 
Channel FITC1 FITC1 






Channel FITC1 FITC1 






Channel N/A Cy3 
Acquisition N/A 2D 
Segmentation N/A Multiscale Top-Hat 
Reference 1 
Channel N/A FITC1 
Segmentation N/A Pseudo 
Reference 2 
Channel N/A Cy3 
Segmentation N/A Pseudo 
Key output 
measures 
Nuclei Cell count Cell count 
Cell N/A N/A 
Organelles 
% cells with >3 
organelles 





Organelles 1 N/A N/A 
  
Table 2.8 INCell Workstation MTA protocol settings for quantification of 
parkin puncta in compound testing experiments. *used for SH-SY5Y 














Objective  40x 20x 
Fields per 
well 
 4 4 
Nuclei  
Channel DAPI DAPI 
Acquisition 2D 2D 
Segmentation Top-Hat Top-Hat 
Cells 
Channel Cy3 Cy3 

















Channel N/A N/A 
Acquisition N/A N/A 
Segmentation N/A N/A 
Reference 1 
Channel N/A N/A 
Segmentation N/A N/A 
Reference 2 
Channel N/A N/A 
Segmentation N/A N/A 
Key output 
measures 
Nuclei Cell count Cell count 








Organelles 1 N/A N/A 
  
Table 2.9 INCell Workstation MTA protocol settings for quantification 





















































Minimum area (µm2) 100 100 60 
Sensitivity 80 70 50 
Cells (Multiscale Top-Hat) 
Area (µm2) 450 200 350 
Sensitivity 30 5 5 
Organelles (Multiscale Top-Hat) 
Minimum area 1 1 1 
Maximum area 5 3 3 
Number of scales 1 2 1 
Sensitivity/Advanced 
sensitivity 
5/1.95 1/2.3  8/2 
Detect  In the cells In the cells In the cells 
Organelles 1 (Multiscale Top-Hat) 
Minimum area N/A 2 N/A 
Maximum area N/A 11 N/A 
Number of scales N/A 1 N/A 
Sensitivity/Advanced 
sensitivity 
N/A 1/1.5  N/A 
Detect N/A In the cells N/A 
Filters 








Value False if ≤3 False if ≤3 False if >1.8 
Table 2.10 INCell Workstation MTA protocol settings for parkin 














Minimum area (µm2) 100 100 
Sensitivity 70 50 
Cells (multiscale Top-Hat) 
Area (µm2) 200 70 
Sensitivity 5 2 
Organelles 
Minimum area 1 1 
Maximum area 3 100 
Number of scales 2 1 
Sensitivity/Advanced sensitivity 1/2.3 1/1.4 
Detect In the cells In the cells 
Organelles 1 
Minimum area 2 N/A 
Maximum area 11 N/A 
Number of scales 1 N/A 
Sensitivity/Advanced sensitivity 1/1.5 N/A 
Detect In the cells N/A 
Filters 
Type N/A Threshold 




Table 2.11 INCell Workstation MTA protocol settings for 
mitochondrial assays. Mito H4 refers to mitochondrial 




2.5 Mitochondrial analysis 
2.5.1 Parkin recruitment assay 
Parkin recruitment to mitochondria was used to screen drug compounds for 
their effect on the mitochondrial network in-vitro. Briefly, H4 and SH-SY5Y 
cells stably expressing eGFP-tagged parkin plated in 96-well plates were 
fixed in 4% PFA and the cell nuclei stained with 1µg/ml Hoechst dye 
(Sigma). Under baseline conditions, eGFP-parkin appears diffuse 
throughout the cell cytoplasm. Upon induction of mitophagy by 
depolarisation of the mitochondrial membrane with CCCP, parkin is 
recruited to the mitochondrial membrane where it appears as small bright 
dots (puncta). The INCell Analyzer 2200 was used to image fluorescent 
signal from Hoechst (nuclear) channel and the eGFP (parkin) channel. The 
formation of parkin puncta was quantified using INCell Analyzer Workstation 
software. Details of the analysis protocol settings can be found in Table 
2.10. 
2.5.2 High-content imaging of mitochondria 
Mitochondria in live cells were stained with 100nM MitoTracker Red CMX 
Ros (ThermoFisher Scientific) for 1 hour at 37oC. MitoTracker Red enters  
mitochondria when the organelles maintain a healthy membrane potential. 
The dye is retained after fixation using 4% PFA. Cell nuclei were 
counterstained with 1µg/ml Hoechst. Mitochondria in cells were imaged 
using the INCell Analyzer 2200 using a 40x objective and 2D-deconvolution 
imaging. An analysis protocol was developed using INCell Analyzer 
Workstation software to segment mitochondria. Output measures of the 
shape and size of the mitochondrial network include the total mitochondrial 
cross-sectional area per cell, and a ratio measure of the elongation of each 
mitochondrial object. Details of the analysis protocol settings can be found 




2.5.3 MPP+ toxicity assay 
H4 eGFP-parkin cells grown in 96-well plates were treated with MPP+ iodide 
(Sigma) for 24 hours in the presence of kenpaullone (5µM) or vehicle control 
(DMSO). MPP+ iodide was dissolved in sterile distilled water and frozen in 
stock aliquots at -80oC until use. MPP+ was protected from light during use. 
Cells were stained with 100nM MitoTracker Red for 1 hour at 37oC, then 
fixed in 4% PFA and cell nuclei stained using 1µg/ml Hoechst. Plates were 
imaged using the INCell Analyzer 2200 and analysed using the INCell 
Workstation software to measure cell number and MitoTracker Red intensity 
within the cytoplasm (Table 2.11). 
2.5.4 Analysis of mitochondrial function in live cells 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
in live cells was measured using a Seahorse XFp analyser (Agilent). H4 
eGFP-parkin cells or SH-SY5Y eGFP-parkin cells were plated into 
Seahorse XFp microplates at a density of 15000 or 20000 cells per well, 
respectively. 24 hours later, cells were treated with kenpaullone (5µM) or 
vehicle control (DMSO) for 24 hours. In the presence of kenpaullone or 
DMSO, cells were challenged with CCCP (15µM) or DMSO for 2 hours 
before OCR analysis. A mitochondrial stress test assay was carried out 
using a Seahorse XFp Cell Mito Stress Test kit (Agilent). Cells were washed 
with assay medium (Seahorse XF DMEM medium supplemented with 
10mM glucose, 1mM pyruvate and 2mM L-glutamine) and kept at 37oC with 
no CO2 for 45 minutes before the assay. The mitochondrial stress test 
involves injecting selective inhibitors of the electron transport chain into the 
cell assay media. Cells were exposed to a final concentration of 1µM 
oligomycin, 2µM FCCP and 0.5µM rotenone/antimycin A. OCR was 
calculated using the standard Mito Stress Test protocol on the XFp 
analyser. Metabolic parameters were calculated from OCR data using the 
formulae in Table 2.12. After the assay, cell media was carefully removed, 
the cells gently washed once in PBS and 20µl RIPA buffer was added to 




used for quantification using a BCA assay (Pierce BCA assay kit). OCR was 
normalised to protein concentration in each well. 
 
2.6 Molecular biology 
2.6.1 Gene knockout using CRISPR-Cas9 
Knockout of the SAFB1/2 dual promoter in human iPSCs was carried out 
using the CRISPR-Cas9 system. In brief, guide RNAs (gRNAs) 
complementary to sequences flanking the promoter sequence were 
combined with a fluorescent tracer RNA (tracrRNA). Cas9 protein was 
combined with the gRNA/tracrRNA complex to make the ribonucleoprotein 
(RNP) complex. iPSC colonies were treated with ROCK inhibitor and 
dissociated to a single cell suspension. One million cells were nucleofected 
with the RNP complex by electroporation and allowed to recover overnight. 
Individual cells were sorted by FACS (fluorescence activated cell sorting) 
and cells in the top 10% of fluorescence intensity were plated to form clonal 
Parameter Value Equation 





(Maximal respiration) – (Basal respiration) 
Maximal Respiration (Maximum rate measurement after FCCP injection)-
(Non-mitochondrial respiration) 
ATP Production (Last rate measurement before oligomycin injection) – 




Minimum rate measurement after rotenone/antimycin A 
injection 
H+ (Proton) Leak (Minimum rate measurement after oligomycin injection) 
– (Non-mitochondrial respiration 
Table 2.12 Seahorse XF Cell Mito Stress Test parameter formulae. Table 





iPSC colonies. Individual colonies were screened for promoter knockout by 
PCR and the deletion confirmed by Sanger sequencing. 
2.6.2 Genomic DNA extraction 
Genomic DNA was extracted from cells using a Wizard Genomic DNA 
Purification Kit (Promega) according to the protocol for Tissue Culture Cells. 
Cells were harvested and pelleted before washing in PBS, and the 
manufacturer’s protocol followed. For PCR screening of iPSC colonies, 
genomic DNA was extracted using DNA QuickExtract solution (Lucigen) 
according to manufacturer’s instructions. Samples were stored at -20oC until 
use. 
2.6.3 RNA extraction and purification 
RNA from frozen human tissue was extracted using a mirVana PARIS kit 
(Life Technologies) according to manufacturer’s instructions. RNA from 
precipitated immunocomplexes and protein lysates from the RNA 
immunoprecipitation protocol were purified using a ReliaPrep RNA cell 
miniprep kit (Promega). Immunocomplexes bound to Proten G magnetic 
beads (Dynabeads, ThermoFisher) were mixed with 250µl of fresh BL+TG 
buffer, vortexed and left to stand for 10 minutes at room temperature. The 
bead supernatant was then used in the kit manufacturer’s protocol. Protein 
lysates were pre-mixed with BL+TG buffer before freezing, or freshly mixed 
with BL+TG buffer, before standing at room temperature for 10 minutes and 
proceeding with the manufacturer’s protocol. RNA samples were handled 
with RNase-free plasticware and reagents, were kept on ice at all times and 
were stored at -80oC. 
2.6.4 Reverse transcription 
Reverse transcription of RNA into cDNA was carried out using a GoScript 
Reverse Transcription System kit (Promega) according to manufacturer’s 
instructions. A maximum of 4µl RNA was added to 1µl of random primers or 
Oligo(dT) primers and incubated at 70oC for 5 minutes before immediately 




according to the kit protocol and 15µl added to each RNA/primer sample. 
Reactions were annealed at 25oC for 5 minutes, extended at 42oC for 1 hour 
and transcriptase was inactivated at 70oC for 15 minutes. cDNA was stored 
at -20oC.  
2.6.5 Quantification of DNA and RNA 
RNA, gDNA, cDNA and plasmid DNA was quantified using either a 
NanoDrop 2000 spectrophotometer (ThermoFisher Scientific) or an Implen 
Nanophotometer (GeneFlow) using a minimum of 1µl of sample.  DNA with 
an A260/A280 ratio of at least 1.8 and an A260/A230 ratio of 2-2.2 was used 
in experiments. RNA with an A260/A280 ratio of at least 2 and an 
A260/A230 ratio of 2-2.2 was used in experiments. 
2.6.6 Quantitative PCR (qPCR) 
cDNA was used in qPCR reactions neat or diluted 1:10. A qPCR mastermix 
was made using Power SYBR Green (ThermoFisher Scientific) including a 
final concentration of 300nM of forward and reverse primers. qPCR was 
carried out using a StepOnePlusTM Real Time PCR system (Thermo Fisher 
Scientific) using a default 2-hour PCR protocol. Sequences for qPCR 
primers can be found in Table 2.5. 
2.6.7 Protein extraction from cells 
Cell culture media was removed and cells washed in ice-cold PBS. PBS 
was removed and cell lysis buffer (typically RIPA buffer) added, and the 
cells scraped on ice to lyse the cells. Lysate was mixed on a rocker for 20 
minutes at 4oC before centrifuging at 14,000rpm at 4oC for 15 minutes. The 
cell debris pellet was discarded and the protein supernatant stored in a fresh 
microtube at -80oC until use. 
2.6.8 Protein extraction from tissue 
Protein extraction from frozen human brain tissue was carried out using a 
mirVana PARIS kit (Life Technologies) according to manufacturer’s 




2.6.9 Protein quantification 
Total protein content of lysed cell samples or tissue extracts was quantified 
using a bicinchoninic acid assay (Pierce BCA protein assay kit, Thermo 
Scientific). A standard curve of albumin protein standards was used on each 
plate. Samples were diluted in lysis buffer to ensure that the optical density 
readings from the BCA assay fell within the linear portion of the standard 
curve within each plate. 2µl of sample or standard was incubated in 100µl 
of BCA assay reagent (made up according to manufacturer’s instructions) 
in a 96-well plate and incubated at 37oC for 30 minutes. The optical density 
of each well was measured using a Glomax plate reader (Promega). 
2.6.10 RNA immunoprecipitation 
A detailed description of RNA immunoprecipitation (IP) techniques can be 
found in Chapter 4. In brief, HeLa cells were transfected with DNA plasmids 
expressing the ATXN1 gene containing either 2, 30 or 85 CAG repeats, with 
an N-terminal FLAG tag (Table 2.2). Protein extracted from transfected 
HeLa cells was pre-cleared by incubating with Protein G magnetic beads 
(Dynabeads, ThermoFisher). Protein concentration of lysates was 
established using a BCA assay (Pierce BCA assay kit, Thermo Fisher 
Scientific), and a known quantity of protein incubated overnight at 4oC with 
Protein G beads cross-linked to either SAFB1 antibody or concentration-
matched rabbit IgG (Cell Signalling Technology). Beads were isolated using 
a magnetic rack and washed before dissociating immunocomplexes from 
the beads. RNA was purified using a Reliaprep RNA cell miniprep system 
(Promega). RNA was reverse transcribed to cDNA and quantified by qPCR 
using primers against ATXN1. Relative quantities of ATXN1 were calculated 
by comparison to a standard curve of serial diluted ATXN1- expressing DNA 
plasmid included on each plate. 
2.6.11 Western blotting 
Typically, 20-30µg of protein per sample was added 1:1 to 2x SDS sample 
buffer and heat denatured at 95oC for 5 minutes. Samples were loaded onto 




in a TRIS-glycine running buffer. Protein was transferred onto PVDF 
membrane by either wet or semi-dry transfer. Semi-dry transfer was carried 
out using a Trans-Blot Turbo transfer system (BioRad) for 10 minutes using 
a high molecular weight transfer protocol with a mini PVDF transfer pack 
(BioRad). For wet transfer, gels were sandwiched against PVDF membrane 
in a transfer cassette and immersed with an ice pack in TRIS-glycine 
transfer buffer with 20% methanol. The transfer cassette was run at 200mA 
for 2 hours. Following transfer, protein on PVDF membranes was blocked 
in 5% milk powder in PBS (w/v) for 1 hour at room temperature on a rocker. 
Membranes were then probed with primary antibody diluted in 1% milk 
powder in PBS on a rocker overnight at 4oC. Membranes were washed 3 
times in PBS with 0.05% Tween (PBS-T) for 5 minutes on a rocker at room 
temperature before probing with secondary antibody diluted 1:10000 in 1% 
skimmed milk powder. For primary antibodies raised in rabbit, membranes 
were incubated in peroxidase-linked anti-rabbit IgG (NA934, GE 
Healthcare). For primary antibodies raised in mouse, membranes were 
incubated in peroxidase-linked anti-mouse IgG (NA931, GE Healthcare). 
Membranes were washed 3 times for 5 minutes with PBS-T. Antibody-
bound protein was visualised using enhanced chemiluminescence (ECL) 
(either ECL Prime reagent (Amersham) or Supersignal West Pico PLUS 
reagent (Thermo Fisher Scientific)). The light signal was imaged using 
either a gel doc CCD (charge-coupled device) imaging system (G:Box F3, 
Syngene), or by exposing the membrane to x-ray film inside a cassette 
before developing the film using a developing machine. 
2.7 Immunostaining 
2.7.1 Immunohistochemical staining of FFPE tissue sections 
Sections were deparaffinised and rehydrated. Antigen retrieval was carried 
out by immersing slides in heated 0.1mM sodium citrate buffer (pH 6) with 
0.05% (v/v) Tween 20. Endogenous peroxidases were neutralised by 
incubating sections in 1% (v/v) hydrogen peroxide diluted in distilled water. 
Immunohistochemical staining was carried out using an avidin-biotin 




PK-6200, Vector Laboratories). Protein blocking to reduce non-specific 
binding was carried out by incubating sections in normal horse serum 
(Vectastain blocking solution) diluted 1:100 in PBS-T. Sections were 
incubated with primary antibody diluted in protein blocking solution 
overnight at 4oC. Sections incubated in antibody diluent only served as no 
primary antibody controls. Sections were incubated in secondary antibody 
(Vectastain biotinylated horse anti-rabbit/mouse, 1:50) diluted in Vectastain 
blocking solution. Following PBS washes, sections were incubated in ABC 
reagent (Vectastain Elite ABC Reagent, 1:50), and antibody binding was 
visualised using 3,3’-diaminobenzidine (DAB) (Vectorlabs DAB substrate 
kit, no nickel). After washing in distilled water, nuclei were visualised by 
counterstaining in Ehrlich’s haematoxylin. Sections were dehydrated, 
cleared and mounted under glass coverslips using DPX mountant.  
2.7.2 Immunofluorescent staining of FFPE and frozen tissue sections 
FFPE sections were placed in an oven at 56oC for at least 1 hour to aid de-
waxing and reduce auto-fluorescence. Slides were dewaxed in Clearene, 
immersed in 100% alcohol then washed in running tap water for 10 minutes. 
Antigen retrieval was carried out as described for immunohistochemical 
staining. Slides were washed in running tap water, then washed in PBS (pH 
7.4). Protein block was carried by incubating with protein blocking solution 
(10% (v/v) normal goat serum diluted in PBS with 0.01% (v/v) Triton X-100) 
for 1 hour at room temperature. Sections were incubated in primary 
antibodies diluted in blocking solution overnight at 4oC. Sections were 
washed in PBS before incubation with fluorescently conjugated secondary 
antibodies diluted in blocking solution for 1 hour, protected from light. 
Sections were washed in PBS, then incubated with DAPI (1µg/ml in PBS) 
(ThermoFisher Scientific, UK) for 5 minutes. Following a final PBS wash, 
sections were mounted in 50% PBS/50% glycerol under glass coverslips 





2.7.3 Immunofluorescent staining of cells 
Cells grown on coverslips were fixed in 4% PFA for 15-20 minutes at room 
temperature, then washed in PBS. Cells were incubated in 5% (v/v) donkey 
serum in PBS with 0.03% (v/v) Triton X-100 for 1 hour at room temperature 
to block proteins and permeabilise the cells. Cells were then incubated in 
primary antibody diluted in 1% (v/v) donkey serum in PBS overnight rocking 
gently at 4oC. Cells were washed in PBS before incubating for 1 hour at 
room temperature with fluorescent-conjugated secondary antibody raised in 
the same species as the serum used for blocking, which was always a 
different species in which the primary antibody was raised. Cells were 
washed in PBS, then the nuclei counterstained using 1µg/ml Hoechst or 
DAPI (ThermoFisher Scientific). Coverslips were mounted using mowiol 
mounting medium, sealed with clear nail varnish and stored at 4oC prior to 
imaging. 
2.7.4 Microscopy 
Image capture of immunohistochemically stained sections was carried out 
using a Nikon eclipse i80 microscope with a Nikon Ci-SMS camera, and 
Image-Pro plus software, or using an Aperio Scanscope CS2 digital slide 
scanner (Leica) and Leica ImageScope software. Immunofluorescent cells 
and tissue sections were imaged using either a Leitz DMRB fluorescence 
microscope (Leica) with a Leica DC500 camera and Leica imaging software, 
or with a Nikon C1 confocal microscope with EZ viewer software. 
2.8 Statistics and data presentation 
2.8.1 Statistical tests and reporting 
Prior to statistical analysis, data distribution of experimental results was 
carried out using a Shapiro-Wilk normality test. For normally distributed 
datasets, parametric statistical tests were carried out. Comparisons 
between two groups were made using a student’s t-test (unpaired, two 
tailed). T-test results are reported in the following format: “t(degrees of 




groups with a single factor (variable) were made using one-way analysis of 
variance (ANOVA) tests. Comparisons between multiple groups with two 
factors (variables) were made using two-way ANOVA tests. If ANOVA tests 
detected a significant difference, an appropriate multiple comparison post-
hoc test was employed to confirm where significant differences occurred 
between groups. Post-hoc test details are included alongside the reporting 
of statistical results. Results of ANOVA tests are reported as p-values. 
Relationships between two sets of parametric data were analysed using 
Pearson’s correlation tests. Non-parametric comparisons between two 
groups were performed using Mann-Whitney tests, the results of which are 
reported as follows: “(group 1 median, group 2 median) U-value, p-value”. 
Non-parametric correlation analysis was carried out using Spearmann’s 
correlation. Parametric data is displayed in bar graphs as group means with 
error bars representing ± standard error of the mean (SEM). Non-parametric 
data is displayed in bar graphs representing the median of each group. 
Individual datapoints (biological replicates) are plotted as circular or square 
symbols on bar graphs. Lines of best fit displayed on scatter plots were 
drawn using a linear regression function. All statistical tests were carried out 
using GraphPad Prism (version 7.04). In all cases, p-values of <0.05 were 
considered statistically significant. P-value significance levels when 
displayed in figures are denoted as follows: ns not significant, * p<0.05, ** 
p<0.01, *** p<0.001. 
2.8.2 Experimental replicates 
Biological replicates (n) in cell-based assays were defined as individual 
plates of cells, prepared on different days and used at different times 
according to the same experimental protocol. Technical replicates were 
included in plate-based assays as replicate wells of the same experimental 
condition within each plate. A minimum of three technical replicates was 
included in each plate-based experiment. In experiments involving human 
tissue, a biological replicate was defined as a single tissue section or 
sample from an individual patient. Statistical analysis was carried out on 
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3. Chapter 3 
Immunohistochemical characterisation of SAFB1 in human 
neurodegenerative disease 
3.1 Overview 
3.1.1 Chapter overview 
This chapter aimed to carry out a novel characterisation of the RNA binding 
protein (RBP) SAFB1 in human neurodegenerative disease. 
Immunohistochemical staining of tissue from patient and control donors was 
performed and the staining patterns quantified. In neurons of control cases 
and patients with the non-polyQ diseases MS and PD, SAFB1 was 
expressed almost exclusively in the nucleus. In contrast, SAFB1 was 
abnormally expressed in the cytoplasm of damaged Purkinje cells of SCA 
patients and striatal neurons of HD patients. Overall this chapter presents 
the finding that SAFB1 expression in the cytoplasm of degenerating neurons 

















RBPs are critical for the regulation of gene expression and are highly 
expressed in neurons, cells which have very complex and active 
transcriptomes (Licatalosi and Darnell 2010, Andreassi et al. 2018). RBP 
dysfunction is now established as an important feature of many 
neurodegenerative diseases (Cookson 2017), and the preservation of RBP 
function is emerging as a potential approach for disease-modifying therapy 
(Nussbacher et al. 2019). The critical role of RBPs in neurodegenerative 
pathology is exemplified by mutations in TDP-43 and FUS which cause 
some inherited forms of ALS and FTD (Kwiatkowski et al. 2009). 
Pathological accumulation of TDP-43 and FUS in the cytoplasm occurs 
frequently in both ALS and FTD (Arai et al. 2006), which may induce a 
nuclear loss of function and/or cytoplasmic gain of function (Birsa et al. 
2019). Recent work showed that the dual nucleic acid binding protein 
SAFB1 binds FUS, regulating its localisation within chromatin and being 
required for its splicing functions (Yamaguchi and Takanashi 2016). SAFB1 
also interacts with Matrin 3, another RBP in which mutations cause familial 
ALS (Johnson et al. 2014). 
Like TDP-43 and FUS, SAFB1 is a DRBP which is characterised structurally 
by the presence of an RRM motif and is highly expressed in the brain 
(Norman et al. 2016). SAFB1 has been shown to exert important RNA 
regulatory functions in neurons, including the splicing of neuronal genes, 
and modulation of dendritic spine formation (Rivers et al. 2015). The same 
study explored the RNA-binding function of SAFB1 in detail using individual-
nucleotide resolution crosslinking and immunoprecipitation (iCLIP) (Figure 
3.2). RNA-protein interactions of purified SAFB1 extracted from cultured 
cells were identified with high resolution to reveal the precise site of 
interaction with gene sequences. This work revealed a significant 
enrichment of SAFB1 iCLIP tags within the ATXN1 gene. SAFB1 tags were 
localised exclusively to exon 8, both within and immediately 5’ to the ATXN1 
CAG repeat site (Rivers et al. 2015). CAG expansions in ATXN1 cause 




severe degeneration of neurons within the cerebellum, a brain region which 
highly expresses SAFB1 (Norman et al. 2016). 
 
 
Overall, SAFB1 binds RBPs directly implicated in neurodegenerative 
disease, is highly expressed in the human brain and cerebellum, regulates 
neuronal function and associates with the polyQ disease-causing gene 
ATXN1. This chapter therefore hypothesised that SAFB1 could contribute 
to the pathogenesis of SCA1 and potentially to other polyQ disorders such 
as HD. The expression of SAFB1 has not previously been characterised in 
the human brain or in any neurodegenerative disease. This chapter 
therefore aimed to carry out a detailed investigation into the expression of 
SAFB1 in human brain from control cases and patients with polyQ and non-
polyQ neurodegenerative conditions. 
  
Figure 3.2 SAFB1 iCLIP tags are enriched in exon 8 of the ATXN1 
gene, both within and immediately 5’ of the CAG repeat site 





3.3.1 Donor tissue 
Human post-mortem tissue was collected via prospective donor schemes 
through the UK Brain Banks Network and utilised under local ethics 
approval. Formalin-fixed paraffin embedded (FFPE) sections from patients 
diagnosed with SCA, HD, PD and control cases with no history of 
neurological disease were obtained from the MRC London 
Neurodegenerative Diseases Brain Bank, UK. This tissue was utilised in this 
study under ethics approval number LNDBB1778. Cerebellar tissue 
sections from patients diagnosed with secondary progressive MS were 
obtained from the Multiple Sclerosis Tissue Bank, Imperial College, London, 
UK and utilised in this study under research ethics committee approval 
08/MRE09/31. Post-mortem donor brain tissue was fixed in neutral buffered 
formalin and embedded in paraffin. Tissue sections were cut to 7-10µm and 
mounted onto glass slides. Clinicopathological details of donors of FFPE 
tissue are given in Table 3.1. Frozen striatal tissue (200mg pieces) from 
patients diagnosed with HD or control cases were obtained from the MRC 
London Neurodegenerative Diseases Brain Bank and utilised under ethics 
approval number LNDBB1788. Clinicopathological details for donors of 
frozen tissue are given in Table 3.2.  
3.3.2 Immunohistochemical staining of human brain tissue 
FFPE sections were immunostained with antibodies raised against SAFB1 
(either A300-811A (1:50) or IHC-00142 (1:50), both Bethyl Laboratories, 
UK). Details of primary antibodies used for human tissue immunostaining 
can be found in Table 2.3. Sections were deparaffinised in Histo-clear and 
rehydrated in graded alcohol solutions. Antigen retrieval was carried out by 
microwaving slides immersed in 0.1mM sodium citrate buffer (pH 6) with 
0.05% (v/v) Tween 20 until boiling. Slides were left to stand for 5 minutes, 
re-heated again and boiled for 1 minute, left to cool in buffer for 20 minutes 















Cause of death 
1 Cerebellum Control 74 66 F Pneumonia 
2 Cerebellum Control 90 45 M Myocardial infarction 
3 Cerebellum Control 66 78 F 
Metastatic colorectal 
cancer 
4 Cerebellum Control 65 26 M 
Metastatic prostate 
cancer 
  Mean 73.8 53.8 50% 
F 
 
  SEM 5.8 11.5  
5 Cerebellum SCA1 76 24 M 
Cancer (unknown 
primary) 
6 Cerebellum SCA 54 31.5 F Not available 
7 Cerebellum SCA 68 48 M Not available 
8 Cerebellum SCA 74 33 F Not available 





  Mean 71.6 34.1 60% 
F 
 
  SEM 5.3 5  
10 Striatum Control 51 33 F Lung cancer 
11 Striatum Control 63 23 M Colon cancer 
12 Striatum Control 89 43 F Cancer 
13 Striatum Control 85 45 M Urethrial cancer 
14 Striatum Control 65 26 M 
Metastatic prostate 
cancer 
15 Striatum Control 82 47 M Congestive cardiac failure 
16 Striatum Control 84 34 F 
Sepsis; metastatic breast 
cancer 
  Mean 74.1 35.9 43% 
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79 45 F 
Acute myocardial 
infarction 
  Mean 69.3 42.8 63% 
F 
 
  SEM 4.6 6.3  
  
















Cause of death 
25 Cerebellum MS 78 5 F 
Metastatic bronchial 
carcinoma 
26 Cerebellum MS 64 7 F 
GI bleed, aspirational 
pneumonia 
27 Cerebellum MS 49 31 F 
Chronic renal failure, 
heart disease 
28 Cerebellum MS 49 7 F Bronchopneumonia 
  Mean 60 12.5 100% 
F 
 








Control 82 47 M Not available 
  Mean 83.5 46 100% 
M 
 








PD 65 26 M Not available 
  Mean 72.5 23 100% 
M 
 














Cause of death 
33 Striatum Control 67 26 M Prostate cancer 
34 Striatum Control 63 51 M Colon cancer 
35 Striatum Control 82 25 M Not available 
36 Striatum Control 91 103 F Cardiac failure 
37 Striatum Control 92 9 F Not available 
38 Striatum Control 84 53 F Myocardial infarction 
39 Striatum Control 82 47 M Cardiac failure 
40 Striatum Control 66 50 F Not available 
41 Striatum Control 76 20 F Kidney cancer 
42 Striatum Control 90 70 M Myocardial infarction 
  Mean 79.3 45.4 50% F  
  SEM 3.4 8.7   
43 Striatum HD 48 65 F Not available 
44 Striatum HD (grade 3) 70 33 M Sepsis 
45 Striatum HD (grade 3) 31 54 F Not available 
46 Striatum HD (grade 3) 68 72 M Chest infection 
47 Striatum HD (grade 4) 29 102 F Huntington’s disease 
48 Striatum HD 83 24 F Not available 
  Mean 54.8 58.3 67% F  
  SEM 9.1 11.5   
Table 3.2 Clinicopathological details for donors of frozen striatal tissue 





Endogenous peroxidases were neutralised by incubating sections for 15 
minutes in 1% hydrogen peroxide diluted in distilled water. 
Immunohistochemical staining was carried out using an avidin-biotin 
complex staining kit (Vectastain Elite ABC HRP Kit (Peroxidase, Universal), 
PK-6200, Vector Laboratories). After washing in phosphate-buffered saline 
(PBS pH 7.4) with 0.05% Triton X-100 (v/v), non-specific binding was 
blocked using normal horse serum (Vectastain blocking solution) diluted 
1:100 in PBS-T for 45 minutes. Sections were incubated with primary 
antibody diluted in blocking solution overnight at 4oC. Sections incubated in 
antibody diluent only served as no primary antibody controls. Sections were 
washed in PBS, then incubated in secondary antibody (Vectastain 
biotinylated horse anti-rabbit/mouse, 1:50) diluted in Vectastain blocking 
solution. Following PBS washes, sections were incubated in ABC reagent 
(Vectastain Elite ABC Reagent, 1:50), and antibody binding was visualised 
using 3,3’-diaminobenzidine (DAB) (Vectorlabs DAB substrate kit, no 
nickel). After washing in distilled water, nuclei were counterstained in 
Ehrlich’s haematoxylin, before rinsing slides in running tap water. Sections 
were dehydrated in graded alcohol solutions, cleared in xylene and mounted 
under glass coverslips using DPX mountant. 
3.3.3 Immunofluorescent labelling of human brain tissue 
FFPE sections were dewaxed in Clearene, immersed in 100% alcohol then 
washed in running tap water for 10 minutes. Antigen retrieval was carried 
out as described for immunohistochemical staining. Slides were washed in 
running tap water, then in PBS. Protein block was carried by incubating with 
protein blocking solution (10% normal goat serum diluted in PBS with 0.01% 
Triton X-100 (v/v)) for 1 hour at room temperature. Cerebellar sections were 
double immunolabelled with rabbit anti-SAFB1 (1:200) (A300-811A, Bethyl 
Laboratories), and either mouse anti-calbindin-D-28K (1:500) (Sigma-
Aldrich, UK) or mouse anti-SMI-34 (hyperphosphorylated neurofilament, 
1:500) (Covance, US). Striatal sections were double labelled with anti-
SAFB1 and anti-polyQ (1:1000) (1C2, Millipore). Sections were incubated 




were washed in PBS before incubation with fluorescently conjugated 
secondary antibodies diluted in blocking solution for 1 hour at room 
temperature, protected from light (Alexa Fluor 488 goat anti-mouse (1:500) 
or Alexa Fluor 555 goat anti-rabbit (1:500) (Invitrogen)). Sections were 
washed in PBS, then incubated with DAPI for 5 minutes (1µg/ml in PBS) 
(ThermoFisher Scientific). Following a final PBS wash, sections were 
mounted in 50% PBS/50% glycerol under glass coverslips sealed with clear 
nail varnish. Slides were stored at 4oC in the dark and imaged within 1 week. 
3.3.4 Analysis of SAFB1 immunohistochemistry in cerebellar Purkinje cells 
Prior to all immunohistochemical analysis, sections were coded, and the 
investigator blinded to their identity by covering the slide label with opaque 
coloured tape. To analyse DAB immunolabelling of SAFB1 in Purkinje cells, 
cerebellar sections were scanned using an Aperio Scanscope digital slide 
scanner. The Purkinje cell layer was traced, and the distance measured 
using annotation tools within Aperio ImageScope software (Figure 3.3A and 
B). Purkinje cells were identified by their characteristic morphology and 
localisation within the cerebellar sections. The number of Purkinje cells was 
counted and normalised to the total length of the Purkinje cell layer to obtain 
a count of Purkinje cells per unit length (mm) (Figure 3.3E). The perikaryon 
of each Purkinje cell that had a clearly visible nucleus was traced and the 
area in µm2 of each perikaryon measured. Each Purkinje cell was 
individually graded as either positive or negative for SAFB1 
immunoreactivity within the nucleus and cytoplasm (Figure 3.3F). This 
methodology was based on that previously described by Kemp et al. (2016). 
3.3.5 Analysis of SAFB1 immunohistochemistry in cerebellar white matter 
neurons 
To analyse DAB immunolabelling of SAFB1 in large neurons within 
cerebellar white matter, the dentate nucleus was identified at low 
microscopic magnification as a characteristic grey matter ribbon running 
through the cerebellar white matter (Figure 3.3C). Images were taken at 




each section. A minimum of 15 images were acquired per section. Large 
principle neurons were identified within each image by their characteristic 
size and morphology and graded as either positive or negative for SAFB1 
immunoreactivity within the nucleus and cytoplasm. 
3.3.6 Analysis of SAFB1 immunohistochemistry in striatal neurons 
To analyse DAB immunolabelling of SAFB1 in the striatum, images were 
captured across the whole stained striatal section using a Nikon eclipse i80 
microscope with a Nikon Ci-SMS camera, and Image-Pro plus software. 
Between 15 and 20 regions of interest were imaged and analysed per 
section (Figure 3.4A). Images containing histological artefacts such as air 
bubbles, tears, high background staining or features such as large blood 
vessels were excluded from quantification. In single labelled sections 
immunohistochemically stained for SAFB1, cells in the striatal tissue were 
categorised by size as neuronal (large) or non-neuronal (small) (Figure 
3.4B). To ensure the same categorisation judgement was utilised between 
micrographs, an initial test count across three randomly selected 
micrographs was carried out, and the nuclear diameter of cells categorised 
as either large or small was recorded. During staining quantification, a scale 
bar equal to the smallest nuclear diameter categorised as large/neuronal 
was used to categorise any cells which were of indeterminate size. 
Large/neuronal cells containing SAFB1 staining in either the nucleus or the 
cytoplasm were counted manually using ImageJ software. 
In tissue dual labelled for SAFB1 and polyQ by immunofluorescence, 
sections were imaged using a Nikon C1 confocal microscope with EZ viewer 
software. Ten micrographs were captured and analysed per section (Figure 
3.4C). The number of neurons positive for polyQ inclusions was counted, 
and within this cell population the number of cells positive for SAFB1 in the 





Figure 3.3 Method for analysis of cerebellar sections immunostained for SAFB1. 
A) Whole human cerebellar section stained for SAFB1 and counterstained with 
haematoxylin (scale bar is 5mm). The Purkinje cell layer (B) and dentate nucleus 
(C) are highlighted in blue. D) Purkinje and dentate cell measurement 
annotations. E) Magnified section of cerebellar tissue featuring annotations to 
measure the length of the Purkinje cell layer, count individual cells, and measure 
the cross sectional area of the cell soma (scale bar is 50µm). F) Purkinje cells  
negative and positive for SAFB1 staining in the nucleus and cytoplasm. Note the 





Figure 3.4 Method for analysis of striatal sections immunostained for SAFB1. A) 
Whole human striatal section immunostained with SAFB1 counterstained with 
haematoxylin. Blue boxes represent example of regions of interest across the 
section, within which an image was captured for quantification (scale bar is 5mm). 
B) Sample image of striatum immunostained for SAFB1 (scale bar is 75µm). 
Magnified region with annotation showing the appearance of both small and large 
cell nuclei within the tissue. C) Illustration of a whole striatal section mounted on a 
slide. Blue lines show the delineation of the sections and the regions of interest 
that were labelled using immunofluorescent techniques. An image was taken 




3.3.7 RNA and protein extraction from human striatum 
Frozen samples of human striatum were processed under RNase-free 
conditions using a mirVana PARIS kit (Life Technologies). All surfaces and 
materials in contact with tissue were treated with RNaseZap (ThermoFisher 
Scientific) and all plasticware was RNase-free. Samples of striatum 
weighing 200mg were removed from -80oC storage on dry ice and ground 
to a course powder using a pre-chilled granite pestle and mortar. Tissue 
was bathed in liquid nitrogen to ensure that the sample remained completely 
frozen. Powdered tissue was rapidly transferred into 700µl of pre-chilled cell 
disruption buffer, mixed, and homogenised using a chilled 2ml glass tissue 
homogeniser. Half the volume was used for RNA extraction and half for 
protein extraction. Extraction of total RNA was carried out in accordance 
with the mirVana PARIS kit manufacturer’s protocol. In brief, the sample 
was mixed with a denaturing solution to prevent RNA degradation, followed 
by organic extraction using acid-phenol chloroform. The aqueous phase 
was precipitated with ethanol, and RNA isolated by centrifuging the sample 
through a proprietary filter cartridge. After washing the filter, RNA was eluted 
in 100µl of pre-warmed nuclease-free water and stored at -80oC. Tissue 
homogenate reserved for protein extraction was incubated on ice for 5 
minutes before repeatedly passing the sample through a sterile needle to 
reduce viscosity. Samples were centrifuged at 14000 rpm at 4oC for 15 
minutes and the cell debris pellet discarded. Protein lysates were quantified 
by BCA assay and stored at -80oC. 
3.3.8 Analysis of striatal SAFB1 protein by Western blotting 
Protein denaturation was carried out by combining 50µg of extracted striatal 
protein with 2xSDS sample buffer and heating at 95oC for 5 minutes. 
Samples were resolved on an 8% polyacrylamide gel by electrophoresis, 
before transferring onto a polyvinylidene difluoride (PVDF) membrane using 
a Trans-blot Turbo Transfer System (Bio Rad). Protein bound to the 
membrane was blocked in 5% (w/v) skimmed milk in PBS for 1 hour at room 
temperature, before incubating with anti-SAFB1 antibody (A300-811A, 




washing, the membrane was incubated in peroxidase-linked secondary 
antibody (Table 2.4) diluted in 1% skimmed milk for 1 hour at room 
temperature. After washing, protein bands were visualised using enhanced 
chemiluminescence (Amersham ECL Prime Western Blotting Detection 
Reagent, GE Healthcare). Digital images were quantified using 
densitometric analysis in Image Studio Lite (Licor). The density of each 
SAFB1 protein band was normalised against total SAFB1 (according to BCA 
assay results) to obtain a relative quantification of SAFB1 protein for each 
striatal tissue sample. 
3.3.9 Analysis of striatal SAFB1 mRNA by qPCR 
RNA extracted from striatal tissue samples was reverse transcribed into 
cDNA with oligoDT primers using a GoScript Reverse Transcription kit 
(Promega). 1µl of undiluted cDNA was added to 19µl of Power SYBR Green 
qPCR mastermix (Thermo Fisher Scientific) containing 300nM of forward 
and reverse primers against SAFB1 or beta-actin (Table 2.5). qPCR 
reactions were carried out using a StepOnePlus Real-time PCR system 
(Applied Biosciences). Comparative threshold (CT) analysis was carried out 
by normalising SAFB1 expression to housekeeping gene expression within 
each sample. 
3.3.10 Statistical analysis 
Results from immunostaining quantification did not pass Shapiro-Wilk 
normality testing. This, alongside the categorical nature of staining 
quantification, indicated that statistical analysis should be carried out non-
parametrically. Non-parametric comparisons between two groups were 
performed using Mann-Whitney tests. Non-parametric correlative analysis 
was carried out using Spearman’s tests. Parametric testing was applied to 
normally distributed data sets, using unpaired two-tailed t-tests to compare 





3.4.1 the anti-SAFB1 antibody A300-811A is specific and suitable for 
immunostaining human brain 
Investigations by our research group have established that some historic 
studies investigating the function of SAFB1 relied upon antibodies which 
were unable to differentiate between SAFB1 and SAFB2. The immunogen 
peptide sequence for the anti-SAFB1 antibody A300-811A (Bethyl 
Laboratories) shares 77% sequence homology with the equivalent epitope 
region of SAFB2, indicating a possibility of cross-reactivity (Table 3.3). With 
this in mind, we previously validated that A300-811A specifically detects 
SAFB1 (Rivers et al. 2015). The first aim of this chapter was to confirm that 
this antibody was appropriate for analysing SAFB1 expression in human 
tissue. 
Prior to carrying out staining in human tissue, antibody specificity was tested 
using an siRNA knockdown approach based on the Rimm Algorithm for 
antibody specificity (Bordeaux et al. 2010). HeLa cells transfected with 
siRNA against SAFB1 or SAFB2 were lysed and the protein run on a 
Western blot probed using A300-811A (Figure 3.5A). The blot showed 
reduced signal with SAFB1 siRNA knockdown but no change with SAFB2 
siRNA in comparison to non-targeting control (NTC) transfected and control 
(untransfected) samples (Figure 3.5A). This result confirmed that A300-
811A does not cross-react with the closely related protein SAFB2. 
To ensure that immunostaining in human tissue visualised by both DAB and 
fluorophores was specific to antibody binding and not background tissue 
reactivity, sections incubated without antibody were included in each 
immunostaining experiment as a negative control. Representative images 
of control staining are shown in Figure 3.5B and C. Sections without primary 
antibody were negative for DAB staining (Figure 3.5B). Representative 
images from a cerebellar section with primary antibody omitted shows 
minimal non-specific auto-fluorescent signal in this tissue (Figure 3.5C). The 




in section 3.4.7. Overall these results show that antibody A300-811A is 










































3.4.2 SAFB1 is expressed in the cytoplasm of damaged Purkinje cells in 
SCA1 
Previous data obtained by our research group demonstrated the interaction 
between SAFB1 protein and ATXN1 RNA using iCLIP. A CAG expansion 
mutation in the ATXN1 gene causes the polyQ disorder SCA1, therefore the 
initial investigation in this chapter characterised the expression of SAFB1 in 
the cerebellum of a SCA1 patient in comparison to a control case with no 
history of neurological disease (Figure 3.6). In both control and SCA1 
cerebellum, frequent SAFB1 immunoreactivity was observed within the 
nuclei of cells within the granular and molecular layers of the folia (Figure 
3.6). In control tissue, SAFB1 staining in Purkinje cells was almost always 
limited to within the nuclei, where it presented in a diffuse pattern spread 
throughout the nucleus (Figure 3.6). 
  
Table 3.3 Immunogen properties of commercially available polyclonal antibodies 





Figure 3.5 Control studies for SAFB1 antibody staining. A) Western blot of lysates 
from HeLa cells (either non-transfected (control), siRNA knockdown of SAFB1, 
knockdown of SAFB2 or non-targeting control (NTC)), probed with anti-SAFB1 
antibody (A300 811-A, Bethyl). The antibody detected a reduction in expression 
of SAFB1 but did not detect a change in SAFB2 indicating specificity for SAFB1 
(uppermost bands). B) Cerebellum and striatum from control and disease patients 
immunohistochemically stained with no primary antibody were negative for DAB 
reactivity. Scale bars are 100µm. C) Cerebellar tissue immunofluorescently 
stained with no primary antibody. There was some minimal autofluorescence in 
the granule cell layer, but no non-specific fluorescence in Purkinje cells. White 




In SCA1 Purkinje cells SAFB1 immunoreactivity was frequently present in 
both the nucleus and within the cytoplasm of the perikaryon and dendrites 
(Figure 3.6). Cytoplasmic SAFB1 staining was evident in SCA1 Purkinje 
cells with mild, moderate and substantial morphological alterations 
indicating increasing severity of neurodegenerative injury (Figure 3.6). It has 
been previously established that under normal conditions, SAFB1 protein is 
localised to within the nucleus (Norman et al. 2016, Hashimoto et al. 2020), 
therefore the presence of cytoplasmic staining in damaged Purkinje cells 
was considered a novel and unusual finding and prompted further 
investigation.   
3.4.3 Cytoplasmic accumulation of SAFB1 in SCA is a novel 
histopathological hallmark 
Post-mortem cerebellar tissue from patients with a neuropathological 
diagnosis of SCA was compared against a control group of patients with no 
history of neurological disease (Table 3.1). There was no significant 
difference in patient age (t(7)=0.27, p=0.79) or post-mortem delay (PMD) 
(t(6)=1.57, p=0.17) between groups (unpaired, two-tailed t-tests). The 
neuropathological findings of the patient autopsies are summarised in Table 
3.4. 
SAFB1 expression in Purkinje cells was quantified by counting the 
percentage of cells positive for SAFB1 (Figure 3.7). The percentage of 
control Purkinje cells with nuclear SAFB1 immunopositivity ranged between 
57% and 83%, which was not significantly different compared to SCA 
patient cerebellum which ranged between 50% and 99% (Figure 3.7B). 
There was, however, a significantly higher percentage of Purkinje cells with 
cytoplasmic SAFB1 staining in SCA patients (between 14% and 80%) 
compared to controls (between 0.6% and 3.1%) (Figure 3.7C). There was 
substantial loss of Purkinje cell numbers and reduction in the cross-
sectional area of Purkinje cell soma in SCA patients compared to control 


















Figure 3.6 SAFB1 is abnormally expressed in the cytoplasm of Purkinje cells in 
SCA1. Representative images of cerebellar tissue from a control case and SCA1 
patient immunostained for SAFB1. In control cerebellum, Purkinje cells often 
featured SAFB1 immunostaining within the nucleus, but cytoplasmic SAFB1 
staining was not present (arrow). In SCA1 cerebellum, Purkinje cells had 
cytoplasmic SAFB1 staining in the soma and dendrites (dotted arrow) in addition 
to strong nuclear staining. Cytoplasmic SAFB1 staining appeared in SCA1 Purkinje 
cells with mild (i-ii), moderate (iii-iv) and substantial (v-vi) morphological alteration 




   




























Severe loss, with 
severe shrinkage 

























8 SCA Not 
available 
Depleted, with 
heterotypic PCs in 
granule cell layer. 
No P62 positivity. 













9 SCA Not 
available 













Axonal torpedoes (swellings) in Purkinje cells are a cerebellar response to 
injury (Takahashi et al. 1992) which have been previously observed in SCA 
patients (Louis et al. 2014). In the present study, torpedoes were not 
observed in any SCA Purkinje cells. Visualisation of torpedoes may be 
occluded by the dense SAFB1 staining of the granule cell layer. 
Furthermore, severe Purkinje cell pathology can be associated with lower 
frequency of torpedoes in ataxias (Louis et al. 2014). 
In addition to atrophy and loss of Purkinje cells within the cerebellar cortex, 
the pathology of polyQ SCA also affects the large principle neurons within 
the dentate nucleus (DN) of the cerebellar white matter. Notably, SAFB1 
staining was not detected in the majority of dentate neurons in control cases 
(Table 3.6, Figure 3.8). However, there was significantly increased 
Table 3.4 Diagnoses and cerebellar neuropathological findings summarised from 





expression of SAFB1 in both the nucleus (Figure 3.8A and B) and cytoplasm 
(Figure 3.8A & C) of DN neurons in SCA patients. 
Nuclear SAFB1 staining was present in 6 - 18% of control DN neurons and 
27 - 80% of SCA DN neurons, and cytoplasmic SAFB1 staining was present 
in 0.6 - 3.9% of control and 32 - 87% of SCA DN neurons. The DN neurons 
of SCA patients appeared smaller and more shrunken, and SAFB1 staining 
was diffuse and distributed throughout the cell bodies (Figure 3.8A), as was 
observed in Purkinje cells. There was, however, less DN neuron cell loss 
compared to that seen in the Purkinje cell population (Table 3.6). Taken 
together, this data shows that abnormal cytoplasmic SAFB1 expression is 
a feature of two neuronal populations specifically affected by polyQ-induced 













1 Control 326 2.36 226 3 775.5 
2 Control 315 3.17 262 2 611.9 
3 Control 321 3.05 182 10 639.2 




1272 2.98 917 18 656.2 
5 SCA 242 1.91 241 137 556.5 
6 SCA 20 0.05 18 16 202.6 
7 SCA 39 0.26 30 12 386.6 
8 SCA 29 0.07 20 4 451.0 




352 0.46 320 180 381.1 
25 MS 316 1.91 298 17 454.5 
26 MS 417 2.9 404 7 494.3 
27 MS 371 2.41 192 38 595.7 




1312 2.62 1086 68 491.1 
Table 3.5 Number of cerebellar Purkinje cells (PC) with SAFB1 staining, and their  





Figure 3.7 SAFB1 expressed in the cytoplasm of cerebellar Purkinje cells is a 
feature of SCAs. A) Representative images of Purkinje cells immunostained for 
SAFB1. In control cases (n=4), SAFB1 was expressed in the nucleus but not in the 
cytoplasm.  In SCA patients (n=5), Purkinje cells were positive for SAFB1 in the 
nucleus and frequently featured abnormal SAFB1 expression in the soma and 
dendrites. Inset numbering represents patient case number, scale bar is 25µm. 
SAFB1 staining was quantified by counting the percentage of Purkinje cells with 
nuclear or cytoplasmic immunopositivity. B) There was no difference between the 
percentage of cells positive for nuclear SAFB1 in SCA patients compared to control. 
C) There was a significant increase in frequency of SAFB1 cytoplasmic staining in 
the SCA patient group compared to control ((ctl=0.94, SCA=50) U=0, p=0.02, Mann-











1 Control 143 21 1 
2 Control 133 27 1 
3 Control 126 17 4 
4 Control 148 10 7 
 Total 550 75 13 
5 SCA 112 81 76 
6 SCA 135 90 46 
7 SCA 148 39 48 
8 SCA 181 135 155 
9 SCA 267 216 233 
 Total 843 561 558 
 
 
To confirm that cytoplasmic SAFB1 staining in SCA was specific to Purkinje 
cells, dual immunofluorescent labelling was performed using antibodies 
against SAFB1 and calbindin-D28k (a calcium binding protein widely used 
as a Purkinje cell marker). Representative images show that cytoplasmic 
SAFB1 was present in cerebellar Purkinje cells, as determined by co-
localisation with calbindin immunoreactivity (Figure 3.9A). To assess 
whether cytoplasmic SAFB1 expression was localised to injured or 
damaged Purkinje cells in SCA, cerebellar sections were dual labelled for 
SAFB1 and SMI-34, an antibody which recognises hyperphosphorylated 
neurofilament as a marker of Purkinje cell damage (Redondo et al. 2015). 
SCA Purkinje cells featuring hallmark morphological features of 
neurodegenerative injury (such as reduced perikaryon size and deflated 
appearance of nuclei) and positive for SMI-34 staining also contained 
abnormal cytoplasmic SAFB1 expression (Figure 3.9B). Dense SMI-34 
staining of basket cell projections surrounding damaged Purkinje cells was 
noted, and has been previously described as a feature of cerebellar 
degeneration (Erickson-Davis et al. 2010). 
  
Table 3.6 Number of cerebellar dentate nuclei (DN) neurons with 






Figure 3.8 SAFB1 expression is increased in the nucleus and cytoplasm of 
cerebellar dentate nucleus (DN) neurons in SCA patients. A) Representative 
images of cerebellar DN immunostained for SAFB1 show large principle neurons 
(identifiable by their morphology) within the neuropil of the DN in control (n=4) and 
SCA (n=5) cases (arrow). Cells within SCA patient DN appeared smaller and 
shrunken (dotted arrow) and showed increased nuclear and cytoplasmic SAFB1 
expression.  Numbering represents patient case number, scale bar is 50µm. 
(continued next page). 





3.4.4 Cytoplasmic SAFB1 expression correlates to a measure of Purkinje 
cell injury in SCA 
The neuropathology of polyQ SCAs has been well characterised and 
frequent pathological hallmarks include a reduction in Purkinje cell number 
and size (Koeppen 2005, Babij et al. 2013). Across the SCA patient cases 
analysed in this study, there was a reduction in the number of Purkinje cells 
per mm length of the cell layer, and in Purkinje cell size, compared to control 
(Table 3.5).  
To determine whether there was a relationship between Purkinje cell 
histopathological characteristics and the frequency of SAFB1 staining, 
correlative analysis was carried out (Figure 3.10). There was no significant 
correlation between Purkinje cell perikaryon area and nuclear SAFB1 
staining (Figure 3.10A). However, there was a significant correlation 
between cytoplasmic SAFB1 staining and Purkinje cell perikaryon area 
(Figure 3.10B). Increasing frequency of abnormal SAFB1 in the cytoplasm 
was associated with Purkinje cell injury, as measured by shrinkage of the 
cell soma and loss of cell number. In a single SCA case (case 5), who died 
as a result of cancer, there was a larger number of surviving Purkinje cells 
(compared to four other SCA patients, Table 3.5) and over 56% of these 
cells stained positive for cytoplasmic SAFB1. 
  
Figure 3.8 (continued from previous page) SAFB1 Immunoreactivity expressed 
as the percentage of large principle neurons positive for SAFB1 in either the 
nucleus or the cytoplasm. B) In SCA patients, a significantly higher percentage 
of neurons were positive for SAFB1 within the nuclei compared to control cases 
((ctl=12.94, SCA=59.31) U=0, p=0.02, Mann-Whitney test). C) Cytoplasmic 
SAFB1 was expressed in a significantly higher percentage of neurons of SCA 
patients compared to control cases ((ctl=2, SCA=65.8) U=0, p=0.02, Mann-




   
Figure 3.9 Cytoplasmic SAFB1 in SCA Purkinje cells colocalises with calbindin 
and SMI-34.  A) Calbindin immunopositivity specifies Purkinje cell soma and 
dendrites. SAFB1 staining was absent from the cytoplasm of control Purkinje 
cells but colocalised with calbindin in SCA (arrows). (B) SMI-34 staining, a 
marker of Purkinje cell damage, colocalised with SAFB1 in the soma and 
dendrites of SCA cerebellum (arrows) but not in control tissue. SMI-34 also 
stained basket cell projections (asterisks), which appear hypertrophied in SCA. 





3.4.5 Cytoplasmic SAFB1 expression is not a feature of non-polyQ 
diseases 
To assess whether abnormal cytoplasmic SAFB1 expression is specifically 
associated with Purkinje cell injury induced by polyQ disease, cerebellar 
tissue sections from four patients diagnosed with multiple sclerosis (MS) 
were immunolabelled for SAFB1 (Figure 3.11). MS causes Purkinje cell 
damage and degeneration (Redondo et al. 2015, Wilkins 2017), but this is 
not caused by polyQ pathology. Analysis of Purkinje cells across whole 
cerebellar sections including those with both normal and dystrophic 
phenotypes showed that SAFB1 immunostaining was confined to the 
nucleus, following the same pattern to that of control patients (Figure 3.11, 
Table 3.5). 
To further investigate SAFB1 expression in non-polyQ neurodegenerative 
disease, substantia nigra from two patients with PD was compared to two 
control patients (Figure 3.12). Overall, SAFB1 immunoreactivity was much 
lower in this area compared to the striatum and cerebellum, but where 
staining was present SAFB1 was confined to the nuclei. There was no 
Figure 3.10 Abnormal cytoplasmic SAFB1 expression is associated with reduced 
Purkinje cell size. A) There was no significant correlation between SAFB1 staining 
in the nucleus and Purkinje cell area. B) Increased frequency of cytoplasmic 
SAFB1 expression is correlated with a decrease in Purkinje cell perikaryon area. 




difference in the SAFB1 staining pattern in the substantia nigra of PD 
patients compared to control (Figure 3.12). This finding further 
demonstrates that abnormal SAFB1 expression in the cytoplasm is 
associated specifically with polyQ-associated injury in neurons. 
3.4.6 SAFB1 accumulates in the cytoplasm of striatal neurons in HD 
As SAFB1 has not previously been characterised in human polyQ disorders, 
its expression was next investigated in HD, the most common 
neurodegenerative disease caused by CAG expansion (Figure 3.13). Post-
mortem striatal tissue was obtained from a cohort of patients diagnosed with 
HD (ranging between Vonsattel grade 2-4) and from control cases with no 
history of neurological disease (Table 3.1). There was no significant 
difference in age (t(13)=0.69, p=0.5) or P MD (t(13)=0.92, p=0.38) between 
groups (unpaired, two-tailed t-tests). 
SAFB1 immunostaining was present within the nuclei of cells throughout 
striatal sections (Figure 3.13A). There was a significant increase in nuclear 
SAFB1 staining in HD patients compared to control striatum (Figure 3.13B). 
In control patients, between 18 - 60% of cells were positive for SAFB1 in the 
nucleus whereas in HD patients nuclear SAFB1 positivity ranged from 61 - 
87%.  
Cytoplasmic SAFB1 staining in HD cases was of greater intensity and 
present in significantly more cells in the striatum of HD patients compared 
to controls (Figure 3.13A and C). In control striatum, the frequency of cells 
positive for cytoplasmic SAFB1 ranged from 5 - 19%, whereas between 23 
- 68% of cells in HD patient tissue contained cytoplasmic SAFB1 staining 







Figure 3.11 SAFB1 expression is unaltered in MS patient Purkinje cells. 
Cerebellar Purkinje cells in patients with MS immunostained for SAFB1 
(representative images from n=4 patients, inset number represents patient case, 
scale bar is 25µm). SAFB1 staining within Purkinje cells with both 
morphologically normal and dystrophic phenotypes was nuclear without 
immunoreactivity in the cytoplasm of the cell soma or dendrites. The percentage 
of Purkinje cells positive for SAFB1 staining in the nucleus in each patient group 
are as follows (mean ± SEM); Control (72.09   ± 4.8), MS (83.3 ± 10.7), SCA 
(77.1 ± 8.6). The percentage of Purkinje cells positive for SAFB1 in the 
cytoplasm per group are as follows; Control (1.7 ± 0.5), MS (5.1 ± 1.9) SCA (46.2 





Figure 3.12 SAFB1 is not abnormally expressed in PD patient substantia 
nigra. Control (n=2) and PD patient (n=2) substantia nigra, immunostained 
for SAFB1. Overall levels of SAFB1 staining in the substantia nigra were 
low compared to the cerebellum and striatum. SAFB1 staining was localised 
to the nuclei. There was no clear difference in the SAFB1 staining pattern 
in control patients compared to PD patients. There was no evidence of 
cytoplasmic SAFB1 staining in control or PD patient substantia nigra. 40x 


































Figure 3.13 SAFB1 is expressed within HD patient striatal cell cytoplasm. A) 
Representative images of striatum immunostained for SAFB1. Within the striatal 
neuropil, large (neuronal) cells can be distinguished (arrow). Dystrophic neurons 
were present within HD striatum (dotted arrow). Numbers inset represent patient 
case, scale bar is 50µm. B) There was a significantly higher percentage of large 
(neuronal) cells with nuclear SAFB1 positivity in HD cases (n=8) compared to 
control cases (n=7) ((ctl=28.52, HD=82.75) U=0, p=0.0003, Mann-Whitney test). 
C) There was a significantly higher percentage of neurons in HD striatum with 
cytoplasmic SAFB1 staining compared to control cases ((ctl= 8.03, HD=46.48) 





Comparison of SAFB1 staining in HD striatum with a published 
histopathological image (Waldvogel et al. 2015) shows that SAFB1 positive 
cells match the morphology of degenerating MSNs in HD (Figure 3.14). The 
staining pattern of striatal SAFB1 staining with antibody A300-811A was 
replicated when sections were labelled with an alternative commercially 
available antibody raised against SAFB1 (IHC 00142, Bethyl) (Figure 3.15, 
Table 3.3). This control adds further validation to the discovery of abnormal 
cytoplasmic SAFB1 expression as a novel histopathological hallmark of 









10 Control 380 229 30 
11 Control 610 174 49 
12 Control 382 143 34 
13 Control 412 84 20 
14 Control 329 75 30 
15 Control 486 89 29 
16 Control 299 108 57 
 Total 2898 902 249 
17 HD (grade 2) 307 236 153 
18 HD (grade 2) 213 131 91 
19 HD (grade 3) 249 166 119 
20 HD (grade 3) 186 152 84 
21 HD (grade 3) 213 181 120 
22 HD (grade 4) 192 167 74 
23 HD (grade 4) 365 317 83 
24 HD (grade 4) 228 191 155 




Table 3.7 Number of striatal neurons with SAFB1 staining in control and 






Figure 3.14 Morphology of cells within HD striatum immunostained for 
SAFB1 in comparison to an H&E stained histological image labelled by a 
neuropathologist (Waldvogel et al. 2015, p45). Image comparison 
demonstrates that the large cells immunopositive for SAFB1 have the same 
morphology as degenerating medium spiny neurons. N=normal medium 
spiny neuron, D=degenerating neuron, A=astrocyte, O=oligodendrocyte. 
Scale bars are 25 µm. Image from Waldvogel et al. 2015 reproduced with 
permission from Springer Nature under licence number 4844250973302. 
Original work: link.springer.com/chapter/10.1007%2F7854_2014_354 
Figure 3.15 Control and HD striatum immunostained with two commercially 
available antibodies raised against SAFB1 both showed the same cellular 





3.4.7 Cytoplasmic SAFB1 is present in polyQ-positive HD neurons, but 
does not co-localise with polyQ inclusions 
To further explore the expression of SAFB1 in relation to polyQ pathology, 
striatal sections from patients with HD and control cases were dual 
immunolabelled with antibodies against polyQ-containing protein (1C2) and 
SAFB1 (Figure 3.16). Representative images of immunofluorescent staining 
in control and HD striatum are shown in Figure 3.16A. Substantial non-
specific intracellular fluorescence was observed within the sections, 
especially in the cytoplasm of large neurons. This fluorescence was 
attributed to the presence of lipofuscin, lipid-containing residue often 
present within aged brain cells. Several protocols were employed in this 
study to quench lipofuscin auto-fluorescence, including incubation of the 
tissue in copper sulphate solution, glycine solution, or Sudan Black. None 
of these methods were effective in reducing auto-fluorescence, so 
quantification was carried out with the caveat of its presence within the cells, 
and every effort was made to distinguish specific staining from auto-
fluorescence. SAFB1 staining in the cytoplasm of striatal cells was overall 
less easily distinguishable in fluorescent sections compared to detection 
using DAB. 
There were significantly more striatal cells positive for polyQ inclusions in 
HD striatum compared to control tissue, indicating that the staining protocol 
was able to specifically detect pathological inclusions (Figure 3.16B). As 
polyQ inclusions in HD are found in degenerating neurons, immunopositivity 
may be considered as a surrogate neuronal marker in this tissue. Within this 
neuronal population, the majority of cells (median 83%) also contained 
cytoplasmic SAFB1 staining, compared to just 13% cytoplasmic positivity in 
cells which did not contain polyQ inclusions (Figure 3.16C). This result 
demonstrates that abnormal cytoplasmic SAFB1 expression is a feature 






Figure 3.16 Cytoplasmic SAFB1 is present in polyQ-positive neurons in HD 
striatum. A) Dual immunofluorescent labelling of polyQ (green) and SAFB1 (red) 
in control (n=7) and HD (n=8) striatum. SAFB1 staining was mostly nuclear in 
control tissue and cytoplasmic SAFB1 was observed in large cells of HD striatum 
which were also positive for polyQ (arrows). Substantial auto-fluorescent lipofuscin 
deposits (asterisks) were observed in both control and HD tissue. Scale bar is 
25µm. B) HD striatum contained significantly more cells per mm2 positive for polyQ 
inclusions compared to control (ctl=0.75, HD=12.75) U=0, p=0.0003, Mann 
Whitney test. C) Cytoplasmic SAFB1 expression was associated with a 
significantly higher percentage of polyQ positive cells than polyQ negative cells 





Due to the auto-fluorescence in the dual labelled striatal sections, serial 
sections from a patient with HD were stained for SAFB1 and 1C2 using DAB 
to obtain a comparison of the distribution of each protein in the same area 
of tissue (Figure 3.17). Control staining demonstrated the specificity of the 
1C2 antibody (Figure 3.17Ai). The frequency of SAFB1 cytoplasmic staining 
compared to polyQ staining in striatal neurons is represented in Figure 
3.17Aii. Quantification showed that the frequency of abnormal SAFB1 
staining and polyQ inclusions was similar (38.6 and 34.5%, respectively). 
High magnification images showed polyQ inclusions in both the nucleus and 
cytoplasm of degenerating neurons which often presented as 
concentrations of large puncta/aggregates (a pattern previously described 
by Herndon et al. 2009). SAFB1 staining was more homogenous and 
diffusely spread throughout the nucleus and cytoplasm, with some evenly 
distributed small puncta present throughout the cytoplasm (Figure 3.17B). 
These differing staining patterns suggest that SAFB1 protein is spatially not 
closely associated with polyQ aggregates in HD neurons. 
3.4.8 There is no overall change in SAFB1 expression levels in the striatum 
of HD patients 
To further investigate the expression of SAFB1 in human polyQ disease, 
frozen striatal tissue from HD patients and control cases was obtained for 
RNA and protein analysis (Table 3.2). HD tissue was donated from patients 
who were significantly younger than control cases, but there was no 
significant difference in PMD between groups (Figure 3.18A). Striatal tissue 
from HD patients yielded a significantly lower amount of protein compared 
to control cases (Figure 3.18A). This could be a result of cell loss within the 
striatum of these patients, although there was no significant difference in 
RNA yield between groups (Figure 3.18A). Correlative analyses determined 
that there was no significant relationship between either age or PMD, and 
total RNA or protein yield (Figure 3.18B and C). qPCR analysis did not 
identify a difference in SAFB1 mRNA expression levels (relative to a 
housekeeping gene, beta-actin) in HD patient striatum compared to control 





Figure 3.17 PolyQ immunohistochemistry compared with SAFB1 
immunohistochemistry in a patient with HD. PolyQ inclusions were visualised using 
the monoclonal antibody 1C2. (A) i) Control staining with no primary antibody in 
HD striatum and using 1C2 to stain the striatum of a control patient shows no 
immunoreactivity. ii) Representative immunostaining for polyQ and for SAFB1 in 
separate, serial striatal sections of an HD patient (case 23). In this patient, 34.3% 
of neurons were polyQ positive and 38.6% of neurons were SAFB1 positive. B) 
SAFB1 and polyQ staining in striatal neurons. SAFB1 staining is quite consistent, 
with diffuse staining throughout the nucleus and cytoplasm, alongside some small 
dark foci throughout the cytoplasm of degenerating neurons. PolyQ staining 
patterns were more variable, presenting as either diffuse or aggregated, within  
both the nucleus and cytoplasm of degenerating neurons. Scale bar in (A) is 50µm, 




Based on recommendations from the literature (Welinder and Ekblad 2011) 
SAFB1 quantified by Western blotting and densitometry was normalised to 
total protein, rather than to a housekeeping protein. There was no difference 
in SAFB1 protein levels in HD patient striatum compared to control, when 
normalised to total protein (Figure 3.18Dii). One HD patient (case 47) 
expressed substantially higher protein levels in the striatum compared to 
the other cases in this study, and also expressed the highest relative level 
of SAFB1 mRNA of all the HD patients analysed. This patient died in her 
20s as a result of complications from HD symptoms, and was the only 
patient with Vonsattel Grade 4 neuropathology in this group. 
 
 
Figure 3.18 (next page) Analysis of protein and mRNA in control (n=10) and 
HD (n=6) patient frozen striatal tissue. A) Descriptive statistics for age, PMD, 
protein yield and mRNA yield. The age of HD patients is significantly lower than 
that of control patients (t(14), t=2.983, p=0.01). There is no significant difference 
in PMD time between control cases and HD patients (t(14), t=0.903, p=0.382). 
B) Across all samples there is no significant correlation between patient age 
(Bi) or PMD (Bii) with total yield of mRNA. C) Across all samples there is no 
significant correlation between age (Ci) or post-mortem delay (Cii) with total 
protein yield. D) SAFB1 expression was analysed at the mRNA and protein 
level in patient striatal tissue. Analysis by qPCR showed no significant 
difference in SAFB1 mRNA expression in HD patients compared to control 
cases when normalised to beta-actin expression (Di) (t(14), t=0.778, p=0.45). 
Analysis by Western blotting showed no significant difference in SAFB1 protein 
expression in HD patients compared to control, when normalised to total protein 
(Dii) (t(14), t=1.11, p=0.29). Correlative analyses were carried out using 
Pearson’s tests. Comparisons between two groups were carried out using 










3.5.1 Key findings 
This chapter utilised brain tissue from 48 patient cases to carry out a novel 
investigation of SAFB1 expression in human neurodegenerative disease. 
SAFB1 is an RBP with important neuronal regulatory functions, which is 
primarily expressed in the nucleus. The current findings show that abnormal 
cytoplasmic expression of SAFB1 in degenerating neurons is a newly 
discovered histopathological feature of human polyQ disorders including 
SCA and HD. Cytoplasmic SAFB1 was present in 56% of Purkinje cell 
neurons and 73% of DN neurons in a SCA1 patient with less severe Purkinje 
cell loss compared to the other SCA cases. This could indicate that 
abnormal SAFB1 expression is associated with relatively early stages of 
pathology in polyQ disease. There was no evidence of abnormal SAFB1 
expression in the brains of control cases, or in patients diagnosed with MS 
or PD.  
There was no overall change in SAFB1 RNA or protein levels in HD patient 
striatum. This may reflect the fact that SAFB1 becomes mislocalised to the 
cytoplasm in the absence of changed expression levels in HD. Alternatively, 
this finding could be a consequence of the experimental techniques not 
being sensitive enough to detect potential changes in the level of SAFB1 in 
degenerating MSNs. This is because any changes in MSN SAFB1 
expression levels will be diluted within the striatal tissue samples, which 
contain MSNs at differing stages of degeneration, amongst many other non-
neuronal cell types. The finding that one patient, who died very early from 
complications of HD, had high SAFB1 protein levels in the striatum, further 
supports the hypothesis that SAFB1 may be associated with the earlier 
stages of polyQ pathology. 
Donated patient tissue is a highly valuable resource which provides direct 
and unparalleled insight into the pathology of neurodegenerative disease. 
The work presented in this chapter is therefore highly translational, directly 




3.5.2 Evaluation of experimental design and methods 
Specificity of the anti-SAFB1 antibody A300-811A was confirmed using 
siRNA knockdown, and non-specific staining was controlled for by the 
inclusion of control sections with no primary antibody. This follows the 
recommendations of Bordeaux et al. (2010), who established the Rimm 
Algorithm for antibody validation. Furthermore, the methods utilised in this 
chapter closely followed the principles outlined by Gibson-Corley et al. 
(2013) in their frequently cited manuscript outlining important principles for 
valid scoring in histopathological research. The analysis of Purkinje cells 
through counting and measuring cross-sectional area have also been 
previously validated as methods of quantifying cell degeneration (Babij et 
al. 2013, Redondo et al. 2015, Kemp et al. 2016). 
There is potential for significant biological variation between patient cases 
(Stan et al. 2006). It is also important to consider variations in the post-
mortem processing of samples including delays in PMD time, alongside 
variations or artefacts conferred from the fixation and embedding 
processes. Control patient tissue was carefully selected based on clinical, 
pathological and diagnostic criteria, as outlined by Ferrer (2015).  Every 
effort was made to balance patient groups for age, PMD and sex, although 
this was not always possible given tissue availability. Variations in PMD are 
often of concern in experimental design, because the post-mortem period is 
associated with autolytic activity and subsequent changes in tissue pH 
which can differentially affect tissue quality, morphology and protein 
expression (Scudamore et al. 2011, Blair et al. 2016). A large 
comprehensive study of PMD times in tissue obtained from UK brain banks 
found no significant correlation between brain pH and either PMD or agonal 
state (Robinson et al. 2016). Therefore, extended post-mortem delays do 
not necessarily preclude the utility of individual patient samples in research. 
Immunostaining with a second SAFB1 antibody, IHC 00142, demonstrated 
the same expression pattern in HD striatal tissue as seen using A300-811A. 
Both antibodies are raised against antigens corresponding to C-terminal 




(Figure 3.19, Table 3.3). SAFB1 can be post-translationally modified by 
methylation within its R/G domain (Thandapani et al. 2013) and has also 
been shown to be cleaved (Lee et al. 2007). In this study, it is presumed 
that the antibodies are not sensitive to post-translational modifications such 
as methylation. Recognition of SAFB1 in the cytoplasm of disease patient 
neurons by these antibodies indicates that cytoplasmic SAFB1 detected by 
IHC is without substantial C-terminal cleavage, as loss of this part of the 
peptide would prevent antibody binding. However, this does not exclude the 
possibility that a proportion of SAFB1 cleaved at the C-terminal could exist 
undetected by the current methods. 
3.5.3 Study limitations 
3.5.3.1 Patient diagnoses 
SCA1 is a very rare disease, and there was only one genetically confirmed 
patient case available within the UK Brain Banks Network. There is also a 
scarcity of patient tissue available with any other genetically confirmed 
polyQ SCA types. The London Neurodegenerative Diseases brain bank has 
Figure 3.19 Diagram summarising SAFB1 antibody binding to SAFB1 protein 
domains. A) Diagram of SAFB1 protein domains with binding regions of antibodies 
indicated. B) Amino acid sequence of SAFB with binding regions of antibodies 
indicated in underline. Highlighted sequences correspond to the colours 




confirmed that no other researchers who have accessed the non-genetically 
confirmed SCA cases used in this study (cases 6, 7, 8 and 9) have carried 
out any genetic analyses.  
The cerebellar neuropathological findings summarised in Table 3.4 justify 
the inclusion of these cases in the present study. Pathological diagnosis of 
SCA is indicated in the post-mortem reports in all cases. Case 8 features 
strong polyQ-positive inclusions in Purkinje cells, strongly suggestive 
of polyQ SCA. Unfortunately, polyQ immunostaining was not carried out in 
the remaining cases (cases 6, 7, and 9) due to tissue availability. It should 
also be noted that lack of 1C2-positive inclusions in surviving Purkinje cells 
would not necessarily exclude the cases as polyQ SCA, as the abundance 
and distribution of inclusion bodies in Purkinje cells does not always 
correlate with disease (Koyano et al. 2002, Koeppen 2005). There is 
evidence to classify case 6 as autosomal dominantly inherited SCA based 
on patient clinical family history, again indicating a likely diagnosis of polyQ 
SCA. 
By a process of exclusion and based upon the observations from the single 
cerebellar section studied from each patient, it can be speculated that the 
undefined cases (6-9) may have suffered from either SCA1, SCA2 or SCA7. 
These patients did not feature grumose reaction in the DN, but all featured 
atrophied DN neurons, alongside substantial Purkinje cell degeneration, 
indicating that SCA3 is unlikely (Koeppen 2018). A diagnosis of SCA6 or 
SCA17 may also be excluded, as DN neurons are mostly preserved in these 
cases (Koeppen 2005, Seidel et al. 2012). The confirmed SCA1 case 
featured a less severe loss of Purkinje cell number, although this does not 
necessarily rule out a diagnosis of SCA1 for the unspecified cases, as there 
are likely to be significant variations in disease progression between 
patients. 
It cannot be ruled out that the undefined cases may have suffered from 
SCA12, caused by a CAG repeat in the non-coding 5’ UTR of the PPP2R2B 




tissue would provide further valuable insight to the mechanisms 
underpinning the abnormal expression of SAFB1. 
As the work in this chapter does feature one case of genetically confirmed 
SCA1, alongside multiple cases of confirmed polyCAG expansion in HD 
patients, the current study overall offers strong histopathological evidence 
for abnormal cytoplasmic expression of SAFB1 being associated with polyQ 
disease. 
3.5.3.2 Dual immunolabelling 
As concluded from Figure 3.16, technical limitations were encountered 
when performing dual fluorescent immunolabelling in human striatal tissue 
due to the accumulation of lipofuscin within cells. Lipofuscin is an auto-
fluorescent pigment made of lipids, metals and misfolded proteins which 
aggregates within neurons, and which is a general feature of aged human 
tissue especially in neurodegenerative disease (Moreno-García et al. 2018). 
Despite considerable attempts to quench this auto-fluorescence, its 
presence unfortunately occluded the clarity of immunostaining in the striatal 
tissue. There were no major accumulations of lipofuscin found in the 
cerebellar tissue of control or disease patients. 
3.5.4 Recommendations for future work 
To further explore the relationship between SAFB1 and other RBPs 
associated with neurodegenerative disease, human tissue sections could 
be immunostained with antibodies raised against FUS, and TDP-43. 
Furthermore, our lab has recently developed an antibody raised against 
SAFB2 (AB1897, Invitrogen custom antibody services) which does not 
cross-react with SAFB1. This antibody could be used to further characterise 
the expression of SAFB proteins in human polyQ disease. In future 
immunostaining studies, increasing the number of confirmed polyQ SCA 
patient cases is recommended, which may require donor tissue to be 
accessed from international repositories. The number of control cases 




SAFB protein expression in brain regions or tissues unaffected by SCA 
pathology, in polyQ SCA patient cases. 
The frozen striatal samples from control cases and HD patients are a 
valuable resource which should be used for further investigation. It is 
recommended that when performing Western blotting, normalisation of 
proteins of interest should not carried out in relation to specific 
housekeeping genes. This is because it is unknown whether there is 
differential vulnerability of proteins to degradation. Indeed, differential 
patterns of protein degradation in human post-mortem tissue were observed 
in Western blotting by Blair et al. (2016). In the current study, SAFB1 protein 
levels were normalised against total protein levels measured using a BCA 
assay. In future, it may be more accurate to normalise to whole protein 
content within each sample quantified by gel electrophoresis and 
Coomassie blue staining (Welinder and Ekblad 2011). It was not possible to 
take this approach in the current study due to unforeseen limitations in 
access to tissue samples. 
It was previously demonstrated that SAFB1 protein can be successfully 
isolated from human striatal tissue lysate by immunoprecipitation (data not 
shown). SAFB1 protein isolated from these samples could be utilised in 
proteomic analysis by tandem-mass tagging to gain further novel 
quantitative insight into the protein-protein interactions of SAFB1 in HD. 
Furthermore, it would also potentially be possible to isolate SAFB1 protein 
from these samples to investigate SAFB1 RNA interactions by iCLIP. These 
detailed biochemical analyses would complement the results of the current 
study and ensure that the valuable human tissue is utilised to its full 
potential. 
3.5.5 Conclusions 
This chapter demonstrates that the RBP SAFB1 is abnormally expressed in 
the cytoplasm of degenerating neurons of polyQ patients. This finding 
contributes to a wider body of evidence which implicates RBPs in 




which could provide insight into potential future therapeutic interventions. 
The use of human tissue confers high translational value to the current 
findings. However, as the experiments were observational, it is not possible 
to obtain any mechanistic insight from this data. Possible hypotheses to 
explain the altered expression of SAFB1 in polyQ disease include aberrant 
interaction of SAFB1 with polyQ protein or polyCAG RNA transcripts, or 
dysregulated nuclear export or import of SAFB1. The role of SAFB1 in polyQ 





4. Chapter 4 
Investigating the mechanism of SAFB1 expression in 
polyglutamine pathology 
4.1 Overview 
4.1.1 Chapter overview 
This chapter investigated the mechanism by which SAFB1 protein may 
contribute to polyglutamine (polyQ) pathology. An RNA immunoprecipitation 
(IP) protocol to quantify the interaction of SAFB1 protein with RNA 
containing expanded polyCAG tracts was successfully developed. Using 
this technique, it was confirmed that SAFB1 protein binds ATXN1 RNA 
containing both physiological and expanded CAG trinucleotide repeats. 
Furthermore, compared to ATXN1 containing a normal CAG tract, there was 
a relative increase in the amount of ATXN1 RNA containing pathologically 
expanded CAG repeats associated with SAFB1 protein. This is a novel 
mechanistic insight into the RNA binding function of SAFB1 in polyQ 
disease. In addition, this chapter describes the establishment of human 
iPSCs with SAFB1 and SAFB2 deletion which can be used in the future to 




4.1.2 Graphical abstract 
 
4.2 Introduction 
PolyQ disorders are caused by an expansion of the CAG trinucleotide 
repeat tract in the coding regions of specific genes. The threshold number 
of CAG codons causing disease varies with the affected gene (Table 1.3). 
Genes containing expanded CAG sequences are transcribed into 
expansion repeat-containing RNA (xtrRNA) and subsequently translated 
into peptide gene products containing polyQ tracts.  
 




The molecular pathology underlying the process of neuronal loss in polyQ 
disorders is not yet fully understood. Much research has focussed on 
understanding the role of polyQ proteins, as their propensity to aggregate 
and form proteinaceous intracellular inclusions is considered a pathological 
hallmark of polyQ disorders. Modifying the misfolding and aggregation of 
polyQ protein has therefore been considered a key therapeutic target 
(Takeuchi and Nagai 2017). However, it is still not understood whether 
formation of polyQ aggregates or inclusions in neurons directly causes 
neuronal loss (Arrasate and Finkbeiner 2012). 
It is now recognised that xtrRNA transcripts are likely to be important 
mediators of polyQ pathology. CAG repeat number correlates to age of 
disease onset across polyQ disorders (Gusella and MacDonald 2000) 
(Figure 1.2) and the number of CAG repeats is the most important predictor 
of pathology, independent of the glutamine tract length of the corresponding 
gene product (Lee et al. 2019). 
RBPs are one of the most important elements of RNA regulation. RBP 
dysregulation in neurodegenerative disease is exemplified by mutations in 
TDP-43 and FUS which cause ALS and FTD. RBPs are implicated in the 
molecular pathology of polyQ disorders including HD (Doi et al. 2008, Kino 
et al. 2016) and SCA (Irwin et al. 2005, Ostrowski et al. 2017). Our research 
group is interested in the RBP SAFB1, which has structural and functional 
similarities to both TDP-43 and FUS (section 1.5, Figure 1.11). 
Although there are currently no known disease-causing mutations in 
SAFB1, our research group has previously established that SAFB1 is highly 
expressed in the brain and mediates neuronal functions (Rivers et al. 2015, 
Norman et al. 2016). SAFB1 is also required for development (Ivanova et 
al. 2005) and is involved in the cellular stress response (Norman et al. 
2016). SAFB1 interacts strongly with RNA transcripts of the ATXN1 gene, 
which is mutated with an expanded polyCAG tract in the polyQ disorder 
SCA1 (section 3.2, Figure 3.2). Proteomic analysis in cell lines does not 




al. 2018, Allahyani 2020). The novel findings presented in Chapter 3 
demonstrate that SAFB1 is abnormally expressed in the cytoplasm of 
degenerating neurons, a pathology specific to patients with polyQ disorders 
including SCA1.  
Based on these findings, this chapter aimed to further understand the 
pathology of SAFB1 in polyQ disease, specifically the interaction of SAFB1 
with ATXN1 RNA. This chapter also describes the creation of human iPSCs 
with knockout of SAFB1 and SAFB2 which can be used as a tool to further 
understand the role of SAFB proteins in polyQ pathology. 
4.3 Methods 
4.3.1 Immunofluorescent labelling of transfected cells 
SH-SY5Y cells (section 2.3.1) were plated in antibiotic-free media at a 
density of 1x105 cells per well in a 24-well plate on sterilised glass coverslips 
pre-coated in poly-d-lysine. After 24 hours, SH-SY5Y cells were transiently 
transfected with DNA plasmids containing N-terminal eGFP-tagged ataxin1 
(ATXN1) with either a subphysiological length CAG tract (pEGFP-ATXN1-
2Q), a normal length CAG repeat tract (pEGFP-ATXN1-30Q) or a 
pathologically expanded CAG repeat tract (pEGFP-ATXN1-52Q). All 
ATXN1 plasmids were kind gifts from Huda Zhoghbi via Addgene (Figure 
4.2). Transfection mixture containing 1.3µl FuGENE 6 transfection reagent 
(Promega) mixed with 48.7µl Opti-MEM reduced serum media 
(ThermoFisher Scientific) was combined with 500ng of DNA plasmid and 
left to stand for 15 minutes. The transfection mixture was added to SH-SY5Y 
cells in a well containing 200µl of growth media. Control cells were 
incubated with transfection mixture but no DNA plasmid. A full media 
change was carried out 6 hours after transfection. Transfected cells were 
left for 48 hours before fixing in 4% PFA and carrying out immunofluorescent 
staining (section 2.7.3). SAFB1 was visualised using antibody A300-811A 
or IHC 00142 (Bethyl) at 1:200 and anti-rabbit Cy3 conjugated secondary 
antibody (Stratech) at 1:300. HeLa cells grown on glass coverslips were 




immunostained according to the protocol in section 2.7.3. FLAG-tagged 
protein was visualised using antibody F3165 (Millipore) at 1:500 and anti-
mouse Cy3 conjugated secondary antibody (Stratech) at 1:300. Cells were 
imaged using a Leitz DMRB fluorescence microscope (Leica) with a Leica 
DC500 camera and Leica imaging software. 
 
4.3.2 RNA immunoprecipitation (IP) of SAFB1 protein and ATXN1 RNA 
4.3.2.1 Transfection of cell lines with ATXN1 plasmids  
HeLa cells (section 2.3.1) were plated in antibiotic-free growth media at a 
density of 9x105 cells per 10cm culture dish. After 24 hours, cells were 
transiently transfected with DNA plasmids containing N-terminal FLAG-
tagged ataxin1 (ATXN1) with either a subphysiological length CAG tract 
(pcDNA1 Flag ATXN1[2Q]), a normal length CAG repeat tract (pcDNA1 




Flag ATXN1[30Q]) or a pathologically expanded CAG repeat tract (pcDNA1 
Flag ATXN1[85Q]). All ATXN1 plasmids were kind gifts from Huda Zhoghbi 
via Addgene (Figure 4.2). Transfection media containing 45µl FuGENE 6 
transfection reagent (Promega) mixed with 925µl Opti-MEM reduced serum 
media (ThermoFisher Scientific) was combined with 15µg of DNA plasmid 
and left to stand for 15 minutes. The transfection mixture was added 
dropwise to HeLa cells in a 10cm dish containing 8ml of growth media. 
Control cells were incubated with transfection mixture but no DNA plasmid. 
A full media change was carried out 6 hours after transfection, and cells 
were left for 48 hours before use in RNA immunoprecipitation (IP) 
experiments. 
4.3.2.2 Cross-linking of antibodies to Protein G beads 
Protein G beads (Dynabeads, ThermoFisher Scientific) were vortexed into 
suspension and the desired volume of bead slurry was pelleted using a 
magnetic rack before washing beads in an equal volume of PBST (wash 
buffer). Wash buffer was added to bring the total volume to 1ml. Anti-SAFB1 
(AB1895, Invitrogen custom antibody services) or rabbit IgG (Cell signalling 
technology) at a concentration of 15µg per 100µl of bead slurry was added 
to the washed beads and rotated overnight at 4oC. Antibody-bound Protein 
G beads were pelleted using a magnetic rack, and washed 3 times in 1ml 
of wash buffer, then 3 times in 1ml of coupling buffer. Beads were pelleted 
and resuspended in freshly prepared 20mM DMP (dimethyl pimelimidate) 
before rotating for 30 minutes at room temperature. This step was repeated 
with another solution of freshly made DMP. The cross-linking reaction was 
quenched by washing beads in 1ml quenching buffer and rotating for 30 
minutes at room temperature. Un-crosslinked antibody was removed from 
the beads by washing 3 times in 1ml of elution reagent. Cross-linked beads 
were resuspended to their original volume in PBST with 0.02% sodium 
azide and stored at 4oC for up to 4 weeks. 
4.3.2.3 RNA IP 
All stages of the RNA IP procedure were carried out in RNase-free 




scraped on ice in 1ml of lysis buffer containing protease inhibitors and 
RNAse inhibitors. Lysates were centrifuged and the supernatant pre-
cleared by incubating with Protein G magnetic beads washed in lysis buffer. 
Pre-cleared protein lysates were quantified using a bicinchoninic acid assay 
(Pierce BCA protein assay kit, Thermo Scientific). Protein was diluted to 
1µg/µl, and a 500µl aliquot incubated with 25µl Protein G beads cross linked 
to either 3.75µg SAFB1 antibody (AB1895, Invitrogen custom antibody 
services) or 3.75µg rabbit IgG (Cell Signalling Technology). Lysates were 
rotated overnight at 4oC with antibody-linked beads. Protein G beads bound 
to immunocomplexes were isolated using a magnetic rack and washed 4 
times with 500µl lysis buffer and once with 500µl RNAse-free PBS. A 
sample of beads in solution from each experimental condition was reserved 
for Western blot analysis. Beads were pelleted and resuspended in fresh 
BL/TG buffer from a Reliaprep RNA Cell Miniprep kit (Promega) and left at 
room temperature for 10 minutes to dissociate immunocomplexes from the 
beads. RNA was purified from immunocomplexes using a Reliaprep RNA 
Cell Miniprep Kit according to manufacturer’s instructions and eluted in 12µl 
nuclease-free water. In each experiment, RNA was purified from a sample 
of input protein, Protein G beads conjugated with antibody and Protein G 
beads conjugated with rabbit IgG. 
4.3.2.4 Western blotting of protein lysates from RNA IP experiments 
To confirm SAFB1 protein was successfully isolated using antibody-linked 
Protein G beads, samples of pre-cleared input were analysed by Western 
blotting (section 2.6.11) alongside samples of antibody-linked and IgG-
linked Protein G beads associated with immunocomplexes. Protein was 
dissociated by resuspending beads in 2xSDS sample buffer and heating at 
95oC for 5 minutes. To quantify relative FLAG-ataxin1 protein expression 
levels, input samples from each experiment were also analysed by Western 
blotting. Samples were run on an 8% polyacrylamide gel then transferred to 
a PVDF membrane using a TransBlot Turbo Transfer System (Bio-Rad). 
Membranes were blocked in 5% milk (in PBS) then probed with either anti-
SAFB1 antibody (1:1000 in 1% (v/v) milk in PBS) (A300-811 A) or anti-FLAG 




with anti-rabbit or anti-mouse peroxidase conjugated secondary antibody 
(1:10000) (GE Healthcare) and antibody signal visualised using ECL. 
Membranes probed for FLAG expression were densitometrically analysed 
using Image Studio Lite (Licor) to quantify the intensity of protein bands. 
4.3.2.5 Quantification of ATXN1 cDNA by qPCR 
RNA was reverse transcribed using a GoScript Reverse Transcription 
System kit (Promega) using random primers according to manufacturer’s 
instructions. cDNA was analysed by qPCR with Power SYBR Green 
(ThermoFisher Scientific) using primers to recognise ATXN1 
(Forward:TCCAGCACCGTAGAGAGGAT, Reverse: 
GCCCTGTCCAAACACAAAAA) with a StepOnePlusTM PCR system 
(ThermoFisher Scientific). cDNA from each condition was run in triplicate. 
4.3.2.6 Analysis of RNA IP qPCR data 
To quantify the relative amount of ATXN1 RNA bound to SAFB1 protein, the 
mean CT value for each experimental condition was compared against the 
CT values of a standard curve of serially diluted ATXN1 DNA which was run 
alongside the experimental wells on each qPCR plate. Each serial dilution 
of the standard curve was assigned a relative value. The relative level of 
ATXN1 in the experimental samples was then determined by comparison to 
the standard curve. For each sample, the mean relative quantity was 
expressed per µg of SAFB1 protein. The mean relative quantity for each 
condition was normalised to the densitometric quantification of FLAG 
protein expression as analysed by Western blotting. Data from n=3 
independent experiments was analysed using a one-way ANOVA with 
Tukey’s post-hoc test to evaluate statistical significance between groups. 
4.3.3 CRISPR-Cas9 knockout of SAFB1/2 dual promoter  
4.3.3.1 Ribonucleoprotein complex preparation 
Guide RNAs (gRNAs) flanking the SAFB1/2 dual promoter were designed 
and compared against the WT genome using BLAST in order to minimise 
off-target effects. Lyophilised gRNAs and fluorescent tagged tracrRNA 




(IDT) to 200µM. Each gRNA was combined with tracrRNA in equimolar 
concentration in nuclease-free duplex buffer (IDT). Oligos were denatured 
at 95oC then annealed by cooling to room temperature for at least 20 
minutes. Cas9 (IDT) was diluted in Cas9 storage buffer to a 1M stock then 
combined with each crRNA/tracrRNA complex before incubating at room 
temperature for 20 minutes. The two ribonucleoprotein (RNP) complexes 
were combined into a single RNP solution prior to nucleofection.  
4.3.3.2 Nucleofection 
Kolf2 iPSCs were obtained from the research lab of Professor Nick Allen 
(Cardiff University) via HipSci. iPSCs were grown in 6-well plates pre-coated 
with vitronectin and maintained as undifferentiated colonies in E8 media 
(Gibco) until reaching 80% confluency. One well of cells was used for each 
nucleofection. Cells were treated with 1µl ROCK inhibitor (Stemcell 
Technologies) per ml culture medium for 30-60 minutes. Media was 
aspirated and cells washed in PBS (no magnesium). Cells were incubated 
with pre-warmed Accutase (Stemcell Technologies) at 37oC for around 5 
minutes until colonies began dissociating. PBS was swirled into each well 
and the suspension collected into a 15ml falcon tube before centrifuging at 
1000rpm for 3 minutes. Cells were resuspended in 1ml PBS and 1x106 cells 
aliquoted in suspension into a fresh 15ml falcon tube. After pelleting again, 
cells were resuspended in 100µl nucleofection solution (P3 primary cell 
nucleofector kit, Lonza) prepared according to manufacturer’s instructions. 
The pre-prepared RNP solution was added, and the whole suspension 
transferred to a cuvette before nucleofecting in an Amaxa 4D nucleofector 
X unit (Lonza). Cells were left to recover for 10 minutes at 37oC post-
nucleofection before combining the suspension with 1ml pre-warmed E8 
media with ROCK inhibitor. Cells were transferred drop-wise to a single well 
of a 6-well dish pre-coated in vitronectin and returned to the incubator 
overnight. 
4.3.3.3 FACS sorting 
Cells were FACS sorted 24 hours after nucleofection with fluorescent 




media with ROCK inhibitor as a single-cell suspension in a 15 ml falcon tube 
and placed on ice. FACS sorting was carried by Mr. Mark Bishop (Cardiff 
University) using a BD FACS Aria Fusion. The top 10% of cells expressing 
the highest tracrRNA fluorescence were collected (typically around 3000 
cells) and kept on ice until plating. Cells in suspension were plated drop-
wise into a well pre-coated in vitronectin containing E8 media plus ROCK 
inhibitor. A full media change was carried out after 24 hours. 
4.3.4 PCR screening of iPSC clones 
iPSC colonies were individually picked and plated into vitronectin-coated 
wells of a 96-well plate. After the colonies became well-established, they 
were passaged to create a duplicate 96-well plate. One plate was kept as a 
growing stock for expansion following PCR screening. Genomic DNA was 
extracted from the duplicate plate using DNA QuickExtract solution 
(Lucigen) according to manufacturer’s instructions. For optimisation of PCR 
screening conditions, genomic DNA from cell lines was extracted using a 
Wizard genomic DNA Purification kit (Promega). To screen iPSC genomic 
DNA for SAFB1/2 dual promoter deletion, PCR reactions were set up using 
a FastStart High Fidelity PCR System kit (Roche) in accordance with Table 
4.1 and run on a thermocycler according to the programme specified in 





















Reaction component µl 
10x buffer 5 
MgCl2 (25mM) 4  
dNTPs (20mM) 1 
DMSO 2.5 
F primer (4µM) 5 
R primer (4µM) 5 
gDNA (100ng/µl) 1 









95 2 minutes 
Denaturation 95 20 seconds 
Annealing 50 30 seconds 
Extension 72 60 seconds 
Final 
Extension 
72 5 minutes 
Table 4.1 PCR reaction conditions 
for screening iPSC gDNA for 
SAFB1/2 promoter deletion 
Table 4.2 Thermocycler parameters for PCR 





4.4.1 SAFB1 and expanded polyQ ataxin1 protein do not co-localise in SH-
SY5Y cells 
To model polyQ protein expression, high copy number DNA plasmids 
expressing ATXN1 with various lengths of CAG repeat tract were transiently 
transfected into cell lines to artificially express ATXN1 RNA and ataxin1 
protein. Constructs were tagged at the N-terminal with either eGFP or FLAG 
to aid visualisation of ataxin1 protein. Figure 4.2 summarises the DNA 
plasmids used in this study. 
To investigate whether overexpression of ataxin1 containing a polyQ 
expansion affected SAFB1 protein expression, SH-SY5Y cells were 
transiently transfected with eGFP-tagged ATXN1 and immunostained using 
a SAFB1-specific antibody (Figure 4.3). Large protein inclusions of eGFP-
ataxin1 were expressed in the nucleus (Figure 4.3A). Less frequently, some 
cells transfected with pathologically expanded eGFP-ataxin1 featured 
cytoplasmic eGFP-ataxin1 expression (Figure 4.3Bi). Nuclear ataxin1 
protein inclusions varied in size between cells within each polyQ repeat 
length, but an overall trend was observed that the size of the inclusions 
appeared to increase with increasing glutamine tract length (Figure 4.3A). 
There was no clear co-localisation of ataxin1 inclusions with immunopositive 
SAFB1 puncta in the nucleus (Figure 4.3A). Furthermore, expression of 
eGFP-ataxin1 did not appear to affect the overall level or distribution of 
SAFB1 nuclear immunopositivity. In some cells transfected with 52Q 
expanded ataxin1, infrequent small cytoplasmic SAFB1 positive inclusions 
were observed in the cytoplasm (Figure 4.3Bii). This staining pattern was 
not present in untransfected cells, or in cells expressing ataxin1 with 2 or 30 
CAG repeat tracts. This finding supports the evidence presented in Chapter 
3, which indicated that SAFB1 protein and expanded polyglutamine 
peptides do not necessarily co-localise in degenerating neurons of patients 
with polyglutamine disorders. Investigations into the interactions of SAFB1 





Figure 4.3 SAFB1 immunostaining in SH-SY5Y cells transfected with eGFP-
ataxin1 constructs with varying CAG repeat lengths. A) eGFP-ataxin1 protein was 
expressed as large well-defined inclusions mostly within the nucleus. Inclusion 
size was variable within conditions, but in some cells there appeared to be an 
increasing size with increasing CAG length. eGFP-ataxin1 inclusions did not co-
localise with areas of bright SAFB1 staining within the nucleus (arrows). Images 
captured with assistance from Mr. Ben Clennel. B) Two separate images 
representing less frequently occurring features observed amongst cells 
transfected with pathologically expanded ataxin1-52Q. i) eGFP-ataxin1 expressed 
both as nuclear inclusions and within the cytoplasm (asterisk). ii) SAFB1 
immunostaining was present as small inclusions within the cytoplasm of some 
cells (arrows). Images are representative of cells across duplicate coverslips. 




4.4.2 Development of an RNA IP technique to study the interaction of 
SAFB1 protein with ATXN1 RNA 
To investigate the interaction between SAFB1 protein and ATXN1 RNA, an 
IP technique was developed. This allowed SAFB1 protein from HeLa cells 
transfected with ATXN1 of varying CAG repeat lengths to be isolated, and 
the relative levels of associated ATXN1 RNA to be quantified. eGFP is a 
32.7KDa protein (239 amino acids) and contains multiple base-pair motifs 
predicted to interact with SAFB1 (Table 4.3). In contrast, FLAG 
(DYKDDDDK) is an eight amino acid tag of just 24 base pairs, containing 
only one possible motif predicted to interact with SAFB1 protein (Table 4.3). 
RNA IP experiments were therefore carried out using FLAG-tagged ATXN1 
constructs to minimise the likelihood of aberrant interaction of SAFB1 
protein with tagged-ATXN1 RNA transcripts. 
RNA IP experiments were carried out in HeLa cells because they are readily 
transfected with DNA plasmids. Immunostaining of HeLa cells transfected 
with FLAG-ATXN1 plasmids confirmed a good transfection efficiency 
(Figure 4.4A) and demonstrated that the expression pattern of FLAG-
ataxin1 was similar to that observed for eGFP-ataxin1 (Figure 4.4B). 
Based on protocols described in the literature (especially Konig et al. (2011), 
Izumikawa et al. (2017) and Volkening et al. (2018)), a workflow for RNA IP 
experiments was established (Figure 4.5). 
Table 4.3 Pentameric and trimeric purine-rich motifs likely to be recognised by 
SAFB1 (Rivers et al. 2015) and their frequency of occurrence in eGFP and FLAG 
tags 
Motif Number occurring in eGFP Number occurring in FLAG 
Pentameric 5 0 
GAAGA 1 0 
AAGAA 1 0 
AGAAG 2 0 
Trimeric 39 1 
GAA 11 0 
AAG 21 1 





Figure 4.4 FLAG immunostaining in HeLa cells transfected with pcDNA1-FLAG-
ataxin1 plasmids containing 2, 30 or 85 CAG repeats. A) Overlay of Hoechst 
fluorescence (blue) and FLAG immunostaining (red). Approximately 70% of cells 
expressed FLAG-ataxin1 48 hours after transfection. Scale bar is 50µm. B) 





4.4.3 Confirmation of SAFB1 protein isolation using RNA IP protocol 
Samples of input protein lysate, unbound lysate, protein bound to SAFB1 
antibody-linked beads (IP) and protein bound to IgG-linked beads (IgG) 





were reserved for Western blotting (Figure 4.6). A clear protein band 
corresponding to SAFB1 was present in the input of each experimental 
condition, and a weaker SAFB1 band was observed in the sample of 
immunoprecipitated protein in each experimental condition. This confirmed 
that SAFB1 protein was successfully isolated by the IP protocol. 
Furthermore, there was no SAFB1 protein present in the isotype control 
(IgG) samples. 
A sample of unbound lysate (UB) was also analysed by Western blotting 
(Figure 4.6). There was no SAFB1 protein present in the unbound lysate 
following overnight immunoprecipitation with SAFB1, confirming that the 
antibody incubation protocol effectively bound and removed SAFB1 protein 
from the input lysates, therefore demonstrating that the antibody 
concentration to protein ratio was optimal. 
To confirm that the protein-RNA immunocomplexes were effectively 
dissociated from the Protein G beads prior to RNA purification, a sample of 
dissociated beads (DB) was analysed by Western blot (Figure 4.6). There 
was a trace of SAFB1 protein remaining in the dissociated beads for the 2 
CAG transfected sample, but overall the low/absent SAFB1 signal indicates 
that the immunocomplex was indeed successfully dissociated from the 
beads. Taken together, these results show that the protein isolation stage 
of the RNA IP was successfully optimised. 
4.4.4 Pathological CAG expansion may increase the association of ATXN1 
RNA with SAFB1 protein 
Following qPCR analysis, the relative levels of ATXN1 RNA were 
normalised per µg of SAFB1 protein (Table 4.4). The relative ATXN1 
expression in the IgG control samples was very low compared to in the IP 
samples. This isotype control, alongside the Western blot results (Figure 






There was an increased relative amount of ATXN1 RNA in the control IP 
samples (non-transfected) compared to the corresponding IgG control. This 
indicates the association of endogenous ATXN1 with SAFB1. There were 
very low endogenous ATXN1 levels relative to the 2, 30, and 85 CAG 
ATXN1 transfected samples. This indicates that a) ATXN1 expression is 
highly enriched in the transfected samples, confirming successful 
transfection and transcription of exogenous ATXN1, and b) the interaction 
Figure 4.6 Western blots of protein samples from RNA IP 
experiments, probed for anti-SAFB1. Protein bands corresponding to 
the approximate molecular weight of SAFB1 (arrows) are visible in 
Input and IP samples but not in IgG samples, DB samples or UB 
samples. Input=protein lysate before IP. IP=protein associated with 
SAFB1 antibody-bound Protein G beads after IP. IgG=protein 
associated with rabbit IgG-bound Protein G beads after IP. 
DB=dissociated beads (Protein G beads after immunocomplex 
dissociation), UB=unbound lysate (protein unbound to SAFB1 




of SAFB1 protein with endogenous ATXN1 transcripts accounts for a small 
proportion of the total quantified in transfected cells.  
ATXN1 RNA was detected in all the transfected samples which were 
immunoprecipitated using the SAFB1 antibody, confirming that SAFB1 
protein interacts with ATXN1 RNA with varying length CAG tracts. Finally, 
results show an overall increase in the mean relative ATXN1 expression in 
IP samples with an increasing CAG repeat length (Table 4.4) 
The original experimental protocol was designed to quantify ATXN1 levels 
in each input sample alongside its associated IP and IgG sample. Relative 
levels of ATXN1 would then be expressed as a percentage of the ATXN1 
levels in the input of each sample. This would correct for transfection and 
transcriptional variations between ATXN1 plasmids. In each of the three 
experimental replicates, the CT values for the input samples were extremely 
low and therefore the relative levels of ATXN1 could not be calculated. This 
meant that the relative ATXN1 levels could not be normalised to account for 
variations in plasmid expression levels. 
To correct for this, protein lysates from the input of each experimental 
condition were analysed for protein-level expression of FLAG-ataxin1 by 
Western blotting with a monoclonal antibody raised against the FLAG tag. 
The relative ATXN1 expression levels were then normalised to their 
respective FLAG-ataxin1 levels as quantified by densitometric analysis 
(Figure 4.7). This analysis aimed to compare the interaction of SAFB1 
protein with ATXN1 with 2, 30 and 85 CAG transcripts and therefore does 
not include the control (non-transfected) samples.  
Upon FLAG protein normalisation of the data, the apparent increase in 
relative 30 CAG ATXN1 levels compared to 2 CAG ATXN1 levels (Table 
4.4) was eliminated, demonstrating the importance of normalisation when 












After normalisation to FLAG-tagged ataxin1 protein expression, RNA IP 
results showed that pathological expansion of ATXN1 (85 CAG) resulted in 
an increased association of ATXN1 RNA with SAFB1 protein when 
compared to 2 CAG and 30 CAG ATXN1 (Figure 4.7). The effect size was 
large, but varied considerably between experimental replicates. In 
particular, experimental replicate 2 (n2) resulted in an approximately 20-fold 
higher percentage increase in 85 CAG vs. 30 CAG ATXN1 levels compared 
to replicates 1 and 3 (Figure 4.7B). The data did not reach statistical 
significance. Given the large yet variable effect size, it is recommended that 
the number of experimental replicates is increased to afford better power in 
statistical testing.   
The secondary structure of RNA transcripts alters binding to RBPs, 
therefore the secondary structure of ATXN1 containing various CAG repeat 









1 0.03 1.68 
2 0.01 2.0 
3 0.04 2.71 
Mean 0.03 2.13 
SEM 0.01 0.3 
2 CAG 
1 0.14 11.80 
2 0.02 4.01 
3 0.20 58.76 
Mean 0.12 24.86 
SEM 0.05 17.1 
30 CAG 
1 0.23 27.22 
2 1.88 19.72 
3 0.44 140.21 
Mean 0.85 62.38 
SEM 0.52 38.97 
85 CAG 
1 0.41 50.83 
2 0.01 54.12 
3 1.0 177.58 
Mean 0.47 94.18 
SEM 0.29 41.71 
Table 4.4 Relative levels of ATXN1 RNA associated with SAFB1 protein 
immunoprecipitated from HeLa cells transfected with ATXN1 with 2 
(subphysiological), 30 (physiological) or 85 (pathological) length CAG repeat 
tracts. Control refers to untransfected cells. IgG refers to immunoprecipitations 




that CAG expansion results in the formation of a typical hairpin loop, the 
length of which was extended with increasing numbers of CAG repeats. 
4.4.5 Establishing human iPSCs with SAFB1/2 dual promoter deletion 
CRISPR-Cas9 was used to genetically modify human iPSCs in collaboration 
with Professor Nick Allen’s research group (School of Biosciences, Cardiff 
University). The aim was to create human iPSCs which can be differentiated 
into neurons which do not express SAFB1 or SAFB2, by deletion of the dual 
promoter. Kolf2 cells derived from the fibroblasts of a control patient were 
used in the CRISPR-Cas9 protocol (Figure 4.9). 
Figure 4.7 Pathological CAG expansion in ATXN1 may increase its association 
with SAFB1 protein. A) Relative ATXN1 RNA levels per µg of SAFB1 protein, 
normalised to FLAG-ataxin1 protein expression. There was no statistically 
significant difference between experimental groups (One-way ANOVA with 
Tukey’s post-hoc test, n=3). B) Table detailing descriptive statistics of the RNA IP 





Figure 4.8 Secondary structure of ATXN1 mRNA with 2 CAG repeats (below 
normal), 30 CAG repeats with one CAT interruption (normal range) and 39 
uninterrupted CAG repeats (pathologically expanded). CAG repeats begin at 
nucleotide 589 in the ATXN1 mRNA sequence, which is shown magnified in the 
inset box.  




Screening to determine which iPSC clones carried the deletion was carried 
out by PCR using primers flanking the dual promoter region. PCR conditions 
were optimised by adjusting reaction parameters until a single clear band of 
PCR product was visible (Figure 4.10Ai-iii). Following implementation of the 
CRISPR protocol, PCR was used to screen genomic DNA extracted from a 
96-well plate of individual iPSC clones. Wildtype cells, heterozygous 
knockout cells and homozygous knockout cells were successfully detected 
(Figure 4.10Aiv). Confirmatory Sanger sequencing demonstrated deletion 
of the SAFB1/2 dual promoter (Figure 4.10B), and clones were frozen in 
liquid nitrogen for future use. 
Figure 4.9 Diagram outlining the protocol for SAFB1/2 promoter knockout in 





Figure 4.10 Screening Kolf2 iPSCs for deletion of SAFB1/SAFB2 dual promoter. 
A) Optimisation of conditions for PCR screening of SAFB1/2 dual promoter 
deletion. Genomic DNA extracted from iPSCs was amplified by PCR using primers 
complementary to sequences flanking the SAFB1/2 dual promoter sequence. In 
wildtype (WT) iPSCs the PCR product is 965bp, in knockout (KO) iPSCs the PCR 
product is 393bp. PCR conditions were optimised for primer concentration, MgCl2 
concentration (i) and annealing temperature (ii). Using optimised conditions (2mM 
MgCl2, 0.4µM primers and 50oC annealing), various PCR enzymes were tested. 
FastStart HiFi polymerase resulted in a clean band at 965bp in WT iPSC gDNA. 
Following CRISPR-Cas9 nucleofection, DNA was screened from clonal colonies 
of iPSCs. A) (iv) demonstrates the results from heterozygous (het. KO), WT and 
homozygous (hom. KO) colonies. B) Sanger sequencing was used to confirm 
deletion of the SAFB1/2 dual promoter in Kolf2 iPSCs. The WT promoter is 
highlighted in grey, whilst forward and reverse PCR primer sequences are 





4.5.1 Key findings 
This chapter used RNA IP to purify SAFB1 protein from HeLa cells, 
demonstrating that it associated with artificially expressed ATXN1 RNA with 
2, 30 or 85 CAG repeats. Pathological expansion of the CAG tract conferred 
an increase in the relative level of ATXN1 RNA associated with SAFB1 
protein. In addition to the RNA IP experiments, a human iPSC line with 
deletion of the SAFB1/2 dual promoter was established. 
4.5.2 Evaluation of RNA IP methodology 
To study RNAs which interact with a protein of interest, most established 
methods require protein purification which is usually carried out by IP 
(Ramanathan et al. 2019). This is often combined with chemical cross-
linking of protein with its associated nucleic acids by irradiation with 245-nm 
UV light. Techniques which do not require protein purification are currently 
less well-established, and are based on chemical modification of RNA by 
artificially fusing the RBP of interest to either an ADAR enzyme (McMahon 
et al. 2016), or poly(U) polymerase (Lapointe et al. 2015), and sequencing 
either deaminated or poly(U) tailed RNAs, respectively. CLIP-seq methods 
combine protein purification and cross-linking with high-throughput 
sequencing to identify multiple RNA binding partners of a protein of interest. 
Many iterations of CLIP-seq exist, utilising different methods of cross-linking 
and RNA processing (reviewed by Ramanathan et al. (2019)). iCLIP was 
used previously by Rivers et al. (2015) to characterise the direct RNA 
binding partners of SAFB1, which include ATXN1. 
In this chapter, protein IP was combined with RNA purification and qPCR to 
quantify the relative levels of ATXN1 transcripts with varying CAG tract 
lengths associated with SAFB1. In preliminary optimisation experiments 
(not shown), HeLa cells were irradiated with UV to cross-link SAFB1 to 
ATXN1 RNA transcripts. However, this requires an additional proteinase K 
processing step, and did not change the yield of SAFB1-associated RNA in 




denaturing conditions, ATXN1 RNAs may either be directly bound to 
SAFB1, or associate to it via “bridging” molecules as part of a larger 
complex. Previous iCLIP results showed that SAFB1 binds to both the CAG 
tract and its flanking regions in ATXN1. The dynamics of RNA-protein 
interactions are highly complex, and it is also possible that even more distal 
regions of the RNA sequence may additionally contribute to the interaction 
of SAFB1 and ATXN1. This study utilised full-length ATXN1, permitting the 
transcript to form into its complete secondary structure, therefore more 
closely representing the in-vivo interaction between molecules.  
RNA IP is a useful and appropriate tool for understanding the interactions 
between SAFB1 and ATXN1 RNA transcripts. It is, however, important to 
consider any limitations of this experimental technique when interpreting the 
results of this chapter.  
4.5.2.1 Variability between experimental replicates 
Although each of the RNA IP experimental replicates showed that 
pathological CAG expansion increased the association of ATXN1 RNA with 
SAFB1, there was variability in the relative increase between experiments. 
It is not clear where this variability arose. Despite this variability in effect 
size, in each experimental replicate the percentage increase in relative 85 
CAG ATXN1 levels associated with SAFB1 compared to 2 or 30 CAG 
ATXN1 levels was substantial and consistent. As previously stated in 
section 4.4.4, further experimental replicates should be carried out to 
confirm statistical significance of the current result.  
4.5.2.2 Copy number of transfected ATXN1 plasmid 
The same molar amount of each ATXN1 DNA plasmid was transfected into 
HeLa cells. The variation in size of the ATXN1 inserts (arising from CAG 
expansion), resulted in a different copy number of plasmid under each 
experimental condition (Table 4.5). Compared to ATXN1 2Q, there were 
1.7% fewer ATXN1 30Q plasmid copies, and 5% fewer ATXN1 85Q plasmid 
copies transfected. It was not considered necessary to correct for this 




effect on the overall result. If the current results were subsequently 
corrected for copy number variation, the reduced number of 85 CAG ATXN1 
plasmids would further increase the difference between the amount of 
expanded ATXN1 compared to non-expanded ATXN1 associated with 
SAFB1. It is important to consider that correcting for plasmid copy number 
does not account for potential variation between transfection efficiency, or 
for variations in transcription or translation rates which could be caused by 
the pathological CAG expansion. 
4.5.2.3 Correcting for transfected ATXN1 RNA levels 
The RNA IP protocol was designed to express ATXN1 RNA levels in the 
experimental IP samples relative to that expressed in their respective input 
sample (total levels prior to isolation of SAFB1). This corrects for variations 
in ATXN1 RNA expression levels in the different experimental conditions. 
It was not possible to carry out this correction in the current study, because 
the CT values of ATXN1 expression in input samples were very low. Instead, 
a surrogate measure of transfection efficiency was used by quantifying 
FLAG-ataxin1 protein expression. This is an acceptable method of 
correcting for transfection efficiency, but not ideal as the experiment 
measures ATXN1 RNA not ataxin1 protein. As previously established in the 
literature, CAG expansion is likely to affect translation efficiency (Raca et al. 
2000, Krauss et al. 2013, Nalavade et al. 2013), therefore the levels of 
FLAG-ataxin1 protein may not correlate equally to levels of ATXN1 RNA 
across experimental conditions. 
Table 4.5 Base pair lengths and approximate copy numbers of ATXN1 plasmids 
transfected into HeLa cells for RNA IP experiments. Plasmid copy number was 






Copies of plasmid 
transfected 
FLAG-ATXN1 2Q 786 4819 2.88x1012 
FLAG-ATXN1 30Q 870 4903 2.83x1012 (-1.7% vs. 2Q) 




4.5.2.4 Other considerations for quantifying CAG expansion repeat 
sequences 
ATXN1 RNA was converted to cDNA to facilitate qPCR analysis. The 
current experimental protocol assumes equal efficiency of reverse 
transcription between samples. However, it cannot be disproved that the 
CAG expansion may have conferred differences in the efficiency of reverse 
transcription. It has previously been established that variations in RT 
efficiency may be an important consideration for data interpretation 
(Schwaber et al. 2019). 
4.5.3 Mechanisms of altered SAFB1 expression in polyQ disease 
4.5.3.1 Causes of altered SAFB1 expression 
As shown in Chapter 3, degenerating neurons in polyQ disease feature 
abnormal expression of SAFB1. In SCA Purkinje cells and HD MSNs, 
SAFB1 is expressed in the cytoplasm, and its expression in the nucleus is 
upregulated in cerebellar DN neurons. Mechanisms underpinning this 
change in SAFB1 expression are currently uncertain but could include 
binding of SAFB1 to expanded polyQ peptides, binding of SAFB1 to 
expanded polyCAG RNA, association of SAFB1 with other peptides altered 
in polyQ disease, or alterations in the nucleocytoplasmic transport of SAFB1 
(Figure 4.11).  
The work in this thesis, combined with published evidence, indicates that 
SAFB1 does not directly associate with expanded polyQ peptides, or with 
wildtype huntingtin or ataxin1: In this chapter it was shown that SAFB1 did 
not co-localise with artificially expressed ataxin1 in SH-SY5Y cells. Chapter 
3 demonstrated that there was also no clear co-localisation of SAFB1 with 
polyQ huntingtin in HD patient striatal cells. Furthermore, proteomic analysis 
of the protein binding partners of SAFB1 in HeLa cells did not identify non-
pathologically expanded ataxin1 or huntingtin as an interactor of SAFB1 
(Allahyani 2020). In addition, SAFB1 was not identified as a protein 
interactor of pathologically expanded ataxin1 in mouse neuroblastoma cells, 




identified as an interacting partner of either physiological or pathological 
huntingtin (Ratovitski et al. 2012). 
The current results indicate that ATXN1 RNA with 2 CAGs does not contain 
a hairpin loop, yet still interacts with SAFB1 at a similar level to ATXN1 RNA 
containing a 30 CAG hairpin loop. Although this indicates that the hairpin 
loop itself may be dispensable for the interaction between SAFB1 protein 
and wildtype ATXN1 RNA, previous iCLIP results demonstrated the 
enrichment of SAFB1 tags within both the CAG repeat tract itself and in the 
adjacent region. This indicates that both the CAG tract and its flanking 
sequence are important in mediating the interaction of ATXN1 RNA with 
Figure 4.11 Illustration summarising the potential mechanisms by 





SAFB1. Indeed, RNA hairpins comprising CAG repeats were previously 
shown to mediate protein interaction (de Mezer et al. 2011), and have been 
specifically shown to modulate binding to RRM motifs (Law et al. (2006), 
Clery and Allain (2011)). Flanking regions of RNA hairpin loops can mediate 
both RNA secondary structure (Sobczak and Krzyzosiak 2004), and RNA 
interaction with proteins (Sobczak et al. 2010). Taken together this indicates 
that both the CAG tract and flanking sequences of ATXN1 may be important 
in the interaction with SAFB1. 
In the case of pathologically expanded ATXN1, it is likely that the CAG 
repeat tract itself mediates the altered interaction with SAFB1. Highly 
structured regions in RNA transcripts (including stable hairpins) confer 
increased potential for protein interaction (Sanchez de Groot et al. 2019). 
As the inclusion of an uninterrupted 85 CAG stretch in ATXN1 induces the 
formation of a highly structured stable hairpin loop, this is likely to directly 
influence the interaction of the RNA transcript with SAFB1, conferring an 
increased association between the two molecules. 
The pathological expression of SAFB1 in the cytoplasm was identified as a 
feature of degenerating neurons in both SCA1 and HD. SAFB1 protein was 
not identified to interact with wildtype or expanded HTT RNA in a recent 
study by Schilling et al. (2019). If SAFB1 does indeed not interact with HTT, 
this would indicate that a) the presence of a CAG hairpin alone is not 
sufficient to mediate an interaction with SAFB1, and b) there may be 
mechanisms underpinning the abnormal expression of SAFB1 in polyQ 
disease additional to its direct association with polyCAG RNA. 
However, the limitations of this single study by Schilling et al. should be 
considered; the work was carried out in Drosophila which only express one 
form of SAFB. Furthermore, the expression levels of SAFB1 itself and its 
potential RNA binding partners may not have been at high enough levels to 
observe an interaction. To date no studies have been carried out to quantify 
the protein binding partners of HTT RNA in patient tissue. These 




tags were present within HTT RNA transcripts (unpublished observation, 
Rivers et al. (2015)), indicating potential for a direct interaction between 
SAFB1 and polyCAG HTT RNA transcripts in HD. 
The processing and transport of RNA containing polyCAG tracts could be 
altered by the increased binding of SAFB1. It is possible that polyCAG 
ATXN1 RNA directly sequesters SAFB1 in the nucleus, then becomes 
exported into the cytoplasm (Figure 4.11A). A preprint (non-peer reviewed 
publication) by Zhang et al. (2018a) reports that expression of ATXN1 with 
85 CAG repeats disrupts multiple nuclear transporters, resulting in the 
increased localisation of CRM1 (a key mRNA nuclear transporter known to 
be involved in the export of xtrRNA) to the nucleus, indicating a possible 
mechanism for the increased export of polyCAG RNA into the cytoplasm. 
SAFB1 binds proteins implicated in neurodegenerative disease pathology 
and repeat expansion disorders including SRSF1 (Denegri et al. 2002, 
Hautbergue et al. 2017), FUS (Yamaguchi and Takanashi 2016), Matrin 3 
(Tada et al. 2018), Sam68 (Sergeant et al. 2007, Sellier et al. 2010) and 
hnRNP K (White et al. 2010). As CAG expansion repeats sequester diverse 
proteins (Nalavade et al. 2013), it is possible that pathological ATXN1 
transcripts in the cytoplasm or nucleus could aberrantly associate with 
proteins which are in turn binding partners of SAFB1, forming a protein-RNA 
complex in the cytoplasm or nucleus (Figure 4.11B).  
Dysregulation of nucleocytoplasmic transport is emerging as an important 
mechanism in neurodegenerative disease (Dormann et al. 2010, 
Fahrenkrog and Harel 2018) and the transport of RBPs is known to be 
altered in polyQ disorders and ALS (Chan et al. 2011, Malik et al. 2018). It 
is possible that expanded ATXN1 RNA in the cytoplasm or nucleus 
sequesters important protein binding partners of SAFB1 which facilitate its 
post-translational nuclear import, rendering SAFB1 trapped in the 
cytoplasmic compartment (Figure 4.11C). This could subsequently lead to 
a nuclear loss of function of SAFB1, inducing a compensatory increase in 




mechanism, thus explaining the increased nuclear expression of SAFB1 
observed in polyQ DN neurons. This hypothesis is supported by the findings 
that polyCAG RNA forms pathological complexes with RNA export proteins 
including the nuclear export receptor NXF1, resulting in abnormal 
nucleocytoplasmic transport of repeat expansion protein and RNA (Tsoi et 
al. 2011). SAFB1 binds SRSF1 (a splicing factor and nuclear export 
adaptor) to mediate the export of pathological repeat RNA into the 
cytoplasm, a process implicated in neurodegeneration (Hautbergue et al. 
2017). It is also possible that an upregulation of SAFB1 export into the 
cytoplasm occurs in polyQ disease neurons, perhaps via increased 
expression of nuclear transporters or SAFB1 export partners (Figure 
4.11D). 
4.5.3.2 Consequences of altered SAFB1 expression 
As SAFB1 is a multifunctional protein which is involved in regulating gene 
expression, DNA repair, apoptosis, dendritic function and the cell stress 
response, it is likely that dysregulated expression of SAFB1 has many 
functional consequences in affected neurons. 
Pathological expression of SAFB1 in the cytoplasm of neurons may cause 
a toxic gain of function. SAFB1 binds to many proteins (Table 1.9) which 
could be sequestered in the cytoplasm by abnormally expressed SAFB1. 
This could affect the functions usually carried out by these proteins, 
including transcriptional regulation and RNA transport in affected neurons. 
Cytoplasmic SAFB1 could also aberrantly bind to both coding and non-
coding RNA transcripts in the cytoplasm, inducing a range of functional 
consequences in affected neurons. 
Altered SAFB1 expression in polyQ disorders could induce a loss or gain of 
function in the nucleus. Nuclear SAFB1 is important in regulating neuronal 
transcription and splicing of many genes, which may become dysregulated 
if SAFB1 levels in the nucleus are disrupted. Variation in DNA repair gene 
expression contributes to age of onset and progression of polyQ disorders 




damage response (Altmeyer et al. 2013), therefore its altered expression in 
the nucleus could contribute to disrupted DNA damage repair processes in 
neurons affected by polyQ pathology. A recent study showed that loss of 
DNA damage response function in FUS was important in mediating its 
pathological effects, and leads to formation of cytoplasmic FUS inclusions 
(Naumann et al. 2018). As SAFB1 both binds to and shares structural and 
functional similarities to FUS, this study draws into consideration the 
possibility that alterations in the DNA damage response function of SAFB1 
could be linked to its altered cytoplasmic expression. As SAFB1 was 
recently discovered to mediate heterochromatin structure (Huo et al. 2019), 
its altered expression in the nucleus could also result in dysregulation of 
chromatin stability. 
During the cellular stress response in-vitro, SAFB1 localises to the SatIII 
locus and recruits HSFs at the site of nSB formation (Denegri et al. 2002, 
Jolly et al. 2004, Norman et al. 2016). nSBs sequester transcription factors 
as a protective response against cellular stress. Neuronal stress response 
pathways have been previously described (Farley and Watkins 2018), and 
may act as protective mechanisms against in-vivo insults which contribute 
to neurodegenerative cell loss in the brain. These insults include 
mitochondrial stress, oxidative stress, neuroinflammation, proteasomal 
dysfunction and toxin exposure (Tofaris and Buckley 2018). Although the 
role of SAFB1 in the cellular stress response in-vivo or in neurons is not yet 
understood, it is hypothesised that SAFB1 may play an important role 
(Norman et al. 2016). Altered expression of SAFB1 (resulting from either 
dysreguated expression levels or protein mislocalisation) could therefore 
potentially dysregulate the protective cell stress response in neurons, 
rendering them more vulnerable to neurodegenerative damage. 
The expression of SAFB1 and SAFB2 is controlled by a bidirectional 
promoter (Townson et al. 2003). It has previously been shown that SAFB1 
and 2 regulate each other’s expression levels; depletion of SAFB1 
expression increases the expression of SAFB2 (Hong et al. 2015). 




expression of SAFB2, potentially inducing further dysregulation of neuronal 
functions. 
4.5.4 Recommendations for future work 
4.5.4.1 Future work using RNA IP 
The RNA IP protocol developed here could be used to further understand 
the role of SAFB proteins in polyQ disease. For example, the experiment 
could be repeated using an antibody raised against SAFB2. This could be 
carried out in parallel with protein-level characterisation of SAFB2 in patient 
tissue to characterise a second member of the SAFB family in 
neurodegenerative disease. Future RNA IP experiments should aim to 
normalise ATXN1 RNA levels in IP samples to that of the corresponding 
input sample. It should be noted that in this study, reverse transcription was 
carried out using random primers. To specifically study the levels of ATXN1 
mRNA, reverse transcription could be carried out in future experiments 
using oligo(dT) primers. 
To further understand the importance of SAFB1 interaction with polyCAG 
RNA transcripts, the RNA IP could be repeated with plasmids containing 
ATXN1 with a mutated or absent start codon. This would prevent translation 
of exogenous ATXN1 into polyQ peptides. If a differential interaction of 
SAFB1 protein with ATXN1 RNA was still found, then this would prove that 
this interaction is independent of polyQ protein. Conversely, if the effect was 
lost, this would indicate that the expression of expanded polyQ peptides 
could be important in mediating the interaction of SAFB1 protein and ATXN1 
polyCAG RNA (for example, SAFB1 might interact with both polyQ peptides 
and polyCAG RNA transcripts in a protein-RNA complex).  
The RNA IP technique may be sensitive enough to measure the interaction 
of SAFB1 with endogenous ATXN1 RNA. For example, neurons 
differentiated from a SCA1 patient-derived iPSC line (Buijsen et al. 2018) 
could be compared to control neurons. This would give a more direct insight 




human disease cells, with a higher translational potential than using the 
HeLa line. 
4.5.4.2 Future work using iPSCs 
Following successful deletion of the SAFB1/2 dual promoter in Kolf2 iPSCs, 
the frozen stocks of iPSCs should be expanded to create a large stock of 
low-passage cells. Undifferentiated iPSCs should be characterised by 
immunostaining and Western blotting to validate deletion of SAFB1 and 
SAFB2. Furthermore, iPSCs could be differentiated into neurons using 
standard protocols established by Professor Allen’s research group, and 
characterised for expression of SAFB1 and SAFB2 protein. As SAFB1 is 
critical for neuronal development and important for neuron function, it is 
quite possible that deletion of the dual promoter could confer toxic effects. 
Indeed, during the CRIPSR process, it was observed that iPSC colonies 
with SAFB1/2 knockout often did not grow and thrive as well as their 
wildtype counterparts. If this was the case, it may be preferable in future to 
delete SAFB1 or SAFB2 alone using modified gRNAs targeting the 
respective gene sequences. Cell lines edited using CRISPR/Cas9 should 
be screened for off-target effects (Zhang et al. 2015). 
There is great potential to further utilise the SAFB dual promoter knockout 
cells. The HD iPSC Consortium (2012) published a landmark 
characterisation of iPSC lines from HD patients with various CAG repeat 
lengths, and from control donors. Professor Nick Allen’s laboratory at Cardiff 
University were involved with this work and have since utilised the HD109.1 
cells to create an isogenic corrected control line expressing 2 CAG repeats. 
Applying the CRISPR procedure detailed in this chapter to both the HD109 
and corrected control iPSCs would establish a neuronal model of polyQ 
disease with SAFB1/2 dual promoter deletion. 
In further association with the consortium, CAG repeat disease phenotyping 
in HD iPSCs was carried out by Mattis et al. (2015). This study established 
protocols for assaying disease phenotype in iPSC-derived striatal neuronal 




by glutamate-induced toxicity. In future, HD 109 and HD 2 CAG lines on 
both a wildtype and SAFB1/2 deletion background could be assayed to 
assess the effect of SAFB protein deletion on CAG-expansion dependent 
disease phenotypes. 
4.5.5 Conclusions 
This chapter built upon the results of Chapter 3 to further investigate SAFB1 
in polyQ disease by developing an RNA IP protocol to quantify the 
association of ATXN1 RNA with SAFB1 protein. Using this technique, it was 
confirmed that SAFB1 interacts with ATXN1 RNA with a physiological CAG 
repeat tract, supporting the results of iCLIP experiments carried out 
previously by our research group. Furthermore, it was demonstrated that 
pathological CAG expansion modulates the interaction of SAFB1 with 
ATXN1, increasing the level of RNA associated with SAFB1. It should be 
noted that, despite the large effect size, further experimental replicates may 
be required for the current data to reach statistical significance. 
This result offers a new insight into the potential mechanism which may 
underpin the role of SAFB1 in polyQ disease. It is possible that the long 
stable hairpin loop formed by the expanded CAG tract in ATXN1 confers 
increased interaction with SAFB1 protein. This in turn could induce 
mislocalised expression of SAFB1, and consequent loss of nuclear function 
and/or gain of cytoplasmic function in polyQ disease patient neurons. 
Overall, the findings presented here (and taken together with Chapter 3) 
support an increasing body of evidence which shows that RBP 





5. Chapter 5  
In-vitro screening identifies kenpaullone as a novel 




5.1.1 Chapter overview and introduction 
Mitochondrial dysfunction contributes to the pathogenesis of PD and other 
neurodegenerative disorders. This is caused by increased mitochondrial 
damage, combined with dysregulation of mitochondrial quality control 
mechanisms including fission and fusion events which regulate the health 
and morphology of mitochondria, and mitophagy to remove irreparably 
damaged organelles (section 1.7.2). Retaining or restoring the health and 
normal function of mitochondria in the brain therefore represents a 
targetable mechanism for therapeutic intervention. The recruitment of 
parkin to mitochondria is an essential early step in mitophagy signalling. 
This study therefore used a high-content assay of parkin recruitment to 
identify neuroactive compounds that modulated this process. This primary 
screen found that kenpaullone (a glycogen synthase kinase-3 beta (GSK-3 
beta) and cyclin-dependent kinase (CDK) inhibitor) negatively modulated 
parkin recruitment. 
Secondary screening assays were also carried out using in-vitro 
mitochondrial assays, and these confirmed kenpaullone as a novel 
pharmacological modulator of both the morphology of the mitochondrial 
network and mitochondrial function. Studies in mixed human neuronal and 
glial cultures differentiated from foetal neuroprogenitors showed that 
kenpaullone modulated the appearance of the mitochondrial network. 
Kenpaullone or its mechanisms of action could represent a novel 
therapeutic approach to ameliorating mitochondrial dysfunction in 













5.2 Methods  
5.2.1 Cell culture 
Two human cell lines (H4 and SH-SY5Y) stably expressing eGFP-parkin 
were used for primary and secondary screening of drug compounds. Human 
foetal neuroprogenitor cells (hfNPCs) were utilised with the technical 
assistance of Ms. Andriana Gialeli for validation experiments. Cell culture 
methods for human cell lines are detailed in section 2.3.1 and for hfNPCs 
(including ethics approval details) in section 2.3.5. In all experiments, cells 
treated with drug compounds were directly compared to a control group 
treated at the same time with an equal volume of the drug solvent DMSO. 
5.2.2 Induction of parkin recruitment 
For experimental assays, parkin recruitment was induced in H4 eGFP-
parkin cells by treatment with 15µM CCCP for 2 hours. Dose-response 
optimisation of CCCP-induced parkin recruitment in SH-SY5Y eGFP-parkin 
cells was previously carried out by Dr. Helen Scott and Mr. Gongyu Shi. 
This work concluded that to induce levels of parkin recruitment equivalent 
to that seen in H4 eGFP-parkin cells with no cell toxicity required exposure 
to 15µM of CCCP for 4 hours. SH-SY5Y eGFP-parkin dose-response 
experiments are not shown here. 
5.2.3 Compound library primary screening 
A small library of neuroactive drug compounds was sourced as a kind gift 
from Takeda, U.K. (Table 5.1). Compounds which crossed the BBB and 
modulated pathways and mechanisms relevant to neurodegeneration were 
selected by Takeda scientists. The compounds have evidence in the 
literature to support their potential as neuroprotective compounds, and 
some are in clinical trials. All compounds were sourced from Tocris except 
Cu-ASTM which was sourced from Sigma. Compounds were quality 
controlled for purity and 1µl of 5mM compound stamped onto daughter 
plates. Upon receipt from Takeda, daughter plates were stored at -80oC, 




each well to give a 50µM stock solution. 25µl of stock compound was added 
to 100µl of media in cell culture plates to give a final concentration of 10µM 
in 0.2% DMSO. Compounds were incubated with H4 eGFP-parkin cells for 
24 hours then tested for their ability to modulate parkin recruitment to 
mitochondria. Details of high-content image acquisition and analysis 
protocols can be found in section 2.4. 
5.2.4 Secondary screening (parkin recruitment and mitochondrial 
morphology) 
Parkin recruitment and mitochondrial morphology analysis in both H4 
eGFP-parkin and SH-SY5Y eGFP-parkin cells was used to assay the effect 
of compounds in secondary screening. Details of high-content image 
acquisition and analysis protocols can be found in section 2.4, and details 
of mitochondrial assays in section 2.5. Kenpaullone was sourced from 
Sigma (K3888) and diluted in fresh, sterile DMSO to a stock concentration 
of 5mM before aliquoting and storing at -20oC until use. Aliquots were 
thawed immediately before use and diluted to final working concentration in 
cell culture media before adding to cells for 24 hours prior to carrying out 
assays. 
5.2.5 Secondary screening (MPP+ assay) 
To assess whether kenpaullone is protective against mitochondrial toxins, 
its effect on mitochondrial MitoTracker Red staining and cell number was 
measured in H4 eGFP-parkin cells challenged with MPP+. Details of the 
MPP+ toxicity assay procedure can be found in section 2.5.3.  
5.2.6 Secondary screening (live cell mitochondrial function assays) 
The effect of kenpaullone on mitochondrial respiration was assessed in live 






Drug compounds  
(library screening) 
Description 
AR-A 014418 Selective GSK-3 inhibitor 
Azoramide Unfolded protein response (UPR) modulator 
B2 Promotes inclusion formation in HD and PD 
BIX BiP (Hsp70-5) ER chaperone inducer 
Cu-ASTM Antioxidant, acts on peroxynitrite 
Dantrolene Ca2+ release inhibitor 
Dimethylfumarate Neuroprotective Nrf2 pathway activator 
Edaravone Anti-ischaemic and antioxidant 
GSK2606414 Potent and selective PERK inhibitor 
Kenpaullone CDK and GSK-3beta inhibitor 
LOE 908 hydrochloride 
Neuroprotective broad spectrum cation channel 
blocker 
Memantine NMDA antagonist  
N-Acetylcysteine amide Cell permeable antioxidant 
Olesoxime Binds VDAC 
PD-150606 Calpain inhibitor 
Rapamycin mTOR inhibitor, immunosuppresant 
Resveratrol Cyclooxygenase inhibitor 
Riluzole Glutamate release inhibitor, GABA uptake inhibitor 
SKF 85536 




HDAC inhibitor, ER stress blocker 
SP600125 Selective JNK inhibitor 
trans-ISRIB Integrated stress response inhibitor 
TRC 051384 Inducer of heat shock protein Hsp70 




AT7519 CDK and GSK-3beta inhibitor 
AZD5438 CDK and GSK-3beta inhibitor 




Modulates mitochondrial permeability transition pore 
opening, binds outer mitochondrial membrane 
proteins (TSPO and VDAC) 
 




5.2.7 Validation study in differentiated foetal neuronal/glial cells 
The effect of kenpaullone on the mitochondria of differentiated foetal 
neuroprogenitor cells was assessed to validate the results of the primary 
and secondary screen. hfNPCs were grown as neurospheres in non-
adherent culture. One or two individual neurospheres were picked and 
plated into each chamber of an 8-well chamber slide (NuncTM, Invitrogen). 
Chamber slides were pre-coated with sterile poly-D-lysine overnight at 
37oC, washed in sterile distilled water, then coated in sterile laminin for 1 
hour at 37oC. Neurospheres were cultured in hfNPC differentiation media 
for 7 days to allow them to adhere and differentiate into mixed neuronal/glial 
cultures.  
For compound validation, foetal cultures which had grown in differentiation 
media for 6 days were pre-treated with 5µM of kenpaullone or DMSO for 24 
hours. To visualise mitochondria, cultures were either incubated with 100nM 
MitoTracker Red for 1 hour at 37oC prior to fixation, or immunolabelled using 
an antibody raised against TOMM20 (Table 2.3). CCCP treatment was 
carried out after MitoTracker Red staining. Immunofluorescent staining of 
foetal cells was carried out inside chamber slides. Culture media was 
removed and the cells gently washed with PBS. Cells were fixed in 4% PFA 
for 20 minutes at room temperature, washed in PBS then permeabilised in 
ice-cold methanol for 20 minutes at -20oC. After washing in PBS, cells were 
incubated in 10% normal goat serum in PBS for 2 hours at room 
temperature to block non-specific binding of primary antibodies. Neurons 
were immunolabelled using an anti-TUBB3 antibody (Table 2.3) diluted in 
blocking solution overnight at 4oC. Cells were washed and incubated in 
Alexa Fluor conjugated secondary antibody(ies) diluted in blocking solution 
for 90 minutes at room temperature (Table 2.4). Nuclei were counterstained 
using 1µg/ml DAPI, before mounting the cells beneath a glass coverslip in 
mowiol mounting medium. Slides were stored in the dark at 4oC and imaged 







5.3.1 Parkin recruitment assay optimisation 
The results of this section detail the process of optimising the induction, 
visualisation, segmentation and quantification of parkin recruitment to 
mitochondria by pharmacological insult using the ionophore CCCP. A 
summary of the optimisation and screening experiments of this chapter can 
be found in Error! Reference source not found.. 
  
Figure 5.2 Overview of experiments carried out in Chapter 5. Assay optimisation 
was followed by screening and then validation of drug effects on the cellular 
mitochondrial network. The figure numbers relating to each experimental stage are 




5.3.1.1 High-content imaging of parkin recruitment to mitochondria 
A human neuroglioma (H4) cell line stably expressing eGFP-tagged parkin 
was previously created by Dr. Helen Scott (University of Bristol). The 
ionophore CCCP induces parkin recruitment to mitochondria by disrupting 
the proton gradient across the inner mitochondrial membrane, leading to 
organelle depolarisation and subsequent induction of mitophagy signalling 
cascades. CCCP-mediated induction of parkin recruitment in H4 eGFP-
parkin cells has previously been used to screen siRNA libraries to identify 
modulators of mitochondrial function (Hasson et al. 2013, Scott et al. 2020). 
Prior to carrying out the drug compound screen in this study, the assay was 
optimised to ensure that parkin recruitment could be reliably visualised, 
induced and measured in-vitro.  
Based on the protocol presented by Scott et al. (2020), H4 eGFP-parkin 
cells were incubated with MitoTracker Red to visualise mitochondria, then 
treated with either DMSO (vehicle control) or CCCP to depolarise 
mitochondria and induce parkin recruitment. Fluorescence microscopy 
showed that under baseline conditions parkin is expressed diffusely 
throughout the cell and upon CCCP challenge parkin forms small puncta 
which co-localise with mitochondria (Figure 5.3). H4 eGFP-parkin cells 
transfected with an siRNA directed against PINK1 and challenged with 
CCCP retained diffuse parkin expression, indicating that CCCP-induced 










After confirming that PINK1-dependent parkin recruitment is inducible in H4 
eGFP-parkin cells, optimisation of high-content imaging was carried out. 
Parkin puncta were successfully imaged using the INCell Analyzer 2200, 
demonstrating a clear difference in parkin phenotype when H4 eGFP-parkin 
cells were challenged with CCCP compared to vehicle treated cells (Figure 
5.4A). Figure 5.4B shows a representative example of cell nuclei, cell 
outline, parkin puncta and mitochondria segmented within H4 eGFP-parkin 
cells using INCell Workstation software. Parkin puncta were rare in control-
treated cells, proving that the analysis protocol was able to specifically 
identify CCCP-induced parkin puncta with a low false-positive rate (Figure 
5.4C). 
Figure 5.3 Parkin recruitment to mitochondria in H4 eGFP-parkin cells. 
Fluorescence images showing H4 eGFP-parkin cells stained with MitoTracker Red 
and treated with either DMSO or 15µM CCCP for 2 hours, with and without addition 
of PINK1 siRNA. Parkin was diffuse throughout the cell at baseline (asterisk), then 
formed small puncta co-localised with mitochondria upon CCCP challenge 
(arrows). Parkin puncta formation was reduced when PINK1 expression was 





Figure 5.4 Parkin recruitment to mitochondria visualised and segmented using 
the INCell Analyzer 2200 high-content imaging and analysis system. A) Parkin 
puncta are clearly visible in H4 eGFP-parkin cells treated with 15µM CCCP for 2 
hours (blue=Hoechst (nuclei), green=eGFP (parkin), orange=MitoTracker Red 
(mitochondria)). Inset squares indicate magnified regions. B) Image 
segmentation using INCell Investigator Workstation software (nuclei (blue), cell 
outline (red/green) and parkin puncta (yellow)). Cells containing more than 3 
parkin puncta are delineated in green, cells with 3 or fewer parkin puncta are 
delineated in red. C) Segmentation of H4 eGFP-parkin cells treated with either 




To optimise the assay window in preparation for drug compound screening, 
H4 eGFP-parkin cells were treated with a range (0-20µM) of CCCP 
concentrations for 2 or 3 hours and the percentage of cells containing at 
least 3 parkin puncta quantified using the INCell Analyzer 2200 and INCell 
Investigator Workstation software (Figure 5.5, Table 2.10). Cell count (the 
mean number of cells in each imaged field identified by Hoechst stained 
nuclei) was used as a measure to indicate whether experimental conditions 
were affecting cell number. Treatment with 15-20µM CCCP for 2-3 hours 
did not reduce cell number (Figure 5.5A) and induced greater than 3 parkin 
puncta to form in approximately 80% of H4 eGFP-parkin cells (Figure 5.5B). 
A low proportion of vehicle control treated cells (less than 10%) were 
classified as containing greater than 3 puncta, demonstrating a good signal 
to noise ratio and a suitable assay window for screening the effect of drug 
compounds (Figure 5.5B). Two hours exposure to 15µM CCCP was 
selected as the protocol to induce parkin recruitment for further 
experiments, as this was the lowest dose and earliest time point to induce 
a high level of parkin recruitment in both experimental replicates. Although 
not statistically significant, there was an enrichment of eGFP fluorescence 
intensity within segmented mitochondria when cells were treated with 15µM 
CCCP compared to vehicle, indicating that segmented parkin puncta 
localise to mitochondria (Figure 5.5C). Co-localisation of parkin puncta with 
MitoTracker Red signal was clearly observed under fluorescence 
microscopy (Figure 5.3). siRNA knockdown of PINK1 significantly reduced 
parkin recruitment in H4 eGFP-parkin cells treated with CCCP compared to 
non-targeting control siRNA (NTC) (Figure 5.5D). This demonstrates that 
CCCP-induced parkin recruitment is dependent on PINK1 mediated 
mitophagy signalling. 
Taken together these results confirm that CCCP can reliably induce PINK1-
dependent parkin recruitment to mitochondria in H4 eGFP-parkin cells, 
which can be imaged and quantified using a high-content assay system. 
With this in mind, a protocol for screening test compounds was devised in 






Figure 5.6 Flow diagram summarising the protocol for drug compound 
screening using the INCell Analyzer 2200 high-content imaging 
system. 
Figure 5.5 Quantification of parkin recruitment in H4 eGFP-parkin cells using 
INCell Workstation software. Cell count (A) and parkin recruitment response as 
percentage of cells with more than 3 parkin puncta (B) in H4 eGFP-parkin cells 
treated with 0, 10, 15 and 20µM CCCP for 2-3 hours. The data represents 
technical replicates of one experiment, therefore no statistical analysis was 
carried out. C) Fluorescence intensity (in arbitrary units) of eGFP-parkin signal 
within segmented mitochondria was increased in CCCP treated H4 eGFP-parkin 
cells compared to control, indicating formation of parkin puncta within 
mitochondria. D) Cells transfected with PINK1 siRNA (siPINK1) demonstrated 
significantly reduced parkin recruitment when compared to cells treated with non-
targeting control (NTC) siRNA (t(4)=4.34, p=0.013, student’s unpaired t-test). 
Data is displayed as mean ± SEM, For A-B n=1 independent plate with 12 




5.3.1.2 Parkin recruitment phenotyping 
A second cell line, SH-SY5Y (human neuroblastoma) stably expressing 
eGFP-parkin was created by Dr. Fella Hammachi (University of Bristol). This 
cell line, in addition to H4 eGFP-parkin, was used in the secondary 
screening stage of this chapter. To achieve a level of parkin recruitment 
equivalent to that observed in H4 eGFP-parkin cells (i.e. visualisation of 
multiple parkin puncta in 70-80% of cells with no cell death) (as in Figure 
5.5A and B), it was determined that SH-SY5Y eGFP-parkin cells require 
exposure to 15µM CCCP for 4 hours (work carried out by Dr. Helen Scott 
and Mr. Gongyu Shi, data not shown here). 
The spatial distribution of parkin recruitment within SH-SY5Y eGFP-parkin 
cells was different to that observed in H4 eGFP-parkin cells (Figure 5.7A). 
H4 eGFP-parkin cells challenged with CCCP expressed almost twice as 
many puncta per cell compared to SH-SY5Y eGFP-parkin cells, and these 
puncta were on average approximately 5 times smaller than those formed 
within SH-SY5Y eGFP-parkin cells (Figure 5.7B). Based on these 
differences in parkin translocation phenotype, parameters measuring a 
change in the number of parkin puncta per cell were not considered to be 
sensitive output measures for assays of parkin recruitment in SH-SY5Y 
eGFP-parkin cells. Instead, the area of parkin puncta per cell and intensity 
of parkin puncta (normalised to cell intensity) were used as measures in the 
secondary screening experiments in this chapter. These measures were 







Figure 5.7 H4 eGFP-parkin and SH-SY5Y eGFP-parkin cells challenged 
with CCCP exhibit different parkin translocation phenotypes. Previously 
optimised protocols which induced optimal parkin recruitment levels for each 
cell line were used (2 hours (H4) and 4 hours (SH-SY5Y) of 15µM CCCP). 
A) Fluorescent images of eGFP-parkin captured using the INCell Analyzer 
2200. Scale bars are 50µm. B) Table summarising the mean number and 
mean area of parkin puncta in H4 eGFP-parkin and SH-SY5Y eGFP-parkin 
cells, according to analysis using the INCell Workstation software. n=3 




5.3.2 Primary screening of a drug compound library identifies kenpaullone 
as a novel negative modulator of parkin recruitment 
To identify drug compounds and signalling pathways which could modulate 
mitochondrial health, a library of 25 pharmacological molecules which target 
cellular mechanisms associated with neurodegenerative disease (Table 
5.1) was screened for modulation of parkin recruitment. This focussed drug 
compound library was provided by and quality controlled at Takeda, UK. 
Compounds were selected based on their neuroactivity and evidence for 
potentially neuroprotective functions. H4 eGFP-parkin cells were treated 
with 10µM of drug compound for 24 hours (a standard recommended 
concentration used in drug screening studies) then challenged with 15µM 
CCCP for 2 hours to induce mitochondrial depolarisation and parkin 
recruitment (Figure 5.8). Based on independent advice from statisticians at 
the University of Bristol School of Mathematics and precedent within the 
literature (e.g. McKenzie et al. (2015), Castell et al. (2018)) a threshold cut-
off of 30% increase or decrease in parkin recruitment or cell count compared 
to vehicle control was employed in this screen. 
GSK 2606414, BIX, Cu-ASTM and TRC 051384 reduced cell count by 
>30% and were therefore excluded as hit compounds in this screen (Figure 
5.8A). Treatment with the kinase inhibitor kenpaullone reduced parkin 
puncta formation in H4 eGFP-parkin cells by 75% compared to vehicle 
control and was therefore classified as a hit compound for secondary 
screening (Figure 5.8B). Rapamycin, a drug previously established as a 
positive modulator of mitophagy (Li et al. 2014), was identified as a positive 
modulator of parkin recruitment in the screen (Figure 5.8B). However, the 
primary screen did not detect any novel drug compound which induced at 






Figure 5.8 Primary screening of pharmacological compound library using 
parkin recruitment assay. H4 eGFP-parkin cells were pre-treated for 24 hours 
with 10µM compound, then challenged with 15µM CCCP for 2 hours. A) Cell 
count data. Orange bars indicate compounds which induced at least a 30% 
reduction in cell number. These were considered as potentially cytotoxic and 
therefore excluded from consideration in parkin puncta analysis. B) Parkin 
puncta formation. Rapamycin was confirmed as a positive modulator of parkin 
recruitment. Kenpaullone, a novel hit, induced a 75% decrease in parkin puncta 
formation in comparison to control and was therefore further tested in 




5.3.3 Secondary screening 
5.3.3.1 Kenpaullone negatively modulates parkin recruitment in H4- and 
SH-SY5Y eGFP-parkin cells 
Following the drug compound primary screen, kenpaullone was sourced 
from Sigma (K3888) to verify its effect on parkin recruitment in both H4 
eGFP-parkin (Figure 5.9) and SH-SY5Y eGFP-parkin cells (Figure 5.10) in 
a secondary screen. There was no change in cell count when H4 eGFP-
parkin cells were treated with up to 10µM kenpaullone for 24 hours, either 
with or without CCCP challenge (Figure 5.9A and B). In the absence of 
CCCP, treatment with kenpaullone did not change the percentage of cells 
containing at least 3 parkin puncta compared to vehicle treated cells (Figure 
5.9A and C). When cells were challenged with CCCP to induce parkin 
puncta formation, the percentage of cells containing at least 3 puncta was 
significantly reduced by both 5µM and 10µM kenpaullone treatment 
compared to control (Figure 5.9A and C).  
In SH-SY5Y eGFP-parkin cells, visualisation of eGFP fluorescence showed 
that CCCP induced recruitment of parkin in a large proportion of cells, which 
was ameliorated by treatment with 10µM kenpaullone (Figure 5.10A). There 
was no significant change in cell count with treatment of up to 10µM 
kenpaullone, either with or without CCCP challenge (Figure 5.10B). 
Kenpaullone treatment did not induce a significant change in the percentage 
of cells containing at least 3 parkin puncta, either with or without CCCP 
(Figure 5.10C). This was not unexpected considering SH-SY5Y eGFP-
parkin cell phenotyping which showed that these cells typically feature low 
numbers of large puncta (Figure 5.7). Less than 3% of cells contained at 
least 3 puncta upon CCCP treatment compared to an induction of around 
60% in the equivalent experiment in H4 eGFP-parkin cells. Quantification of 
actual number of parkin puncta (as opposed to using a percentage 
threshold) was not considered as a solution because the typically low 
number of individual puncta would not provide a large enough assay window 
to observe the effect of drug compounds. When cells were challenged with 




puncta total area compared to vehicle control treated cells (Figure 5.10D). 
With CCCP challenge, kenpaullone treatment at 1, 5 and 10µM induced a 
significant reduction in parkin puncta intensity compared to CCCP-
challenged vehicle control treated cells (Figure 5.10E). There was no effect 
of kenpaullone on parkin puncta total area or intensity without CCCP 
challenge. Taken together, these results confirm that kenpaullone 
negatively modulates the formation of parkin recruitment to mitochondria in 





Figure 5.9 Validation of negative modulation of CCCP-induced parkin 
recruitment by kenpaullone in H4 eGFP-parkin cells. A) Representative images 
of eGFP fluorescence showing H4 eGFP-parkin cells treated with either DMSO 
or kenpaullone for 24 hours, then challenged with 15µM CCCP or DMSO for 2 
hours. Scale bar is 50µm. B) There was no significant change in cell count when 
cells were treated with up to 10µM kenpaullone compared to vehicle control, 
either with or without the presence of CCCP. C) Parkin puncta formation was 
significantly reduced when cells were treated for 24 hours with 5µM or 10µM 
kenpaullone compared with DMSO vehicle control in the presence of CCCP 
(vehicle vs 5µM p=0.027, vehicle vs 10µM p=0.009). In cells treated with 0µM 
kenpaullone, CCCP induced a significant increase in parkin recruitment 
(p=0.0008). Kenpaullone did not alter parkin recruitment in the absence of CCCP 
challenge. Statistical analysis carried out by two-way ANOVA with Tukey’s post-
hoc test. n=3 plates, data is displayed as mean ± SEM. *p<0.05, ** p<0.01. 
Asterisks denote comparisons within DMSO or CCCP treated groups, hashes 







































Figure 5.10 (Previous page) Validation of negative modulation of CCCP-
induced parkin recruitment by kenpaullone in SH-SY5Y eGFP-parkin cells. A) 
Representative images of eGFP fluorescence showing SH-SY5Y eGFP-parkin 
cells treated with either DMSO or kenpaullone for 24 hours, then challenged with 
15µM CCCP or DMSO for 4 hours. Scale bar is 50µm. B) There was no 
significant change in cell count when cells were treated with up to 10µM 
kenpaullone compared to vehicle control, either with or without the presence of 
CCCP. C) There was no significant difference in percentage of cells containing 
more than 3 parkin puncta with CCCP or kenpaullone treatment. D) The total 
area of parkin puncta per cell was significantly reduced when cells were treated 
with 10µM kenpaullone compared with DMSO vehicle control in the presence of 
CCCP (p=0.03). In cells treated with 0µM and 1µM kenpaullone, CCCP induced 
a significant increase in parkin puncta  total area (p=0.005 and p=0.009, 
respectively). Kenpaullone did not alter parkin puncta area in the absence of 
CCCP challenge. E) There was a significant decrease in parkin puncta intensity 
when cells were treated for 24 hours with 1µM, 5µM or 10µM kenpaullone 
compared with DMSO vehicle control in the presence of CCCP (vehicle vs 1µM 
p=0.004, vehicle vs 5µM p=0.0006, vehicle vs. 10µM p=0.0008). There were no 
significant differences in parkin puncta intensity detected in the absence of 
CCCP. In cells treated with 0µM kenpaullone, CCCP induced a significant 
increase in parkin puncta  intensity (p=0.0006). Kenpaullone did not alter parkin 
puncta area in the absence of CCCP challenge. Statistical analysis carried out 
by two-way ANOVA with Tukey’s post-hoc test. n=3 plates, data is displayed as 
mean ± SEM. *p<0.05, ** p<0.01, *** p<0.001. Asterisks denote comparisons 
within DMSO or CCCP treated groups, hashes denote comparisons between 





5.3.3.2 Development of a high-content imaging protocol to analyse the 2D 
shape of the cellular mitochondrial network 
To analyse mitochondria in-vitro, a method to quantify changes in the 2D 
cross-sectional structure of the mitochondrial network was developed. A 
literature review was carried out to ensure that the method developed for 
this study would be aligned with the standards of recent peer-reviewed 
publications. Table 5.2 summarises a selection of key research articles 
which represent current techniques. Mitochondria were frequently 
visualised using fluorescent MitoTracker dyes and there was a trend 
towards more advanced software and machine learning scripts being 
utilised in the more recent publications. Amongst the most frequently 
reported measures of the mitochondrial network were the 2D area of 
mitochondria within the cell and the shape (elongation or circularity) of 
mitochondrial organelles. 
In this study, analysis of the 2D morphology (shape and size) of the 
mitochondrial network was carried out in H4 eGFP-parkin cells, due to their 
flattened cell shape and consistent size which makes them amenable to 
accurate segmentation of organelles using high-content imaging. 
MitoTracker Red was used to visualise mitochondria because it is specific 
for mitochondria, it is suitable for fixation, and although its initial uptake into 
mitochondria is dependent on an intact mitochondrial membrane potential, 
the dye forms covalent bonds within the organelles and therefore remains 
within mitochondria irrespective of future changes in membrane potential. 
Mitochondria stained with MitoTracker Red could be clearly imaged using 
the INCell Analyzer 2200 (Figure 5.11A). An analysis protocol was 
developed using INCell Workstation software to segment the areas of the 
cell stained with MitoTracker Red (Tables 2.9 and 2.11). Visual inspection 
confirmed that the software was able to accurately delineate mitochondria 
(Figure 5.11A). To verify the ability of the analysis protocol to quantify a 
change in the morphology of the mitochondria, H4 eGFP-parkin cells 
challenged with 15µM CCCP for 2 hours as a positive control were 




inspection of images showed that CCCP challenge reduced the area of 
mitochondria in each cell. The organelles also appear more rounded and 
condensed towards the nucleus compared to control cells (Figure 5.11B). 
Based on the parameters described in the literature, four output measures 
were chosen: total mitochondrial area per cell, mitochondrial count (the 
number of individually segmented objects per cell), mitochondrial elongation 
and mitochondrial distance to the cell nucleus.  
Cells challenged with CCCP had significantly decreased total mitochondrial 
area per cell compared to vehicle control treated cells (Figure 5.11C). The 
mitochondria in CCCP challenged cells were also significantly less 
elongated (more circular) in comparison to control (Figure 5.11C). CCCP 
did not result in a significant change in mitochondrial count per cell, or 
alteration in the distance of mitochondrial organelles to the cell nucleus 
(Figure 5.11C). Based on these results, mitochondrial area and elongation 
were used as measures to test the effect of kenpaullone on mitochondria 
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Table 5.2 Literature summary providing an overview of methods used to image and 
measure mitochondrial networks within the cell using fluorescence. Literature 









5.3.3.3 Kenpaullone rescues mitochondria from morphological changes 
induced by CCCP challenge 
H4 eGFP-parkin cells were pre-treated with up to 10µM kenpaullone for 24 
hours, stained with MitoTracker Red, then challenged with 15µM CCCP or 
vehicle control for 2 hours (Figure 5.12A). The mitochondrial network within 
the cells was analysed using the newly developed protocol (section 5.3.3.2). 
Under baseline conditions (in the absence of CCCP challenge), H4 eGFP-
parkin cells treated with up to 10µM kenpaullone for 24 hours had no 
significant change in either mitochondrial total area per cell (Figure 5.12B) 
or mitochondrial elongation (Figure 5.12C). In the presence of CCCP, 
mitochondria within H4 eGFP-parkin cells pre-treated with 10µM 
kenpaullone had significantly increased total area of mitochondria (Figure 
5.12B) and significantly more elongated mitochondria compared to control 
cells pre-treated with vehicle (Figure 5.12C). These results demonstrate that 
kenpaullone ameliorates the effects of the mitochondrial toxin CCCP on the 
shape and size of the mitochondrial network as visualised with high-content 
imaging in-vitro. 
  
Figure 5.11 (Previous page) Analysis of mitochondria visualised with 
MitoTracker Red using INCell Analyzer 2200 high-content imaging system. A) 
H4 eGFP-parkin cells under baseline conditions stained with MitoTracker Red, 
imaged using the INCell Analyzer 2200 2D deconvolution setting. In the 
segmented image, cell nuclei (blue), cell outline (green) and mitochondria 
(yellow) were successfully delineated using INCell Workstation software. B) 
Representative image of the mitochondrial network in H4 eGFP-parkin cells in 
the presence of DMSO (vehicle) or 15µM CCCP for 2 hours. Scale bars are 
25µm. C) Output measures from the INCell Workstation software based on 
those observed most frequently in the published literature. Of the selected 
measures, CCCP treated cells had a significant decrease in total mitochondrial 
area per cell (t(4)=4.68, p=0.0095) and were also significantly less elongated 
(t(4)=6.23, p=0.0034) compared to vehicle control (unpaired, two-tailed t-tests). 
There was no significant difference in mitochondrial count or distance to nuclei 
(in arbitrary units, AU) with CCCP treatment compared to vehicle control. n=3 
plates, data was analysed by unpaired, two-tailed t-tests. Data is displayed as 






Figure 5.12 Kenpaullone modulates mitochondrial morphology in H4 eGFP-parkin 
cells challenged with CCCP. Mitochondria were quantified by staining cells with 
MitoTracker Red, and imaging them using an INCell Analyzer 2200. 
Measurements refer to mitochondria segmented using Workstation analysis 
software. A) Representative images of MitoTracker Red fluorescence showing H4 
eGFP-parkin cells treated with either DMSO or kenpaullone for 24 hours, then 
challenged with 15µM CCCP or DMSO for 2 hours.  Scale bar is 25µm. B) The 
total area of mitochondria per cell was significantly increased when cells were 
treated with 10µM kenpaullone compared with DMSO vehicle control in the 
presence of CCCP (p=0.04). CCCP treatment with no kenpaullone significantly 
reduced mitochondrial total area (p=0.02), and this effect was ameliorated with 
kenpaullone treatment.  





5.3.3.4 Kenpaullone rescues mitochondria from MPP+ insult 
To further explore the findings that kenpaullone affects parkin recruitment 
and the shape and size of the mitochondrial network, a series of 
experiments to test the effect of kenpaullone on mitochondrial function were 
carried out. The first of these experiments utilised 1-methyl-4-
phenylpyridinium (MPP+), the active metabolite of the complex I inhibitor 
MPTP. MPP+ is a mitochondrial toxin which disrupts mitochondrial 
membrane potential and generates reactive oxygen species to ultimately 
cause cytotoxicity and cell death.  
H4 eGFP-parkin cells were challenged with MPP+ with or without the 
presence of kenpaullone for 24 hours before staining the mitochondrial 
network with MitoTracker Red. As the uptake of MitoTracker Red is 
dependent on mitochondrial membrane potential, the amount of dye taken 
up into the network reduces under conditions which induce mitochondrial 
depolarisation. This effect was observed when cells were exposed to either 
vehicle (DMSO) or 500µM MPP+ for 24 hours (with no kenpaullone). MPP+ 
challenged cells had significantly decreased MitoTracker Red intensity 
within the cell cytoplasm (Figure 5.13A and B). MPP+ challenge also 
significantly reduced cell number compared to vehicle treated cells (Figure 
5.13C). Treatment with 10µM kenpaullone rescued the depletion of 
MitoTracker Red staining as indicated by a significant increase in 
fluorescence intensity compared to vehicle control in cells challenged with 
MPP+ (Figure 5.13B). There was no significant difference in cell number 
when MPP+ challenged cells were treated with kenpaullone up to 10µM 
(Figure 5.13C), indicating that kenpaullone was unable to rescue cell loss 
Figure 5.12 (continued from previous page) C) Mitochondria became 
significantly more elongated and less circular when cells were treated with 
10µM kenpaullone compared with DMSO vehicle control in the presence of 
CCCP (p=0.04).  CCCP treatment significantly reduced mitochondrial 
elongation in the presence of 0, 1, 5 and 10µM of kenpaullone (p=0.0002, 
p=0.0007, p=0.02, p=0.01 respectively). Statistical analysis carried out by two-
way ANOVA with Tukey’s post-hoc test. n=3 plates, data is displayed as mean 
± SEM. *p<0.05, ** p<0.01, *** p<0.001. Asterisks denote comparisons within 
DMSO or CCCP treated groups, hashes denote comparisons between DMSO 




in this assay. The increase in MitoTracker Red staining observed when 
MPP+ challenged cells were treated with kenpaullone could be attributable 
to either the existing mitochondria better maintaining a healthy membrane 
potential (and therefore taking up more MitoTracker dye), or an increase in 
the size or number of mitochondria. Taken together these results show that 
kenpaullone protects mitochondria against changes induced by the 
mitochondrial toxin MPP+ but was unable to rescue MPP+ induced cell loss. 
5.3.4 The effect of kenpaullone on mitochondria in live cells 
The effect of kenpaullone on mitochondrial function was next tested in live 
cells using the Seahorse Bioanalyzer XFp system (Agilent). At this stage in 
the study, it was observed that when kenpaullone was applied to cells at 
10µM, the compound began precipitating out of solution. This effect was 
attributed to difference in the batch of kenpaullone, as this effect was not 
observed in previous assays. With this in mind, live cell assays were carried 
out using 5µM kenpaullone, a concentration previously shown to be 
effective at reducing parkin recruitment, and for which there was no 







Figure 5.13 Kenpaullone ameliorates MPP+ induced loss of cytoplasmic 
MitoTracker Red staining, but does not rescue cell loss. H4 eGFP-parkin cells were 
treated with MPP+ or vehicle plus kenpaullone or vehicle for 24 hours. A) 
Representative images from each experimental condition showing Hoechst 
(nuclear) and MitoTracker Red (mitochondrial) staining. Scale bar is 25µm. B-C) 
The mitochondrially toxic effect of MPP+ was verified by treating cells with or 
without 500µM MPP+ (no kenpaullone). MPP+ induced a significant reduction in 
MitoTracker Red intensity (p=0.037) and cell count (p=0.0031). In the presence of 
MPP+, cells treated with 10µM kenpaullone had significantly higher MitoTracker 
Red intensity compared to vehicle treated cells (p=0.037). There was no significant 
difference in cell count when MPP+ challenged cells were treated with kenpaullone 
compared to vehicle control. Statistical analysis carried out by one-way ANOVAs 
within each dataset with Tukey’s post-hoc test. Image capture and fluorescence 
intensity analysis were carried out using the INCell Analyzer 2200 and INCell 
Analyzer Workstation software. n=3 plates, data is displayed as mean ± SEM. * 




5.3.4.1 Kenpaullone reduces mitochondrial maximum respiratory capacity 
in live cells 
The Seahorse Bioanalyzer XFp (Agilent) was utilised to investigate the 
effect of kenpaullone on mitochondrial function in live cells (Figure 5.14 and 
Figure 5.15). The Mitochondrial Stress Test protocol analyses oxidative 
phosphorylation by measuring oxygen consumption rate (OCR) and 
glycolysis by measuring extracellular acidification rate (ECAR). Functions of 
the electron transport chain (ETC) are isolated by sequentially injecting cell 
culture media with drugs to disrupt specific ETC complexes (Figure 5.14A). 
Oligomycin inhibits ATP production, FCCP (a derivative of the ionophore 
CCCP) acutely disrupts the proton gradient across the inner mitochondrial 
membrane, stimulating maximum OCR, and antimycin A/rotenone inhibits 
ETC function (Figure 5.14B). H4 eGFP-parkin and SH-SY5Y eGFP-parkin 
cells were used in Seahorse experiments to maintain continuity with the 
majority of previous screening assays. Prior to use of these cell lines, a 
technical support scientist at Agilent was consulted to confirm that the eGFP 
tag expressed within the cells would not interfere with the proprietary 
fluorophore system used in the Seahorse probes which detects oxygen and 
proton flux. 
The dose of FCCP which induces peak OCR was titrated in H4 eGFP-parkin 
and SH-SY5Y eGFP-parkin cells (Figure 5.14C and D). In H4 eGFP-parkin 
cells, maximal OCR was observed with 2µM FCCP, with OCR decreasing 
at doses above 2µM (Figure 5.14C). Doses of FCCP up to 2µM were unable 
to induce OCR above baseline levels in SH-SY5Y eGFP-parkin cells 
following oligomycin treatment (Figure 5.14D). FCCP dose-response curves 
for both cell lines are plotted in Figure 5.14E. H4 eGFP-parkin cells were 
chosen as the cell line to test the effect of kenpaullone on mitochondrial 
function in live cells because their higher maximal OCR in comparison to 
SH-SY5Y eGFP-parkin cells provides a better assay window. 
H4 eGFP-parkin cells were treated with kenpaullone and challenged with 
CCCP according to the experimental protocol summarised in Figure 5.15A. 




experiment. There was no significant difference in the mean protein yield 
between experimental groups (Figure 5.15B). This, alongside visual 
inspection of the cells before and after each assay, confirms that treatment 
with 5µM kenpaullone for 24 hours does not affect cell number compared to 
control. There was however a trend towards an increase in protein yield in 
cells treated with kenpaullone compared to vehicle control (Figure 5.15B). 
In the context of the previous results of this chapter, it is reasonable to 
speculate that this increase in protein in the absence of a change in cell 
number may be attributable to increased number or size of organelles within 
the mitochondrial network. 
Cells exposed to kenpaullone alone, CCCP challenge alone, or kenpaullone 
with CCCP challenge had a reduced OCR over time (both at baseline and 
in response to ETC inhibitors) in comparison to control treated cells, as 
indicated by the trend lines in Figure 5.15C. Changes in OCR over time 
were used to quantify specific mitochondrial functions (Figure 5.15D). In 
cells challenged with CCCP, cellular maximal respiration and spare capacity 
was significantly reduced in comparison to vehicle control (Figure 5.15D). 
Pre-treatment with kenpaullone for 24 hours also induced a significant 
reduction in both spare capacity and maximal respiration, both with and 
without CCCP challenge (Figure 5.15D). There was no significant difference 
in any OCR measure when CCCP-challenged cells were treated with 
kenpaullone, compared to vehicle control (Figure 5.15D). 
Plotting OCR against ECAR allows the overall metabolic state of the cells 
to be assessed at a given timepoint. Metabolic profiles were plotted at 
baseline respiration (Figure 5.15E) and maximal respiration (Figure 5.15F). 
Overall, regardless of experimental condition, treatment with FCCP to 
induce maximal OCR caused a shift towards a more energetic energy 
phenotype. When comparing the different experimental conditions at each 
timepoint, cells treated with kenpaullone and/or CCCP displayed a less 
energetic phenotype. At both timepoints, ECAR data indicate that cells 
under all conditions express a relatively glycolytic and quiescent energy 




account when interpreting the results of this experiment. Overall these 
results show that kenpaullone modulates/decreases mitochondrial function 
in live cells under baseline conditions. 
  
Figure 5.14 (next page) Optimisation of conditions for Mitochondrial Stress Test 
using Agilent Seahorse Bioanalyzer. A) Diagram of the electron transport chain 
indicating the pharmacological mechanisms of action of oligomycin, FCCP, 
antimycin A and rotenone. B) Illustrative graph depicting a model example of 
oxygen consumption rate (OCR) over time during the Mitochondrial Stress Test 
protocol. Coloured blocks represent the various respiratory measures. FCCP 
titration tests were carried out in H4 eGFP-parkin (C) and SH-SY5Y eGFP-
parkin cells (D) to ascertain optimal FCCP concentration for the Mitochondrial 
Stress Test (see table for details of FCCP concentrations). H4 eGFP-parkin 
cells exhibited a maximal OCR in the presence of 2µM FCCP. FCCP did not 
induce maximal OCR above baseline levels in SH-SY5Y eGFP-parkin cells. E) 
FCCP dose-response plot for H4 and SH-SY5Y eGFP-parkin cells. Data is 















5.3.5 The effect of kenpaullone on parkin recruitment and mitochondrial 
morphology is replicated using two kinase inhibitor compounds 
To further investigate the mechanisms underlying the modulation of 
mitochondria by kenpaullone, parkin recruitment and mitochondrial 
morphology were measured in H4 eGFP-parkin cells treated with a small 
panel of additional compounds (Figure 5.16, Table 5.1). AT7519 and 
AZD5438 were chosen because they are kinase inhibitors which act as 
substrates against which kenpaullone is most potent (GSK3-beta, CDK1, 
CDK2 and CDK5). Both drugs have also been evaluated clinically to treat 
solid tumours and in pre-clinical research were found to protect cells from 
damage in a screen for ototoxicity therapeutics (Boss et al. 2010, Hazlitt et 
al. 2018). There is currently no published evidence suggesting a direct effect 
on the mitochondrial network for either compound. 
In contrast, the effect of these compounds was compared against 
dexpramipexole and olesoxime (TRO19622) which have been previously 
characterised as modulators of mitochondrial function (Bordet et al. 2010, 
Alavian et al. 2012). Dexpramipexole has been evaluated in clinical trials for 
the treatment of ALS and AD (Bozik et al. 2014, Bennett et al. 2016). 
Olesoxime has been investigated clinically for the treatment of ALS and 
spinal muscular atrophy (Lenglet et al. 2014, Bertini et al. 2017). Neither 
Figure 5.15 (previous page) The effect of 5µM kenpaullone treatment for 24 hours 
on live cell mitochondrial function in H4 eGFP-parkin cells. A) Experimental 
protocol and plate layout for testing the effect of kenpaullone in H4 eGFP-parkin 
cells using the Seahorse XFp Bioanalyzer (Agilent). B) Protein yields per well for 
each experimental condition. There was no significant difference in total protein 
per well between experimental groups (one-way ANOVA). C) Oxygen 
Consumption Rate (OCR) (normalised to protein) over time. D) OCR (normalised 
to protein) for respiratory functional measurements. Treatment of H4 eGFP-parkin 
cells for 2 hours with CCCP significantly reduced spare capacity (p=0.0002) and 
maximal respiration rate (p=0.0002) compared to vehicle treated cells (two-way 
ANOVA with Tukey’s post-hoc test). Kenpaullone significantly reduced spare 
capacity (p=0.014) and maximal respiration rate (p=0.0043) of cells without CCCP 
challenge, but did not have a significant effect on respiration in comparison to 
vehicle control on any parameters in the presence of CCCP challenge. Metabolic 
profiles at baseline (E) and at maximal respiration (F) provide a snapshot at 
individual timepoints throughout the Mitochondrial Stress Test protocol. OCR is 
plotted against ECAR (extracellular acidification rate, a measure of proton flux 






drug is a kinase inhibitor; dexpramipexole is a weak dopamine agonist 
which also interacts with and increases activity of ATP-synthase (Muzzi et 
al. 2018), whilst olesoxime modulates mPTP opening (Bordet et al. 2010). 
Results from two independent experiments evaluating the effect of these 
four compounds in comparison to kenpaullone on parkin recruitment and 
mitochondrial morphology are summarised in Figure 5.16. Both AT7519 and 
AZD5438 reduced cell number compared to control treated cells, but 
dexpramipexole and olesoxime had no effect on cell number. As AT7519 
and AZD5438 are both potent inhibitors of CDKs with IC50 values in the low 
micromolar range (Table 5.3), it is likely that treatment of cells with 5µM of 
the drug for 24 hours could interrupt cell cycle and slow cell division. It is 
also not possible to rule out a cytotoxic effect of the drugs which could have 
reduced cell number by inducing apoptosis.  
Dexpramipexole and olesoxime did not have an effect on parkin recruitment 
in cells challenged with CCCP, nor did they modify the total area of the 
mitochondrial network or elongation of mitochondrial organelles (Figure 
5.16B and C). In contrast, the CDK and GSK-3 beta inhibitors AT7519 and 
AZD5438 replicated the effects of kenpaullone, negatively modulating 
parkin recruitment (Figure 5.16A) and protecting mitochondria against 
morphological changes induced by CCCP challenge (Figure 5.16B). 
 
Table 5.3 IC50 values of drug compounds at selected kinases. Values 
were obtained by conducting a search of two NIH information portals 
(National Centre for Advancing Translational Sciences (NCATS): 
Drugs and PubChem), accessed on 25/01/20. N/A indicates no effect.  
 IC50 (µM) 
Drug GSK3-beta CDK1 CDK2 CDK5 
AT7519 0.089 0.21 0.047 0.013 
AZD5438 0.017 0.016 0.006 0.014 
Dexpramipexole N/A N/A N/A N/A 
Olesoxime 
(TRO19622) N/A N/A N/A N/A 






Figure 5.16 The effect of drug compounds on parkin recruitment and 
mitochondrial morphology in H4 eGFP-parkin cells. Representative images of 
parkin recruitment (A) and MitoTracker Red staining (B) in H4 eGFP-parkin cells 
treated with 5µM drug compound for 24 hours, with or without CCCP challenge 
(15µM for 2 hours). Scale bar for (A) is 50µm, for (B) is 25 µm. C) Summary of 
the effect of drug compounds on cell count, parkin recruitment and mitochondrial 
morphology relative to the effect of kenpaullone. Arrows indicate the direction of 
change, and the number of arrows indicates strength of the effect relative to 
kenpaullone. An X indicates no effect. Data was summarised from two 




5.3.6 Validation: Kenpaullone changes morphology of the mitochondrial 
network in human neurons and glia 
To test the effect of kenpaullone in human neurons, human foetal 
neuroprogenitor cells (a kind gift from Dr. Oscar Cordero-Llana, University 
of Bristol) were differentiated into human neurons and glia. Differentiated 
cells were treated with CCCP or vehicle control, fixed, and the mitochondria 
visualised using fluorescence microscopy (Figure 5.17). These experiments 
were not quantified, nor were enough independent replicates carried out to 
allow certainty of the result. However, the preliminary work shown provides 
important initial data to describe the effect of kenpaullone in differentiated 
human neurons and glial cells. 
In the absence of CCCP, mitochondria could be clearly visualised within 
foetal neurons and glial cells by immunostaining with an antibody against 
TOMM20 (a mitochondria-specific protein of the OMM) (Figure 5.17A). 
Treatment with CCCP depleted TOMM20 fluorescence signal, indicating 
that challenging these cells with the ionophore reduces mitochondrial area 
and number in a similar way to human neuroglioma and neuroblastoma cells 
(Figure 5.17A). There appeared to be a greater loss of mitochondria with 
increasing concentration and time of CCCP treatment. Differentiated foetal 
cells were more sensitive to CCCP treatment in comparison to the 
neuroglioma and neuroblastoma cell lines, as treatment with 10µM CCCP 
for up to an hour induced significant cell death (image not shown). 
The effect of kenpaullone on mitochondria within human foetal cells was 
tested under baseline conditions (with no CCCP treatment). Representative 
images show that treatment with 5µM kenpaullone appeared to increase the 
size, number and staining intensity of mitochondria within human foetal 
neuronal and glial cells (Figure 5.17B). This effect was visualised in two 
separate experiments, once using MitoTracker Red and once using 
TOMM20 immunostaining. These results demonstrate that CCCP can be 
used as a mitochondrial toxin in human foetal neuronal/glial cultures, and 
that mitochondria can be clearly visualised by both MitoTracker dye and 




images indicate that kenpaullone could increase mitochondrial staining in 
differentiated human cells when compared to control treated cells. It is 
possible that the effect of kenpaullone on the mitochondrial network in 
human neuroglioma and neuroblastoma cell lines could therefore be 
replicated in human neuronal and glial cells. This result also shows that 
initial screening of compounds using cancerous human cell lines can 
successfully detect hit compounds which may have effects in human 
neurons and glia, demonstrating potential for translational capability of the 
screen.  
Overall, kenpaullone modulates parkin recruitment and protects 
mitochondria against insult with CCCP and MPP+ in human cancerous cell 
lines and modulates mitochondrial staining in human differentiated foetal 
neuronal and glial cultures. Kenpaullone, or the mechanism of action 
underlying its effect, warrants further investigation as a potential therapeutic 
candidate for correcting mitochondrial dysfunction which underpins 






Figure 5.17  Visualisation of mitochondria and the effect of kenpaullone on human 
foetal neuroprogenitor cells (hfNPCs) differentiated in DMEM with N2 supplement 
for 7 days, immunostained for DAPI (nuclei) and beta-III-tubulin (neurons). 
Mitochondria were visualised either by immunolabelling with anti-TOMM20 
antibody or by treating live cells with MitoTracker Red dye prior to fixation. A) 
Differentiated hfNPCs were treated with either DMSO (vehicle control), 1µM or 
5µM of CCCP for either 30 minutes or 1 hour. CCCP treatment reduced 
mitochondrial staining with TOMM20, indicating that this protocol could be used 
as a model to induce mitochondrial damage by depolarisation and subsequent 
reduction in mitochondrial mass. B) Cells pre-treated with 5µM kenpaullone or 
DMSO for 24 hours. Treatment with kenpaullone appeared to increase the 
intensity and area of red mitochondrial staining with both immunodetection and 
dye-based visualisation. Two representative images are shown for each condition. 
A) n=1. B) n=1 experiment for MitoTracker staining and n=1 experiment for 





5.4.1 Key findings 
Mitochondrial dysfunction contributes to pathological loss of neurons in 
human neurodegenerative diseases such as PD. This chapter aimed to 
identify pharmacological compounds and druggable cell signalling 
pathways as novel mitochondrial modulators. A phenotypic in-vitro assay of 
PINK1-dependent parkin recruitment was successfully utilised as a tool to 
screen a small compound library, which identified the kinase inhibitor 
kenpaullone as a novel negative modulator of parkin recruitment. Validation 
experiments demonstrated that kenpaullone negatively modulates parkin 
recruitment in two neurological human cell lines. Furthermore, kenpaullone 
was protective against detrimental morphological changes to mitochondria 
induced by the ionophore CCCP, and protected against loss of MitoTracker 
Red dye uptake in the presence of the complex I inhibitor MPP+. Neuronal 
and glial cells differentiated from human foetal tissue treated with 
kenpaullone appeared to exhibit a morphologically enhanced mitochondrial 
network, as visualised with both MitoTracker Red and immunostaining. 
Establishment of a negative modulator of parkin recruitment as a potentially 
therapeutically useful tool gives reason to draw into consideration previously 
established understanding whereby primary consideration has been given 
to positive modulators of mitophagy. 
5.4.2 Evaluation of the in-vitro parkin recruitment assay as a drug 
screening tool 
Cells expressing fluorescently tagged parkin have been used widely and 
successfully in assays to screen libraries of drug compounds (Villace et al. 
2016), siRNA (Lefebvre et al. 2013, Scott et al. 2020) and shRNA constructs 
(McCoy et al. 2014). Here, an in-vitro phenotypic screen of PINK1-
dependent parkin recruitment was successfully optimised as a primary 
screening tool and used to screen a small library of 25 repurposed, 
neuroactive pharmacological compounds to identify novel modulators of 




this screen measured only parkin recruitment, other forms of mitophagy 
such as receptor-mediated or lipid-mediated (Villa et al. 2018) would not be 
detected. It is therefore possible that compounds which primarily modulate 
mitophagy through non-parkin dependent mechanisms would not be 
identified using the current screening method. 
H4 cells are derived from the brain tissue of a neuroglioma patient. They 
are an appropriate choice of cell line for use in this screen because they are 
readily grown under standard cell culture conditions, easily transfected and 
have an epithelial morphology conducive to high-content imaging. SH-SY5Y 
cells are derived from a metastatic bone tumour biopsy from a 
neuroblastoma patient and exist as both an adherent and a floating 
population. SH-SY5Y cells can be differentiated using retinoic acid to a 
more neuronal-like phenotype with some dopaminergic features 
(Kovalevich and Langford 2013). In this study the adherent, undifferentiated 
cell population was used because they are morphologically the most 
suitable for use in high-content fluorescence imaging. Both H4 and SH-
SY5Y cells are cancerous lines with abnormal karyotypes (H4 cells are 
near-triploid, whilst SH-SY5Y cells carry a chromosome 1q duplication). 
These genetic alterations confer phenotypes which differ to normal human 
cells in-vivo, particularly non-dividing neurons. Expression of key cell 
signalling molecules including GSK-3 beta are dysregulated in glioma cells 
(Zhao et al. 2015), a finding which should be taken into account when 
assessing compounds which act on this target. Despite this, the 
neurological origin of these human cells means they are widely accepted as 
an appropriate model system for screening and first-line investigation into 
the cellular signalling pathways related to neurodegenerative disease. 
The primary screen was developed with an assay window capable of 
detecting both positive and negative modulators of parkin recruitment. 
Rapamycin is a widely prescribed immunosuppressant and enhancer of 
autophagy which inhibits mTOR, a PI3-kinase family member involved in 
mitochondrial metabolism (Schapira 2012). Rapamycin positively 




2014, Wang et al. 2017), and reduces mitochondrial dysfunction in a 
neuroprotective manner in a Drosophila model of PD (Tain 2009). 
Rapamycin was included as a positive control compound in the parkin 
recruitment screen, and was identified as a positive modulator of parkin 
recruitment using this assay.  
Parkin recruitment to mitochondria is an indirect measurement of 
mitochondrial quality control by mitophagy. Methods to directly quantify 
mitophagy by measuring mitochondrial localisation to autophagosomes and 
lysosomal degradation have previously been utilised in high-content 
screening studies (Chandrachud et al. 2015, Diot et al. 2015). Although 
PINK1/parkin dependent mitophagy has been demonstrated to occur in-vivo 
(Vandenberghe et al. 2018), the scarcity of such evidence is recognised as 
a limitation within the research field (Chu 2018). There is particularly limited 
evidence of PINK1/parkin mediated mitophagy in neuronal tissue. These 
considerations highlight the importance of validating the current results in 
neuronal cells. The fact that the Hit compound from primary screening may 
modulate mitochondria in a preliminary validation experiment using human 
neuronal and glial cells differentiated from foetal neuroprogenitors indicates 
that use of H4 and SH-SY5Y cells in screening studies is translational to 
primary human neurons. 
5.4.3 Previous evidence for the effects of kenpaullone 
This chapter identified kenpaullone as a novel negative modulator of parkin 
recruitment. Kenpaullone also ameliorated damage-induced changes to the 
2D morphology of the mitochondrial network in H4 eGFP-parkin cells by 
rescuing CCCP-induced fragmentation of mitochondria and attenuating 
reduction in mitochondrial area. Furthermore, kenpaullone rescued loss of 
MitoTracker Red dye uptake in cells challenged with MPP+, and affected 
mitochondrial metabolism by reducing the effect of FCCP on maximally-
induced mitochondrial respiration. 
Kenpaullone is a small molecule kinase inhibitor which was originally 




(Zaharevitz et al. 1999). It acts as a potent inhibitor of both GSK-3 beta and 
various CDKs including CDK5 (Leost et al. 2000). As both GSK3-beta and 
CDK5 are implicated in neurodegenerative disease (see 5.4.8 and 5.4.9.1), 
many studies have further investigated the neuronal effects of kenpaullone. 
Petit-Paitel et al. (2009) demonstrated that kenpaullone is protective against 
MPP+ induced neurotoxicity in mouse primary neurons and immortalised 
cell lines. Kenpaullone also enhanced neurogenesis (increased the number 
of beta-tubulin positive cells) in differentiating human neuroprogenitor cells 
with no effects on cell cycle or cell survival (Lange et al. 2011). There is also 
evidence to show that kenpaullone exerts protective actions. Pre-treatment 
with kenpaullone reduced ROS and downregulated autophagy markers and 
expression of apoptosis-activating genes in cardiomyocytes exposed to 
experimental oxidative stress (Joo et al. 2018). The actions of kenpaullone 
also translate into other terminally differentiated cell types, as it was recently 
demonstrated to protect podocytes (the highly specialised cells responsible 
for filtration at the kidney glomerulus) against puromycin-induced injury in-
vitro (Lee et al. 2017). Kenpaullone has also been demonstrated as 
neuroprotective in a human model of neurodegenerative disease. It 
promoted survival of human induced motor neurons from ALS patients, and 
furthermore rescued disease cells from neurodegenerative functional 
deficits (increased cell survival, ameliorated electrophysiological deficits 
and restored normal synaptic function) (Yang et al. 2013, Liu et al. 2016). 
A small number of studies have investigated the protective effect of 
kenpaullone in-vivo. Trans-tympanic kenpaullone was reported to protect 
mice and rats against cisplatin- and noise-induced hearing loss (Teitz et al. 
2018). This efficacy in post-mitotic cochlear cells in-vivo is a promising 
insight suggestive that kenpaullone may also be efficacious and potentially 
neuroprotective in the brain. Indeed, Kitabayashi et al. (2019) demonstrated 
that kenpaullone contributes to suppression of glioblastoma in mice, further 




Taken together, these studies indicate that kenpaullone is efficacious in 
neurons in-vitro and in-vivo and may exert neuroprotective effects. Until 
now, the mechanisms underlying these effects have not been elucidated. 
The current study describes for the first time the mitochondrial actions of 
kenpaullone which may contribute to its previously described 
neuroprotective functions. 
5.4.4 Effect of kenpaullone on mitochondrial morphology 
A high-content protocol for analysing the 2D shape and size of the 
mitochondrial network visualised using MitoTracker Red was successfully 
developed. MitoTracker Red was chosen because it is specific for 
mitochondria, it is suitable for fixation, and although its initial uptake into 
mitochondria is dependent on an intact mitochondrial membrane potential, 
the dye forms covalent bonds within the organelles so remains within 
mitochondria irrespective of future changes in membrane potential.  
The INCell Analyzer 2200 is a suitable screening tool because it allows rapid 
analysis of numerous experimental conditions. This chapter demonstrated 
that the INCell system was able to accurately segment and quantify 
mitochondria. A lower throughput but more detailed analysis of the 
mitochondrial network would be possible utilising more recently described 
techniques. For example, use of Image J plugins to quantify 3D changes in 
mitochondria imaged using confocal microscopy could be used in future 
validation studies in neuronal cultures (Chaudhry et al. 2019). 
The elongation of the cross-sectional area of segmented mitochondria was 
used to indicate organelle shape. In the presence of CCCP, the 
mitochondria of cells treated with kenpaullone were more elongated than 
those treated with vehicle and became morphologically more similar to cells 
at baseline (those not challenged with CCCP).  Although not a direct 
measurement of mitochondrial fission or fusion, this result is an indirect 
indication that kenpaullone may be influencing mitochondrial dynamics to 
induce a fusion-rich phenotype. Mitochondrial fusion can be considered a 




these results suggest that kenpaullone could be exerting a protective effect 
over mitochondrial network dynamics. As kenpaullone negatively modulates 
parkin recruitment to mitochondria, this result is in line with previous findings 
which demonstrate that PINK1/parkin signalling promotes mitochondrial 
fission (Poole et al. 2008). 
Kenpaullone was also found to increase the total cross-sectional area of the 
mitochondrial network in CCCP-challenged cells. This increase in the size 
of the mitochondrial network supports the finding that kenpaullone reduces 
parkin recruitment and is therefore a negative modulator of mitophagy. 
Furthermore, this increase in size of the network could be considered a 
protective mechanism against the loss of mitochondria which occurs in the 
presence of CCCP. Baseline effects of kenpaullone (in the absence of 
CCCP) were observed in the preliminary validation study in neuronal/glial 
cells derived from human foetal neuroprogenitors. Using this model, 
kenpaullone treatment appeared to increase the size of the mitochondrial 
network in neuronal and glial cells. It was observed that the most noticeable 
change appears to be in glial (βIII-tubulin negative) cells. This may be 
because the majority of cells in the cultures were non-neuronal. The 
involvement of glial cell mitochondrial dysfunction in neurodegenerative 
diseases is now being increasingly well-understood, as recently reviewed 
by McAvoy and Kawamata (2019). 
No experiments were performed to directly analyse the effect on 
kenpaullone on mitochondrial biogenesis. Indirect evidence from protein 
quantification analysis identified a trend towards increased protein content 
in kenpaullone-treated H4 eGFP-parkin cells in the absence of changes in 
cell number, potentially indicating an increase in mitochondrial protein. This 
could be confirmed by carrying out specific assays to look at mitochondrial 
biogenesis (see 5.4.10). 
5.4.5 Effect of kenpaullone on mitochondrial membrane potential 
In the MPP+ assay, MitoTracker Red was employed to indirectly assay 




cells were stained with the dye before mitochondrial challenge with CCCP, 
where it binds covalently to the organelles irrespective of future changes to 
mitochondrial membrane potential. In contrast, in the MPP+ assay, cells 
were stained with MitoTracker Red after applying the mitochondrial insult 
(MPP+). 
Kenpaullone is protective against MPP+ induced neurotoxicity in-vitro (Petit-
Paitel et al. 2009), and this effect has been partially replicated in human 
immortalised cells in the present study. Treatment of cells with kenpaullone 
for 24 hours protected against MPP+-induced loss of MitoTracker Red 
uptake, providing indirect evidence that the compound is attenuating loss of 
mitochondrial membrane potential induced by MPP+ challenge. Although 
kenpaullone did not rescue MPP+ induced cell death, this assay used a 
relatively harsh treatment protocol (inducing 50% cell death) and 
furthermore kenpaullone was administered at the same time as MPP+. Pre-
treatment of cells with kenpaullone prior to a milder MPP+ challenge may 
reveal a cytoprotective effect of kenpaullone. 
It is important to consider that, the increase in MitoTracker Red staining 
observed when MPP+ challenged cells were treated with kenpaullone could 
be attributable to either the existing mitochondria better maintaining a 
healthy membrane potential (and therefore taking up more MitoTracker 
dye), or an increase in the size or number of mitochondria. As MitoTracker 
Red dye was administered after 24 hours of kenpaullone treatment, uptake 
would also be reduced if there was a kenpaullone-mediated reduction in 
mitochondrial number. However, in the context of other experiments of this 
chapter which evidence the opposite effect, on balance it is unlikely that loss 
of mitochondrial number is responsible for the decreased uptake of 
MitoTracker Red. This hypothesis is supported by the results presented in 
Figure 5.12 and Figure 5.17 which demonstrate that kenpaullone treatment 
may increase the area of the mitochondrial network in both neuroglioma 




Because depolarised mitochondria with low uptake of MitoTracker Red were 
below the sensitivity threshold of the INCell mitochondrial organelle 
segmentation protocol, the MitoTracker Red fluorescence staining intensity 
was assessed in the whole cytoplasm to measure the effect of MPP+ on 
mitochondrial membrane potential. This means that the area and shape of 
the mitochondrial network was not measurable in this experiment. 
Complementing this study with a repeat experiment using mitochondrial 
immunostaining or MitoTracker Green (a membrane potential-independent 
dye) would clarify the current results. 
5.4.6 Effect of kenpaullone on mitochondrial respiration in live cells 
The Seahorse Bioanalyzer XFp system is a gold-standard assay for 
quantifying mitochondrial respiratory function in intact cells (Brand and 
Nicholls 2011). Kenpaullone reduced maximal respiration (maximal oxygen 
uptake into mitochondria stimulated by acute FCCP treatment) both with 
and without the presence of CCCP challenge. Kenpaullone had no effect on 
basal respiration or ATP production. It is important to distinguish the 
difference between use of CCCP and FCCP in this experiment. Acute and 
low-dose administration of FCCP is used to stimulate maximal oxygen 
uptake into mitochondria. In contrast, higher dose exposure to CCCP for a 
number of hours is used to induce mitochondrial stress via global 
mitochondrial depolarisation. 
It is generally accepted that compounds which enhance mitochondrial 
function induce an increase in either basal or FCCP-stimulated oxygen 
consumption and ATP production. Kenpaullone did not achieve this effect. 
In contrast, kenpaullone attenuated FCCP-induced oxygen consumption. 
This finding does not necessarily preclude its actions as an overall enhancer 
of mitochondrial function. Although it does not affect mitochondrial 
respiration at baseline, it is possible that temporary kenpaullone-induced 
dampening of mitochondrial oxygen uptake in damaged cells could induce 
a subsequent protective shift in the balance of mitochondrial biogenesis, 




It has been previously established that bioenergetic differences between 
cultured cell lines and neurons can substantially impact the effect of 
experimental modulation of mitochondrial quality control pathways (Van 
Laar et al. 2011). Neurons are highly dependent on oxidative 
phosphorylation to generate energy. In contrast, cancerous cells (including 
H4 and SH-SY5Y) are adapted through the Warburg effect to primarily 
generate energy through glycolysis (cytoplasmic conversion of glucose into 
pyruvate to make ATP) (Aminzadeh et al. 2015). This difference should be 
taken into account when evaluating the current results. Culturing of H4 or 
SH-SY5Y cells in high-glucose media allows the cells to respirate primarily 
through glycolysis, explaining the relatively small increase in OCR in 
response to acute FCCP induced in both cell lines. Culturing of cells in 
glucose-free or glucose-reduced media could induce an energy phenotype 
more dependent on oxidative phosphorylation. Furthermore, differentiation 
of SH-SY5Y cells may alter their cellular metabolism to become more 
dependent on oxidative phosphorylation compared to undifferentiated cells, 
therefore more closely replicating neuronal bioenergetics (Schneider et al. 
2011).  
5.4.7 Pharmacological mechanisms underlying the effects of kenpaullone 
on mitochondria 
The IC50 values of kenpaullone at its main targets are summarised in Table 
5.4. Although the pharmacological promiscuity of kenpaullone could draw 
into question its direct applicability as a potentially therapeutic agent, it is 
possible that synergistic mechanisms relating to its effect at multiple 
substrates are responsible for its novel and potentially therapeutic effects 
on the mitochondrial network.  
Kenpaullone acts with highest potency at GSK3-beta, and CDK1, 2 and 5. 
AT7519 and AZD5438 are potent inhibitors of these kinases (Table 5.3) and 
were demonstrated to mimic the effects of kenpaullone on both parkin 
recruitment and mitochondrial area in H4 eGFP-parkin cells challenged with 
CCCP. The strength of these effects appears to correlate to the compounds’ 




5.3 and Figure 5.16C). The following sections describe the potential 
pharmacological mechanisms underlying the action of kenpaullone on 
mitochondria at GSK3-beta, and CDK1, 2 and 5.  
 
5.4.8 Inhibition of GSK-3 beta 
Kenpaullone acts as an inhibitor of GSK-3 beta at low micromolar potency. 
GSK-3 beta is a serine-threonine kinase with over 100 substrates, 
implicated in many diseases including cancer, inflammatory conditions and 
neurological disorders (Beurel et al. 2015). GSK-3 beta has been 
established as a mediator of neuronal oxidative stress and apoptosis (Lee 
et al. 2007), and dysregulated GSK-3 beta signalling is known to contribute 
to the cellular pathology of neurodegenerative diseases such as PD 
(Golpich et al. 2015). GSK-3 beta is partially localised to mitochondria in 
both SH-SY5Y cells (Bijur and Jope 2003) and in mouse primary and 
immortalised neurons (Petit-Paitel et al. 2009). This mitochondrial 
population of GSK-3 beta is more active under apoptotic stimuli in 
comparison to that within the cytosolic compartment (Bijur and Jope 2003). 
As a signalling protein which can mediate neuronal death by mitochondrial 
dysfunction, GSK-3 beta inhibition has previously been hypothesised as 
protective against mitochondrial induced neuronal stress, and evidence 
suggests that GSK-3 inhibition can ameliorate pathological signalling which 
causes dopaminergic neuronal death (Golpich et al. 2015).  
Target IC50 (µM) 
GSK-3 beta 0.23 
CDK1/cyclin B 0.4 




Casein kinase 2 20 
ERK1 20 
MAP4K4 not established (effect described by (Yang et al. 
2013)) 
Table 5.4 IC50 values of kenpaullone in cell-free assay conditions (Zaharevitz 




Pharmacological inhibition of GSK-3 reduces mitochondrial biogenesis in 
SH-SY5Y cells under metabolic stress induced by 2-deoxyglucose 
treatment, but not under baseline conditions (Ngamsiri et al. 2014). This 
implies that the increase in mitochondrial area induced by kenpaullone 
treatment during experimentally induced mitochondrial stress observed in 
the present study may not be mediated by enhanced biogenesis. 
Mitochondrial-E.R. interaction via mitochondria-associated membranes 
(MAMs) is an important aspect of regulation of mitophagy signalling in 
health and disease (Rodriguez-Arribas et al. 2017). Activation of GSK-3 
beta destabilises MAM tethering proteins, leading to disrupted ER-
mitochondrial signalling and consequent disruption to mitophagy (Stoica et 
al. 2016). Kenpaullone-induced inhibition of GSK-3 beta could reduce 
disruption of MAM tethering, thereby contributing towards re-balanced 
mitophagy signalling and healthy mitochondrial quality control. Previous 
research demonstrated that kenpaullone promotes neurogenesis in 
differentiating neuroprogenitor cells without influencing cell cycle or cell 
survival, and this action is dependent on stimulation of Wnt/beta-catenin 
signalling which is antagonised by GSK-3 beta (Lange et al. 2011). 
The data from this chapter combined with that in the published literature 
demonstrates that the action of kenpaullone on GSK-3 beta could contribute 
to the mitochondrial effects observed in the present study. However, further 
indications of kenpaullone’s mechanism of action on parkin recruitment can 
be inferred from the effect of other compounds tested in the primary screen. 
AR-A 014418 is a kinase inhibitor highly specific for GSK-3 (IC50=0.10µM) 
which does not inhibit CDK2 or CDK5 (Bhat et al. 2003). Despite the fact 
that the reported IC50 value of AR-A 014418 on GSK-3 beta is approximately 
half that of kenpaullone, AR-A 014418 induced only a modest reduction in 
parkin recruitment in the primary screen. Furthermore, the neuroprotective 
effect of kenpaullone on motor neuron survival was previously 
demonstrated to be dependent on pharmacological inhibition of CDK2 and 
MAP4K4, as opposed to an isolated effect of GSK-3 beta inhibition (Yang 




effect of kenpaullone on mitophagy signalling is unlikely to be attributable to 
its action on GSK-3 beta alone.  
5.4.9 Inhibition of cyclin-dependent kinases 
5.4.9.1 CDK5 
Cyclin-dependent kinases (CDKs) are serine/threonine kinases which 
interact with particular cyclin subunits to regulate cell cycle. Activation of 
CDK5 requires association with p35 or p39, and kenpaullone inhibits CDK5 
with an IC50 of 0.85. Unlike its homologous family members, CDK5 does not 
regulate cell cycle in proliferating cells and is unique in that it is critical to 
the function of post-mitotic neurons (Cortes et al. 2019). CDK5 is 
dysregulated in a number of human neurodegenerative conditions including 
AD, HD and PD (Shah and Lahiri 2014, Mushtaq et al. 2016, Gupta and 
Singh 2019) and is therefore considered as a drug target for many 
neurological disorders. In this chapter, the potent CDK5 inhibitors AT7519 
and AZD5438 were found to mimic the effect of kenpaullone on CCCP-
induced parkin recruitment and mitochondrial morphology. 
There are a number of signalling pathways downstream of CDK5 which 
could mediate the mitochondrial actions of kenpaullone. CDK5 regulates the 
activity of parkin through serine phosphorylation (Avraham et al. 2007), 
therefore the modulation of parkin recruitment by kenpaullone could be 
mediated by its inhibition of CDK5. CDK5 is upregulated in MPTP-treated 
mice (Smith et al. 2003) and neurotoxic insults activate CDK5, mediating 
activation of Bcl-2 family proteins and inducing mitochondrial dysfunction 
(Nikhil and Shah 2017). Kenpaullone-induced inhibition of CDK5 may 
therefore attenuate this pathway and promote healthy mitochondrial 
function. Indeed, Smith et al. (2003) demonstrated that pharmacological 
inhibition of CDK5 attenuated loss of dopaminergic neurons and rescued 
motor deficits in MPTP treated mice. CDK5 phosphorylates and promotes 
the degradation of E3 ubiquitin ligases including glycoprotein 78 (GP78), an 




al. 2018). Kenpaullone treatment may therefore upregulate levels of 
neuroprotective molecules such as GP78. 
Using a novel lysosomal trafficking probe, Ishii et al. (2019) showed that 
kenpaullone upregulated lysosomal biogenesis in HeLa cells. This effect 
was proven to occur independently of cell cycle arrest, and to be dependent 
on the action of kenpaullone as a CDK5 inhibitor (Ishii et al. 2019). As 
lysosomal trafficking is integral to mitochondrial quality control by induced 
mitophagy (section 1.8), this study supports the hypothesis that kenpaullone 
may enhance mitochondrial quality control. The ability of kenpaullone to 
upregulate lysosomal biogenesis also raises the question of whether the 
compound can also regulate mitochondrial biogenesis, a hypothesis which 
requires further experimental investigation (section 5.4.10). 
Kenpaullone-mediated CDK5 inhibition could also directly modulate 
mitochondrial dynamics. Wong et al. (2011) demonstrated that CDK5 
mediated phosphorylation of endophilin B1 is necessary for neuronal 
autophagy, and dysregulation of this pathway was shown to contribute to 
the pathophysiology of PD. Endophilin B1 is an important modulator of 
mitochondrial morphology (Karbowski et al. 2004), implicating that 
kenpaullone-mediated CDK5 inhibition could directly contribute to the effect 
of kenpaullone on mitochondrial dynamics. Utilising MPTP to model PD in 
non-human primates, Park et al. (2019) demonstrated that excessive 
mitochondrial fission associated with parkinsonian neurodegeneration was 
driven by CDK5-induced phosphorylation of Drp1. Although the ethics of 
using non-human primates here should be questioned, the results do 
provide insight into mitochondrial dynamics in the primate brain. By 
inhibiting neuronal CDK-5, kenpaullone could counteract excessive 
disease-associated mitochondrial fission and rebalance mitochondrial 
dynamics towards a healthier, fusion-associated phenotype. Indeed, the 
current results support this hypothesis, as kenpaullone was demonstrated 




5.4.9.2 CDK1 and CDK2 
Although there is evidence to indicate that kenpaullone may be acting on 
the non-mitotically associated CDK5, its pharmacodynamics imply that its 
effect could be partially exerted by inhibition of CDKs associated with cell 
cycle progression. Kenpaullone inhibits both CDK1 and CDK2 with IC50 
values in the low micromolar range (Table 5.4). CDK1 acts at mitochondria 
to modulate respiration (Qin et al. 2015, Xie et al. 2019), whilst CDK2 is 
required for mPTP-mediated control of apoptosis (Park and Jin 2004, Choi 
et al. 2007). 
 
The potent inhibitors of CDK1 and 2, AT7519 and AZD5438, were found to 
mimic the effect of kenpaullone on parkin recruitment and mitochondrial 
area, but also dramatically reduced cell number. Although loss of cell 
number due to cytotoxicity (for example through induction of apoptosis) 
cannot be ruled out at this stage, it is reasonable to assume that the loss in 
cell number following 24 hours of treatment is attributable to cell cycle arrest 
via CDK1 and CDK2 inhibition.  
 
Compared to AT7519 and AZD5438, kenpaullone acts with much lower 
efficacy at CDKs 1 and 2. Pre-treatment with kenpaullone for 24 hours at 
the same concentration (5µM) does not alter cell number yet still induces 
significant modulation of parkin recruitment and mitochondrial area. This 
indicates that the cell-cycle modulatory effects of these kinase inhibitors are 
dispensable for their actions at the mitochondria. This hypothesis is further 
supported by the preliminary findings in human differentiated neuronal/glial 
cultures, which featured enhanced mitochondrial networks when treated 
with kenpaullone. 
5.4.10 Recommendations for future work 
As kenpaullone was demonstrated to affect the shape and size of the 
mitochondrial network, it is recommended that future and ongoing work 
should seek to gain further mechanistic insight into the effect of kenpaullone 




whether the compound is directly affecting mitochondrial biogenesis. 
ELISAs to quantify inhibitors and activators of biogenesis would give an 
overall indication of whether kenpaullone modulates generation of new 
mitochondria. Alternatively, detection of mtDNA-encoded genes such as 
MTCO1 by qPCR and expressing this as a ratio to a nuclear encoded gene 
would give a quantitative measure of biogenesis, whilst mtDNA expression 
levels alone would represent the relative quantity of total mitochondria in 
cells treated with kenpaullone compared to control. Immunostaining of 
mtDNA-encoded proteins and fluorescent imaging (especially using 
confocal microscopy) would act as a validation experiment to complement 
the results of the current study which describe kenpaullone-induced 
changes to the mitochondrial network using MitoTracker Red. These assays 
could be readily implemented into a modified battery of screening tests for 
use with various drug compound libraries in the future. 
Although requiring more intensive optimisation and a heavier investment of 
time, it would be possible to assay the effect of kenpaullone specifically on 
mitochondrial fusion. Jourdain and Martinou (2010) describe a fusion assay 
whereby different domains of Renilla luciferase are expressed within 
mitochondrial matrix of two different cell lines, and after mixing of the two 
isolated mitochondrial populations, functional luciferase is produced upon 
mitochondrial fusion. This assay only permits assessment of fusion in cell-
free conditions. The Youle research group previously described use of a 
mitochondrial matrix targeted photoactivatable-GFP, imaged using time-
lapse confocal microscopy to assess fusion events in whole cells 
(Karbowski et al. 2004). The effect of kenpaullone on mitochondrial fission 
could potentially be measured by assessing expression and/or localisation 
of Drp1 by immunofluorescence, Western blotting or qPCR. Alternatively, 
immunofluorescent labelling of mitochondria after kenpaullone treatment 
could be readily combined with 3D confocal microscopy to gain a more 
detailed insight into the shape of the organelles in a variety of cell types, as 




It would be useful to determine whether kenpaullone directly affects 
mitochondrial membrane potential. Mitochondrial probes such as JC-1 can 
be used to assay mitochondrial membrane potential, although as a single 
excitation/dual emission probe, would not be suitable for use with the INCell 
Analyzer. Alternative membrane-potential dependent dyes such as TMRM 
may be preferable for use in plate-based assays (Nicholls 2012, Lefebvre 
et al. 2013). 
In addition to clarifying the specific effects of kenpaullone on mitochondrial 
dynamics, it is recommended that ongoing work should focus on 
understanding which pharmacological targets of kenpaullone are important 
in mediating its mitochondrial effects. The use of cell lines carrying a 
knockout of specific kenpaullone targets would contribute to our 
understanding of the relative importance of the various substrates. Bristol 
Renal research group at Bristol Medical School, University of Bristol, have 
developed GSK-3 knockout podocyte lines and have agreed to a 
collaborative project to assess the effect of kenpaullone on mitochondrial 
health and function in these cells. This would be especially interesting 
considering recent evidence which reports that kenpaullone protects 
podocytes (Lee et al. 2017). 
As kenpaullone acts with low micromolar efficacy on cell-cycle mediating 
CDKs (CDK1 and CDK2), it is important to investigate whether kenpaullone 
treatment modulates cell cycle progression and how this may relate to its 
mitochondrial effects. Although CDK1 and CDK2 may not have significant 
functional importance in the cell cycle of post-mitotic neurons, they are likely 
to play an important role in the phenotype of human cancerous cell lines 
such as H4 and SH-SY5Y. 
 
In a future experiment, the effect of kenpaullone should be compared 
against that of a cell-cycle modulator which works via mechanisms 
unrelated to CDK inhibition and which are not candidate drugs for 
mitochondrial modulation. Suitable examples include either ABT 751 or 




polymerisation or CFM4 which induces cell cycle arrest by preventing 
function of cell cycle and apoptosis regulator-1 (CARP-1). Preference could 
be given to drugs which do not target microtubules, as mitochondrial 
dynamics (movement, fission and fusion) are in part mediated by 
mitochondrial association with microtubules. Importantly, the evidence 
presented in this chapter suggests that kenpaullone induces modulation of 
the mitochondrial network in post-mitotic human neurons and glia 
differentiated from foetal cells. This indicates that kenpaullone is not entirely 
dependent on cell-cycle modulation to exert its effects on mitochondria. 
 
Further validation experiments must be carried out to confirm and quantify 
the effect of kenpaullone in foetal-derived neuronal/glial cultures. Capture 
of mitochondrial immunofluorescence should be carried out using confocal 
microscopy under blinded conditions, and images quantified using software 
such as ImageJ. Further study into the effect of kenpaullone in neurons 
could be executed by culturing primary neurons from rodents and 
measuring the effect on kenpaullone on mitochondria visualised by 
immunostaining or MitoTracker Red uptake. This could be taken further by 
utilising cells from rodent models of PD. Likewise, neurons derived from 
human iPSCs derived from either control patients, or patients diagnosed 
with neurodegenerative conditions such as PD could be used to test the 
potentially therapeutic potential of kenpaullone.  
 
There have been very few in-vivo studies of kenpaullone carried out to date. 
Ultimately, it will be unknown whether kenpaullone is capable of exerting 
potentially neuroprotective effects until testing is carried out in a mouse 
model of neurodegenerative disease. Animal testing should only be carried 
out after in-vitro studies (as recommended above) have taken place and 
indicated therapeutic promise and should be initially restricted to using mice. 
Kenpaullone has a relatively low molecular weight (327.2 g/mol) and is 
lipophilic and therefore likely to pass the blood-brain barrier (Kitabayashi et 
al. 2019). The same study reported intraperitoneal administration of 
kenpaullone for 9 weeks with no obvious adverse effects. As previously 




mouse models of glioblastoma and hearing-loss (Teitz et al. 2018, 
Kitabayashi et al. 2019), setting a precedent for its efficacy at terminally 
differentiated cells in-vivo including within the CNS. 
 
It should also be noted that other drugs in the paullone family, such as 
alsterpaullone and 1-azakenpaullone, are also potent inhibitors of GSK-3 
beta and CDK5 (Leost et al. 2000, Kunick et al. 2004) which have been 
previously demonstrated as cytoprotective (Lee et al. 2017)). Further 
investigation into these closely related chemical compounds should be 
considered, as they may confer pharmacological properties more suitable 
for in-vivo application. 
 
5.4.11 Conclusions 
In summary, this chapter reports the development and implementation of in-
vitro assays to screen the effects of drug compounds on parkin recruitment, 
mitochondrial morphology and mitochondrial respiratory function. 
Kenpaullone was identified as a novel negative modulator of parkin 
recruitment to mitochondria. Further analysis revealed that kenpaullone 
modulated the 2D morphology of the mitochondrial network, and protected 
mitochondria against the mitochondrial toxin MPP+. Initial experiments 
suggest that kenpaullone could alter the morphology of the mitochondrial 
network in human foetal-derived neurons and glial cells, enhancing the size 
and number of organelles which could be bioenergetically favourable and 
increase resilience to pathogenic change. This finding implies that negative 
modulators of parkin recruitment may exert beneficial effects on the 
mitochondrial network. This in turn indicates that modulators of 
mitochondrial health and function with potentially therapeutic applications 
need not push the balance of mitophagy in one particular direction. 
Overall this chapter identifies kenpaullone as a novel modulator of 
mitochondria which could ameliorate bioenergetic failure and cellular stress 
caused by mitochondrial dysfunction, perhaps through enhanced 




action could be mediated by inhibitory actions on important neuronal 





6.  Chapter 6 
General Discussion 
6.1 Thesis results and wider context 
Neurodegenerative disease represents a critical area of unmet clinical need. 
This complex and usually fatal group of disorders results in economical and 
medical impact at both the societal and individual patient level. There are 
currently no curative or disease-modifying therapies approved for the 
treatment of any neurodegenerative condition, whilst prevalence of 
neurodegenerative diagnoses is predicted to continue to increase alongside 
an ageing population. 
In addition to improvement of clinical trial design and development of 
biomarkers to facilitate early diagnoses, further developing knowledge of 
the molecular pathology of neurodegenerative disease is considered a high-
priority research area (The Royal Society). As neurons have highly active 
and complex transcriptomes, they are especially vulnerable to alterations in 
RNA processing which occurs as a result of altered RBP expression and 
function. Neuronal function necessitates high energy expenditure, and 
neurons are therefore also highly susceptible to imbalances in energy 
homeostasis which occur as a result of impaired mitochondrial health and 
function. Abnormal RBP function and mitochondrial dysfunction are both 
linked to genetically inherited neurodegenerative conditions, and are also 
associated with idiopathic disease. This thesis aimed to investigate both 
RBP dysfunction and mitochondrial dysfunction as two important molecular 
hallmarks of neurodegenerative disease with future therapeutic promise. 
6.1.1 Chapters 3 and 4: Investigating the RNA binding protein SAFB1 
SAFB1 is an RBP of increasing importance to human disease pathology. 
The structure and diverse functions of SAFB1 have been previously 
established using in-vitro cell models and transgenic animals (reviewed by 




cancer (Oesterreich et al. 2001, Hong et al. 2012, Allahyani 2020) and 
indicated that it could be associated with the pathology of 
neurodegenerative disease ((Rivers et al. 2015, Norman et al. 2016). 
Although it was previously shown that SAFB1 is highly expressed in the 
rodent and human brain (section 1.5, Figures 1.12 and 1.13), 
characterisation of its expression pattern in either aged or degenerating 
human brain had not been previously characterised. 
Chapter 3 presents a detailed immunohistochemical analysis of SAFB1 in 
human brain areas affected by neurodegenerative disease. In patients with 
no history of neurological illness, immunohistological staining showed that 
SAFB1 was highly expressed in the cerebellum, in the nuclei of granule 
cells, molecular layer cells, and Purkinje cells. There was low expression of 
SAFB1 in the large principle neurons of the cerebellar DN. SAFB1 was 
highly expressed in the nuclei of both glial and neuronal cells in control 
patient striatum. In contrast, there was low expression of SAFB1 in the 
substantia nigra. The nuclear expression pattern of SAFB1 was unaltered 
in the cerebellum of patients with MS, and in the substantia nigra of patients 
with PD. However, the expression pattern of SAFB1 was markedly different 
in the brains of patients with polyQ disease. In SCA cerebellum, SAFB1 was 
expressed throughout the cytoplasm of Purkinje cell soma and dendrites, 
alongside expression in the nuclei. There was also a dramatic increase in 
the nuclear expression of SAFB1 in DN neurons of SCA patients, alongside 
cytoplasmic immunopositivity. In the striatum of patients with HD, nuclear 
SAFB1 expression was accompanied by abnormal cytoplasmic staining in 
neurons which morphologically resembled degenerating MSNs. 
SAFB1 has structural and functional similarities to RBPs implicated in 
neurodegenerative disease (e.g. TDP-43 and FUS). These RBPs have 
been shown to bind expanded polyQ peptides (Doi et al. 2008, Schwab et 
al. 2008, Kino et al. 2016, Coudert et al. 2019), associate with other proteins 
altered in polyQ disorders (Becker et al. 2017), and have altered 
nucleocytoplasmic transport (Fahrenkrog and Harel 2018). Because SAFB1 




did not associate with ataxin1 protein (Rivers et al. (2015), sections 3.2 and 
4.2), the RNA binding functions of SAFB1 were further investigated. 
Chapter 4 interrogated the interaction of SAFB1 with ATXN1 RNA with 
varying polyCAG tract lengths, to model the interaction of SAFB1 with 
expanded CAG RNA in polyQ disease. RNA IP experiments demonstrated 
that SAFB1 binds to ATXN1 RNA with varying CAG repeat tract lengths. 
Pathological expansion resulted in increased levels of ATXN1 RNA 
associated with SAFB1. This may be mediated by the altered secondary 
structure of the 85 CAG tract, which is predicted to form a highly stable long 
hairpin loop. 
Consequences of the altered RNA binding function of SAFB1 are currently 
uncertain. It is possible that increased binding of SAFB1 to polyCAG xtrRNA 
facilitates the aberrant export of SAFB1 into the cytoplasm, in turn inducing 
a cytoplasmic gain of function or nuclear loss of function. Alternatively, 
newly translated SAFB1 could be sequestered in the cytoplasm by polyCAG 
mRNA transcripts which cause it to be pathologically retained in the 
neuronal cytoplasmic compartment. Previous proteomic evidence (Zhang et 
al. 2018, Allahyani 2020), combined with the current immunostaining data, 
do not support a direct protein-protein interaction of SAFB1 and expanded 
polyQ peptides. However, as expanded CAG tracts are associated with 
dysregulated translation, it is possible that pathological RAN peptides of the 
ATXN1 or HTT gene could be interacting with SAFB1 in the nucleus or 
cytoplasm of polyQ neurons. These hypotheses pose unanswered 
questions which could inform the basis for future research into the role and 
mechanism of SAFB1 in polyQ disease pathogenesis. 
Wider reaching questions are also raised by this work. For example, could 
furthering our understanding of the mechanisms behind SAFB1 expression 
in polyQ disease provide clues to help explain the elusive selective 
vulnerability of neurons in polyQ disease? Furthermore, is abnormal SAFB1 
expression a cause or consequence of neuronal pathology? The 




SAFB1 expression are based on previous research which postulates that 
altered RBP expression is detrimental to cells and induces toxic loss or gain 
of function contributing to neuronal damage. However, it cannot currently 
be disproved that the altered expression of SAFB1 may in fact be protective. 
In human polyQ patient brains, the surviving neurons at end stage disease 
are indeed the ones which abnormally express SAFB1. 
6.1.2 Chapter 5: identification of kenpaullone as a novel mitochondrial 
modulator 
Mitochondrial dysfunction and impaired mitochondrial quality control have 
been well-established as mechanisms associated with several 
neurodegenerative diseases including PD (section 1.9). This knowledge 
has been used to drive the development of disease-modifying therapies, 
some of which have been tested in clinical trials (section 1.9.2). In Chapter 
5, an in-vitro screen of parkin recruitment was used to test pharmacological 
compounds from a repurposed drug library. Kenpaullone was identified as 
a negative modulator of parkin recruitment, which also increased the size 
and elongation of the mitochondrial network in human cell lines. 
Kenpaullone protected against the mitochondrial toxin MPP+ and altered 
mitochondrial respiratory function. In neuronal and glial cells derived from 
foetal neuroprogenitors, kenpaullone dramatically increased the size of the 
mitochondrial network. Of note, the most apparent change to the 
mitochondrial network appeared to be within the non-neuronal (glial) cells. 
As previously described, non-neuronal cells make up half of the cells in the 
human brain, and their role in neurodegenerative pathology is becoming 
increasingly well understood.  
Previously published research established that kenpaullone downregulates 
autophagy and apoptosis (Joo et al. 2018), promotes neurogenesis (Lange 
et al. 2011), protects podocytes (Lee et al. 2017) and promotes survival of 
motor neurons from ALS patients (Liu et al. 2016). Kenpaullone also 
ameliorated in-vivo pathology in mice (Teitz et al. 2018, Kitabayashi et al. 




kenpaullone, which may underpin its previously established cyto- and 
neuro-protective effects. 
However, there are still outstanding research questions to be considered. 
The most important of these relate to a) confirming the mechanism of action 
which mediates the mitochondrial effects of kenpaullone and/or its related 
compounds, and b) further validating the effect of kenpaullone in neurons 
and in-vivo, with the ultimate aim of studying the compound in a model of 
neurodegeneration to test its neuroprotective potential. 
The current model of parkin function in PD relates primarily to its role as a 
critical component for stress-induced mitophagy signalling and therefore the 
removal of damaged mitochondria. The fact that PINK1 or parkin mutations 
directly cause familial PD leave little doubt that mitophagy and/or quality 
control signalling is critical for dopaminergic neuron survival in the SNpc. 
However, it is important to contextualise this against the current mechanistic 
knowledge regarding mitophagy in neurons in-vivo (section 1.8.3). To date, 
studies have generated mixed and sometimes apparently contradictory 
results which suggest that both parkin function and control of mitophagy in 
neurons in-vivo is rather more complex than originally hypothesised. 
Indeed, parkin is known to have diverse functions in addition to its 
established role in mitophagy signalling. Its ubiquitin ligase activity regulates 
apoptosis, cell cycle control and neuroinflammation, in addition to other 
mitochondria related functions such as biogenesis, transport and 
morphological regulation of the mitochondrial network (reviewed by Shires 
et al. (2017) and Montava-Garriga and Ganley (2020)).  
In addition to the role of kenpaullone as a modulator of parkin recruitment, 
its ability to increase the elongation and number of mitochondria hint 
towards a function in modulating mitochondrial dynamics and possibly 
biogenesis. This may be especially important when considering the 
inconsistent evidence for parkin-mediated mitophagy signalling in neurons; 
it is possible that alternative mitochondrial quality control mechanisms may 




cell lines. Even when analysing mitochondrial quality control in mammalian 
in-vivo systems, this could differ greatly to the situation in the aged human 
brain, where individual neurons survive and function for many decades and 
therefore may require species-specific mitochondrial quality control 
systems. This in turn highlights the importance of a) developing pre-clinical 
models of mitochondrial dysfunction which are relevant to the mechanisms 
underpinning human disease, and b) the need for good experimental design 
in clinical trials, such as patient stratification using biomarkers of 
mitochondrial dysfunction. 
If future work were to confirm kenpaullone as a neuroprotective or disease-
modifying compound, this would highlight a wider consideration for research 
into mitochondrial targeted therapeutics. Consensus within the field has 
previously established that mitochondrial quality control is impaired in PD, 
and that mitophagy is downregulated, resulting in impaired ability of neurons 
to clear damaged and dysfunctional mitochondria (section 1.9). This has 
naturally led to research efforts biased towards the discovery of 
interventions which upregulate mitophagy signalling. However, it is possible 
that downregulation of mitophagy, or of a specific mitophagy signalling 
pathway, could also be therapeutically beneficial.  Downregulation of 
mitophagy could result in increased overall number of mitochondria in the 
cell, either through reduced clearance and/or a feed-forward effect which 
upregulates mitochondrial biogenesis and/or fusion. In the presence of this 
increased mitochondrial number, dysfunctional organelles may then be 
primed to undergo increased fusion with healthy ones, increasing the overall 
health of the mitochondrial network. This may be a direct result of increased 
organelle number or could occur as a result of downstream signalling events 
initiated by the action of compounds such as kenpaullone. 
6.2 Crosstalk between RBPs and mitochondria 
The mechanisms which underpin the molecular pathology of 
neurodegenerative disease are often considered in isolation to facilitate 




different pathological mechanisms which converge to result in neuronal loss 
in-vivo. The combination of mechanisms is likely to vary with disease type, 
disease stage, and between individual patients. 
RBPs are important modulators of mitochondrial function (Koc and 
Spremulli 2003, Schatton and Rugarli 2018, Gopalakrishna et al. 2019) and 
mitochondrial damage is known to be an aspect of RBP proteinopathy. This 
mitochondrial crosstalk has been most well-studied in the “prototypical” 
RBPs associated with neurodegenerative disease, FUS and TDP-43, which 
both interact with mitochondria and induce the mitochondrial unfolded 
protein response (Deng et al. 2018, Wang et al. 2019). TDP-43 was shown 
to interact with proteins required for mitochondrial dynamics and with 
mitophagy associated proteins (Davis et al. 2018), whilst inhibiting 
mitochondrial localisation of TDP-43 in ALS neurons abolished 
mitochondrial dysfunction and neuronal loss (Wang et al. 2016). PINK1 or 
parkin downregulation rescued locomotor deficits in Drosophila expressing 
mutant FUS (Chen et al. 2016), demonstrating that genes involved in 
mitochondrial quality control act as modifiers of RBP pathology. This finding 
further supports the argument established in Chapter 5, that downregulation 
of parkin function may be a potentially therapeutically useful mechanism, 
and that modulation of mitophagy signalling in either direction may result in 
correction of pathological mitochondrial imbalances in neurons. 
Several other RBPs have also been implicated in mitochondrial dysfunction. 
Mitochondrial impairment is a feature of SCA1 (Stucki et al. 2016), and 
mutant forms of the DRBP ataxin1 impair the function of DNA damage 
response proteins responsible for mtDNA repair (Ito et al. 2015). The RBP 
ataxin2 modifies PINK1 expression levels and modifies its signalling (Sen 
et al. 2016, Sen et al. 2017). TIA-1, an RBP implicated in AD, ALS and FTD, 
regulates mitochondrial dynamics by enhancing the expression of genes 
which control mitochondrial fission (Tak et al. 2017) and downregulates 




It is also important to consider the communication between mitochondria 
and other organelle systems within degenerating neurons. Mitochondria are 
physically associated with the E.R. through mitochondria-associated 
membranes (MAMs). Disruption to E.R.-mitochondrial signalling is 
implicated in the pathology of FTD and ALS (Lau et al. 2018). The E.R.-
mitochondrial tethering protein complex VAPB-PTPIP51 is important in 
regulation of autophagy (Gomez-Suaga et al. 2017) and its function is 
disrupted by both TDP-43 (Stoica et al. 2014) and FUS (Stoica et al. 2016). 
Interestingly, this is dependent on GSK-3 beta activation by both FUS and 
TDP-43, which disrupt binding of the protein complex through an unknown 
mechanism. Inhibiting GSK-3 beta was shown to correct FUS-induced 
disruptions to E.R.-mitochondrial signalling (Stoica et al. 2014, Stoica et al. 
2016). This holds further implications for kenpaullone and its related 
compounds, which are potent inhibitors of GSK-3 beta. 
6.3 Translational and therapeutic potential of the current findings 
Further research to elucidate the mechanisms of abnormal SAFB1 
expression and its role in polyQ disease may identify new therapeutic 
approaches. If SAFB1 expression level is pathologically altered in polyQ 
disease, restoration of normal expression could be clinically beneficial. This 
could be achieved using antisense oligonucleotides (ASOs) which target 
and bind mRNA transcripts to prevent translation. This therapeutic approach 
has already been used clinically in the case of spinal muscular atrophy to 
correct pathological splicing and expression of the SMN2 gene (Mercuri et 
al. 2018). If it was demonstrated that SAFB1 in the cytoplasm of 
degenerating neurons was aggregation prone, it may be therapeutic to 
prevent or reverse this. ASOs have also been previously utilised for this 
purpose, for example, targeting ataxin2 with ASOs reduced aggregation of 
mutant TDP-43 and improved survival in mice (Becker et al. 2017). 
Modulation of RBP chaperone proteins may also reduce RBP aggregation 




As SAFB1 was shown to sequester pathological expansion repeat RNA, 
interventions to downregulate this interaction may be therapeutically useful. 
Both ASOs and small molecules have previously been utilised for this 
purpose. Oligonucleotides which bind xtrRNA repeats or alter their 
secondary structure attenuate RBP binding (Wheeler et al. 2009). Small 
molecules designed to either bind RNA trinucleotide repeat sequences or 
disrupt mRNA structural motifs have also been shown to reduce RBP 
binding (Childs-Disney et al. 2013, Coonrod et al. 2013). 
The novel findings presented in Chapter 5 are highly translational. 
Kenpaullone crosses the BBB, and a precedent for clinical trials for 
mitochondrial modifying drugs for PD and other neurodegenerative 
conditions has already been well-established (section 1.9.2). Mitochondrial 
dysfunction is implicated in many neurodegenerative disease (PD, HD, AD, 
ALS, FTD) and is also involved in the pathogenesis of ageing, cancer, heart 
and liver disease, alongside specific mitochondrial disorders such as 
mitochondrial myopathy. This implies that compounds which restore 
mitochondrial quality control and function may have wider clinical 
applications. 
6.4 Final summary and conclusions 
In summary, this thesis has contributed to the knowledge that RBPs play a 
role in the pathology of polyQ disease. SAFB1 was found to be abnormally 
expressed in the degenerating neurons of patients with polyQ disorders. It 
was then confirmed that SAFB1 interacts differentially with physiological 
and pathologically expanded ATXN1 RNA, offering a novel mechanistic 
insight into the RNA binding properties of SAFB1 in polyQ disease. This 
also implicates that RBP dysfunction may lead to neurodegenerative 
pathology. The second part of this thesis identified the kinase inhibitor 
kenpaullone as a novel modulator of mitochondrial health and function 
which increased mitochondrial area in human neuronal and glial cells. It is 
hypothesised that these effects may be attributable to its inhibition of GSK-




explore kenpaullone and/or its related compounds as potentially 
neuroprotective in diseases including PD, and to further understand the 
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